 EXHIBIT 2.1      

* * *

 

Exhibit 2.1 
 

 

 


 

 

AGREEMENT AND PLAN OF MERGER

 


 

 

dated as of

 


 

 

January 2, 2019

 


 

 

among

 


 

 

BRISTOL-MYERS SQUIBB COMPANY,

 


 

 

BURGUNDY MERGER SUB, INC.

 


 

 

and

 


 

 

CELGENE CORPORATION

 


 

     

TABLE OF CONTENTS

  
         |   |  

_Page_

    
---|---|--- 
      |   |   
     

ARTICLE I DEFINITIONS

    |  

2

    
     

Section 1.01

    |  

Definitions

    |  

2

    
     

Section 1.02

    |  

Other Definitional and Interpretative Provisions

    | 19  
      |   
     

ARTICLE II CLOSING; THE MERGER

    |  

19

    
     

Section 2.01

    |  

Closing

    |  

19

    
     

Section 2.02

    |  

The Merger

    |  

20

    
     

Section 2.03

    |  

Conversion of Shares

    |  

20

    
     

Section 2.04

    |  

Surrender and Payment

    |  

21

    
     

Section 2.05

    |  

Dissenting Shares

    |  

24

    
     

Section 2.06

    |  

Company Equity Awards

    |  

24

    
     

Section 2.07

    |  

Adjustments

    |  

27

    
     

Section 2.08

    |  

Fractional Shares

    |  

28

    
     

Section 2.09

    |  

Withholding Rights

    |  

28

    
     

Section 2.10

    |  

Lost Certificates

    |  

28

    
     

Section 2.11

    |  

Further Assurances

    |  

28

    
      |   
     

ARTICLE III ORGANIZATIONAL DOCUMENTS; DIRECTORS AND OFFICERS

    |  

29

    
     

Section 3.01

    |  

Certificate of Incorporation and Bylaws of the Surviving Corporation

    |  

29

    
     

Section 3.02

    |  

Directors and Officers of the Surviving Corporation

    |  

29

    
      |   
     

ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE COMPANY

    |  

29

    
     

Section 4.01

    |  

Corporate Existence and Power

    |  

29

    
     

Section 4.02

    |  

Corporate Authorization

    | 30  
     

Section 4.03

    |  

Governmental Authorization

    |  

30

    
     

Section 4.04

    |  

Non-contravention

    |  

30

    
     

Section 4.05

    |  

Capitalization

    |  

31

    
     

Section 4.06

    |  

Subsidiaries

    | 32  
     

Section 4.07

    |  

SEC Filings and the Sarbanes-Oxley Act

    |  

32

    
     

Section 4.08

    |  

Financial Statements and Financial Matters

    |  

34

    
     

Section 4.09

    |  

Disclosure Documents

    |  

34

    
     

Section 4.10

    |  

Absence of Certain Changes

    |  

34

    
     

Section 4.11

    |  

No Undisclosed Material Liabilities

    |  

35

    
     

Section 4.12

    |  

Litigation

    |  

35

    
     

Section 4.13

    |  

Permits

    |  

35

    
     

Section 4.14

    |  

Compliance with Laws

    |  

36

    
     

Section 4.15

    |  

Regulatory Matters

    |  

36

    
     

Section 4.16

    |  

Material Contracts

    |  

38

    
     

Section 4.17

    |  

Taxes

    |  

41

    
     

Section 4.18

    |  

Employees and Employee Benefit Plans

    |  

43

    
     

Section 4.19

    |  

Labor Matters

    |  

45

    
     

Section 4.20

    |  

Intellectual Property

    |  

45

    
    


 

 

 

i         

Section 4.21

    |  

Properties

    |  

47

    
---|---|--- 
     

Section 4.22

    |  

Environmental Matters

    |  

47

    
     

Section 4.23

    |  

FCPA; Anti-Corruption; Sanctions

    |  

48

    
     

Section 4.24

    |  

Insurance

    |  

49

    
     

Section 4.25

    |  

Transactions with Affiliates

    |  

49

    
     

Section 4.26

    |  

Antitakeover Statutes

    |  

49

    
     

Section 4.27

    |  

Opinions of Financial Advisors

    |  

49

    
     

Section 4.28

    |  

Finders' Fees

    |  

49

    
     

Section 4.29

    |  

No Ownership of Parent Common Stock

    |  

50

    
     

Section 4.30

    |  

No Other Company Representations and Warranties

    |  

50

    
      |   
     

ARTICLE V REPRESENTATIONS AND WARRANTIES OF PARENT

    |  

51

    
     

Section 5.01

    |  

Corporate Existence and Power

    |  

51

    
     

Section 5.02

    |  

Corporate Authorization

    |  

51

    
     

Section 5.03

    |  

Governmental Authorization

    |  

52

    
     

Section 5.04

    |  

Non-contravention

    |  

52

    
     

Section 5.05

    |  

Capitalization

    |  

53

    
     

Section 5.06

    |  

Subsidiaries

    |  

54

    
     

Section 5.07

    |  

SEC Filings and the Sarbanes-Oxley Act

    |  

54

    
     

Section 5.08

    |  

Financial Statements and Financial Matters

    |  

56

    
     

Section 5.09

    |  

Disclosure Documents

    |  

56

    
     

Section 5.10

    |  

Absence of Certain Changes

    |  

56

    
     

Section 5.11

    |  

No Undisclosed Material Liabilities

    |  

57

    
     

Section 5.12

    |  

Litigation

    |  

57

    
     

Section 5.13

    |  

Permits

    |  

57

    
     

Section 5.14

    |  

Compliance with Laws

    |  

58

    
     

Section 5.15

    |  

Regulatory Matters

    |  

58

    
     

Section 5.16

    |  

Taxes

    |  

60

    
     

Section 5.17

    |  

Employees and Employee Benefit Plans

    |  

61

    
     

Section 5.18

    |  

Labor Matters

    |  

63

    
     

Section 5.19

    |  

Intellectual Property

    |  

63

    
     

Section 5.20

    |  

Environmental Matters

    |  

65

    
     

Section 5.21

    |  

FCPA; Anti-Corruption; Sanctions

    |  

65

    
     

Section 5.22

    |  

Transactions with Affiliates

    |  

66

    
     

Section 5.23

    |  

Antitakeover Statutes

    |  

66

    
     

Section 5.24

    |  

Opinions of Financial Advisors

    |  

66

    
     

Section 5.25

    |  

Finders' Fees

    |  

66

    
     

Section 5.26

    |  

No Ownership of Company Common Stock

    |  

67

    
     

Section 5.27

    |  

Financing

    |  

67

    
     

Section 5.28

    |  

No Other Parent Representations and Warranties

    |  

68

    
      |   
     

ARTICLE VI COVENANTS OF THE COMPANY

    |  

69

    
     

Section 6.01

    |  

Conduct of the Company

    |  

69

    
     

Section 6.02

    |  

No Solicitation by the Company

    |  

73

    
     

Section 6.03

    |  

Financing Assistance

    |  

77

    
     

Section 6.04

    |  

Cooperation as to Certain Indebtedness

    |  

80

    
     

Section 6.05

    |  

Abraxis CVR Agreement

    | 81  
    


 

 

 

ii         

ARTICLE VII COVENANTS OF PARENT

    |  

82

    
---|--- 
     

Section 7.01

    |  

Conduct of Parent

    |  

82

    
     

Section 7.02

    |  

No Solicitation by Parent

    |  

83

    
     

Section 7.03

    |  

Obligations of Merger Sub

    |  

87

    
     

Section 7.04

    |  

Director and Officer Liability

    |  

87

    
     

Section 7.05

    |  

Employee Matters

    |  

89

    
     

Section 7.06

    |  

Financing

    |  

91

    
     

Section 7.07

    |  

New CVR Agreement

    |  

93

    
      |   
     

ARTICLE VIII COVENANTS OF PARENT AND THE COMPANY

    |  

93

    
     

Section 8.01

    |  

Access to Information; Confidentiality

    |  

93

    
     

Section 8.02

    |  

Reasonable Best Efforts

    |  

94

    
     

Section 8.03

    |  

Certain Filings; SEC Matters

    |  

97

    
     

Section 8.04

    |  

Stockholder Meetings

    |  

99

    
     

Section 8.05

    |  

Public Announcements

    |  

101

    
     

Section 8.06

    |  

Notices of Certain Events

    |  

102

    
     

Section 8.07

    |  

Section 16 Matters

    |  

102

    
     

Section 8.08

    |  

Transaction Litigation

    |  

102

    
     

Section 8.09

    |  

Stock Exchange Delisting

    |  

103

    
     

Section 8.10

    |  

Governance

    |  

103

    
     

Section 8.11

    |  

State Takeover Statutes

    |  

103

    
      |   
     

ARTICLE IX CONDITIONS TO THE MERGER

    | 103  
     

Section 9.01

    |  

Conditions to the Obligations of Each Party

    | 103  
     

Section 9.02

    |  

Conditions to the Obligations of Parent and Merger Sub

    |  

104

    
     

Section 9.03

    |  

Conditions to the Obligations of the Company

    |  

105

    
      |   
     

ARTICLE X TERMINATION

    |  

105

    
     

Section 10.01

    |  

Termination

    |  

105

    
     

Section 10.02

    |  

Effect of Termination

    |  

108

    
     

Section 10.03

    |  

Termination Fees

    |  

108

    
      |   
     

ARTICLE XI MISCELLANEOUS

    |  

111

    
     

Section 11.01

    |  

Notices

    |  

111

    
     

Section 11.02

    |  

Survival

    | 112  
     

Section 11.03

    |  

Amendments and Waivers

    | 112  
     

Section 11.04

    |  

Expenses

    |  

113

    
     

Section 11.05

    |  

Disclosure Schedule References and SEC Document References

    |  

113

    
     

Section 11.06

    |  

Binding Effect; Benefit; Assignment

    |  

114

    
     

Section 11.07

    |  

Governing Law

    |  

114

    
     

Section 11.08

    |  

Jurisdiction/Venue

    | 114  
     

Section 11.09

    |  

WAIVER OF JURY TRIAL

    |  

115

    
     

Section 11.10

    |  

Counterparts; Effectiveness

    |  

115

    
     

Section 11.11

    |  

Entire Agreement

    |  

116

    
     

Section 11.12

    |  

Severability

    |  

116

    
     

Section 11.13

    |  

Specific Performance

    |  

116

    
    


 

 

 

iii  

EXHIBITS

 


 

 

Exhibit A - Form of Contingent Value Rights Agreement

 


 

 

 

 

iv  

 

AGREEMENT AND PLAN OF MERGER

 


 

 

This AGREEMENT AND PLAN OF MERGER (this " _Agreement_ "), dated  as of
January 2, 2019 is by and among Bristol-Myers Squibb Company, a Delaware
corporation (" _Parent_ "), Burgundy Merger Sub, Inc., a Delaware corporation
and a direct,  wholly owned Subsidiary of Parent (" _Merger Sub_ "), and
Celgene Corporation, a Delaware corporation (the " _Company_ ").

 


 

 

WHEREAS, the Board of Directors of the Company has unanimously (i) determined
that this Agreement and the transactions contemplated  hereby (including the
Merger) are fair to and in the best interests of the Company and its
stockholders, (ii) approved, adopted and declared advisable this Agreement and
the transactions contemplated hereby (including the Merger), (iii) directed 
that the adoption of this Agreement be submitted to a vote at a meeting of the
Company's stockholders, and (iv) recommended the adoption of this Agreement by
the Company's stockholders;

 


 

 

WHEREAS, the Board of Directors of Parent has (i) determined that this
Agreement and the transactions contemplated hereby (including the  Parent
Share Issuance) are fair to and in the best interests of Parent and its
stockholders, (ii) approved, adopted and declared advisable this Agreement and
the transactions contemplated hereby (including the Parent Share Issuance),
(iii) directed  that the Parent Share Issuance be submitted to a vote at a
meeting of Parent's stockholders, and (iv) recommended the approval of the
Parent Share Issuance by Parent's stockholders;

 


 

 

WHEREAS, the Board of Directors of Merger Sub has unanimously (i) approved,
adopted and declared advisable this Agreement and the  transactions
contemplated hereby (including the Merger), and (ii) directed that this
Agreement be submitted to Parent for its approval and adoption in its capacity
as the sole stockholder of Merger Sub;

 


 

 

WHEREAS, at or immediately prior to the Merger  Effective Time, Parent and a
trustee selected by Parent and reasonably acceptable to the Company (the "
_New CVR Trustee_ ") will enter into a Contingent Value Rights Agreement (the
" _New        CVR Agreement_ "), in substantially the form attached
hereto as _Exhibit A_ (subject to modification contemplated by _Section 7.07_
); and

 


 

 

WHEREAS, the Company, Parent and Merger Sub desire to make certain
representations, warranties, covenants and agreements specified in  this
Agreement in connection with the transactions contemplated hereby (including
the Merger) and to prescribe certain conditions to the transactions
contemplated hereby (including the Merger).

 


 

 

NOW, THEREFORE, in consideration of the foregoing and the representations,
warranties, covenants and agreements contained in this  Agreement, the
parties agree as follows:

 


 

     

ARTICLE I 
  
  DEFINITIONS

 


 

 

Section 1.01 _Definitions_.

 


 

 

(a) As used in this Agreement, the following terms have the following
meanings:

 


 

 

" _1933 Act_ " means the U.S. Securities Act of 1933, as  amended.

 


 

 

" _1934 Act_ " means the U.S. Securities Exchange Act of 1934,  as amended.

 


 

 

" _Abraxis CVR_ " means a CVR, as defined in the Abraxis CVR  Agreement (as
in effect as of the date hereof).

 


 

 

" _Abraxis CVR Agreement_ " means that certain Contingent Value  Rights
Agreement, dated as of October 15, 2010, by and between the Company and
American Stock Transfer and Trust Company, LLC (the " _Abraxis CVR Trustee_ ").

 


 

 

" _Affiliate_ " means, with respect to any Person, any other  Person directly
or indirectly controlling, controlled by, or under common control with such
Person. The term "control" means the possession, directly or indirectly, of
the power to direct or cause the direction of the management and policies of
a  Person, whether through the ownership of voting securities, by contract or
otherwise, and the terms "controlled" and "controlling" have meanings
correlative thereto.

 


 

 

" _Antitrust Laws_ " shall mean the Sherman Act of 1890, the  Clayton Act of
1914, the Federal Trade Commission Act of 1914, the HSR Act and all other
federal, state and foreign Applicable Laws in effect from time to time that
are designed or intended to prohibit, restrict or regulate actions having
the  purpose or effect of monopolization, lessening of competition or
restraint of trade.

 


 

 

" _Applicable Law(s)_ " means, with respect to any Person, any  federal,
state or local law (statutory, common or otherwise), constitution, treaty,
convention, ordinance, code, rule, regulation, executive order, Order or other
similar requirement enacted, adopted, promulgated or applied by a
Governmental  Authority that is binding upon or applicable to such Person, as
the same may be amended from time to time unless expressly specified otherwise
in this Agreement. References to "Applicable Law" or "Applicable Laws" shall
be deemed to include the  FDCA, the rules, regulations and administrative
policies of the FDA, the PHSA, the EMA, the Bribery Legislation, the Sanction
Laws and the Antitrust Laws.

 


 

 

" _Bribery Legislation_ " means all Applicable Laws relating to  the
prevention of bribery, corruption and money laundering, including the United
States Foreign Corrupt Practices Act of 1977, the Organization For Economic
Co-operation and Development Convention on Combating Bribery of Foreign Public
Officials in  International Business Transactions and related implementing
legislation, the UK Bribery Act 2010 and the Proceeds of Crime Act 2002.

 


 

 

 

2  

" _Business Day_ " means a day, other than Saturday, Sunday or  other day on
which commercial banks in New York, New York are authorized or required by
Applicable Law to close.

 


 

 

" _Code_ " means the U.S. Internal Revenue Code of 1986, as  amended.

 


 

 

" _Company Acquisition Proposal_ " means any indication of  interest,
proposal or offer from any Person or Group, other than Parent and its
Subsidiaries, relating to any (i) direct or indirect acquisition (whether in a
single transaction or a series of related transactions) of assets of the
Company or any  of its Subsidiaries (including securities of Subsidiaries)
equal to twenty percent (20%) or more of the consolidated assets of the
Company, or to which twenty percent (20%) or more of the revenues or earnings
of the Company on a consolidated basis  are attributable for the most recent
fiscal year in which audited financial statements are then available, (ii)
direct or indirect acquisition or issuance (whether in a single transaction or
a series of related transactions) of twenty percent (20%)  or more of any
class of equity or voting securities of the Company, (iii) tender offer or
exchange offer that, if consummated, would result in such Person or Group
beneficially owning twenty percent (20%) or more of any class of equity or
voting  securities of the Company, or (iv) merger, consolidation, share
exchange, business combination, joint venture, reorganization,
recapitalization, liquidation, dissolution or similar transaction or series of
related transactions involving the Company  or any of its Subsidiaries, under
which such Person or Group or, in the case of clause (B), the stockholders or
equityholders of any such Person or Group would, directly or indirectly, (A)
acquire assets equal to twenty percent (20%) or more of the  consolidated
assets of the Company, or to which twenty percent (20%) or more of the
revenues or earnings of the Company on a consolidated basis are attributable
for the most recent fiscal year in which audited financial statements are
then  available, or (B) immediately after giving effect to such
transaction(s), beneficially own twenty percent (20%) or more of any class of
equity or voting securities of the Company or the surviving or resulting
entity in such transaction(s).

 


 

 

" _Company Balance Sheet_ " means the unaudited consolidated  balance sheet
of the Company and its Subsidiaries as of September 30, 2018, and the
footnotes to such consolidated balance sheet, in each case set forth in the
Company's report on Form 10-Q for the fiscal quarter ended September 30, 2018.

 


 

 

" _Company Balance Sheet Date_ " means September 30, 2018.

 


 

 

" _Company Common Stock_ " means the common stock, par value  $0.01 per
share, of the Company.

 


 

 

" _Company Disclosure Schedule_ " means the Company Disclosure  Schedule
delivered to Parent on the date of this Agreement.

 


 

 

 

3  

" _Company Employee Plan_ " means any (i) "employee benefit  plan" as defined
in Section 3(3) of ERISA, (ii) compensation, employment, consulting,
severance, termination protection, change in control, transaction bonus,
retention or similar plan, agreement, arrangement, program or policy or (iii)
other plan,  agreement, arrangement, program or policy providing for
compensation, bonuses, profit-sharing, equity or equity-based compensation or
other forms of incentive or deferred compensation, vacation benefits,
insurance (including any self-insured  arrangement), medical, dental, vision,
prescription or fringe benefits, life insurance, relocation or expatriate
benefits, perquisites, disability or sick leave benefits, employee assistance
program, workers' compensation, supplemental unemployment  benefits or post-
employment or retirement benefits (including compensation, pension, health,
medical or insurance benefits), in each case whether or not written (A) that
is sponsored, maintained, administered, contributed to or entered into by
the  Company or any of its Subsidiaries for the current or future benefit of
any director, officer, or employee (including any former director, officer, or
employee) of the Company or any of its Subsidiaries or (B) for which the
Company or any of its  Subsidiaries has any direct or indirect liability and,
in each case, other than any benefit or compensation plan, program or other
arrangement maintained by a Governmental Authority.

 


 

 

" _Company Equity Awards_ " means the Company Stock Options,  the Company RSU
Awards, the Company PSU Awards, and the Company RSAs.

 


 

 

" _Company Intellectual Property_ " means the Owned  Intellectual Property
and the Licensed Intellectual Property, in each case, of the Company and its
Subsidiaries.

 


 

 

 

4  

" _Company Material Adverse Effect_ " means any event, change,  effect,
development or occurrence that, individually or together with any other event,
change, effect, development or occurrence, has had or would reasonably be
expected to have a material adverse effect on the financial condition,
business or  results of operations of the Company and its Subsidiaries, taken
as a whole; _provided_ that        no event, change, effect,
development or occurrence to the extent resulting from, arising out of, or
relating to any of the following shall be deemed to constitute a Company
Material Adverse Effect or shall be taken into account in determining 
whether there has been, or would reasonably be expected to be, a Company
Material Adverse Effect: (i) any changes in general United States or global
economic conditions, (ii) any changes in conditions generally affecting the
industries in which the  Company or any of its Subsidiaries operates, (iii)
any decline, in and of itself, in the market price or trading volume of the
Company Common Stock (it being understood and agreed that the foregoing shall
not preclude Parent from asserting that any  facts, events, developments or
occurrences giving rise to or contributing to such decline that are not
otherwise excluded from the definition of Company Material Adverse Effect
should be deemed to constitute a Company Material Adverse Effect or  should
be taken into account in determining whether there has been, or would
reasonably be expected to be, a Company Material Adverse Effect), (iv) any
changes in regulatory, legislative or political conditions or in securities,
credit, financial,  debt or other capital markets, in each case in the United
States or any foreign jurisdiction, (v) any failure, in and of itself, by the
Company or any of its Subsidiaries to meet any internal or published
projections, forecasts, estimates or  predictions, revenues, earnings or
other financial or operating metrics for any period (it being understood and
agreed that the foregoing shall not preclude Parent from asserting that any
facts, events, developments or occurrences giving rise to or  contributing to
such failure that are not otherwise excluded from the definition of Company
Material Adverse Effect should be deemed to constitute a Company Material
Adverse Effect or should be taken into account in determining whether there
has  been, or would reasonably be expected to be, a Company Material Adverse
Effect), (vi) the execution and delivery of this Agreement, the public
announcement or the pendency of this Agreement or the pendency or consummation
of the transactions  contemplated by this Agreement (including the Merger),
the taking of any action required or expressly contemplated by this Agreement
or the identity of, or any facts or circumstances relating to Parent or any of
its Subsidiaries, including the  impact of any of the foregoing on the
relationships, contractual or otherwise, of the Company or any of its
Subsidiaries with Governmental Authorities, customers, suppliers, partners,
officers, employees or other material business relations (it  being
understood and agreed that the foregoing shall not apply with respect to any
representation or warranty that is expressly intended to address the
consequences of the execution, delivery or performance of this Agreement or
the consummation of  the transactions contemplated hereby (including _Section
4.04 (c)_) or with respect to the condition to Closing contained in _Section
9.02(b)_ , to the extent it  relates to such representations and warranties),
(vii) any adoption, implementation, promulgation, repeal, modification,
amendment, authoritative interpretation, change or proposal of any Applicable
Law of or by any Governmental Authority,  (viii) any changes or prospective
changes in GAAP (or authoritative interpretations thereof), (ix) any changes
in geopolitical conditions, the outbreak or escalation of hostilities, any
acts of war, sabotage, cyberattack or terrorism, or any  escalation or
worsening of any such acts of war, sabotage, cyberattack or terrorism
threatened or underway as of the date of this Agreement, (x) the taking of any
action at the written request of or with the written consent of Parent, (xi)
any  reduction in the credit rating of the Company or any of its Subsidiaries
(it being understood and agreed that the foregoing shall not preclude Parent
from asserting that any facts, events, developments or occurrences giving rise
to or contributing  to such reduction that are not otherwise excluded from
the definition of Company Material Adverse Effect should be deemed to
constitute a Company Material Adverse Effect or should be taken into account
in determining whether there has been, or  would reasonably be expected to
be, a Company Material Adverse Effect), (xii) any epidemic, plague, pandemic
or other outbreak of illness or public health event, hurricane, earthquake,
flood or other natural disasters, acts of God or any change  resulting from
weather conditions, (xiii) any claims, actions, suits or proceedings arising
from allegations of a breach of fiduciary duty or violation of Applicable Law
relating to this Agreement or the transactions contemplated hereby
(including  the Merger), or (xiv) any regulatory or clinical changes,
effects, developments or occurrences relating to any Company Pipeline Product
(including (A) any suspension, rejection, refusal of, request to refile or any
delay in obtaining or making any  regulatory application or filing relating
to any Company Pipeline Product, (B) any negative regulatory actions,
requests, recommendations or decisions of any Governmental Authority relating
to any Company Pipeline Product or any other regulatory or  clinical
development relating to any Company Pipeline Product, (C) any clinical
studies, tests or results or announcements thereof with respect to any Company
Pipeline Product, and (D) any delay, hold or termination of any clinical trial
or any  delay, hold or termination of any planned application for marketing
approval with respect to any Company Pipeline Product) except in the case of
each of clauses (i), (ii), (iv), (vii), (viii), (ix) or (xii), to the extent
that any such event,  change, effect, development or occurrence has a
disproportionate adverse effect on the Company and its Subsidiaries, taken as
a whole, relative to the adverse effect such event, change, effect,
development or occurrence has on other companies  operating in the industries
in which the Company and its Subsidiaries operate.

 


 

 

 

5  

" _Company Permitted Settlement_ " means, subject to the CPS  Company
Disclosure (as defined in _Section 6.01_ of the Company Disclosure Schedule),
any settlement or compromise of, or any agreement to avoid, any claim, action
or  proceeding or threatened claim, action or proceeding (or series of
related, claims actions or proceedings), where such settlement, compromise or
agreement (i) does not involve payments (contingent or otherwise) by the
Company or any of its  Subsidiaries in excess of $100,000,000 in the
aggregate with all other such settlements, compromises or agreements that
relate to the applicable claim, action or proceeding (but, with respect to
Intellectual Property, that relate to the applicable  Company Product), (ii)
would not, at the time such settlement, compromise or agreement is executed,
be expected to violate any Applicable Laws as reasonably determined by the
Company in good faith, or (iii) does not impose any materially burdensome 
monitoring or reporting obligations to any other Person outside of the
ordinary course of business or any material restrictions, liabilities or
obligations (unless such restrictions, liabilities and obligations are
ordinary course terms typically  included in the settlement or compromise of
the applicable type of claim, action or proceeding (e.g., the inclusion of
licenses and covenants-not-to-sue in the settlement of a claim of Intellectual
Property infringement)) on the Company or any of  its Subsidiaries (or,
following the Closing, on Parent or any of its Subsidiaries).

 


 

 

" _Company Pipeline Product_ " means any Company Product that,  as of the
date of this Agreement, is not being sold or distributed by or on behalf of
the Company or any of its Subsidiaries.

 


 

 

" _Company Product_ " means each product or product candidate  that is being
researched, tested, developed, commercialized, manufactured, sold or
distributed by or on behalf of the Company or any of its Subsidiaries.

 


 

 

" _Company Registered IP_ " means all Scheduled Covered Product  IP and all
other issued patents and other registrations (including patents, trademarks
and copyrights, and domain name registrations) and patent applications  and
other applications for registration for Owned Intellectual Property included
in the Company Intellectual Property.

 


 

 

" _Company Stock Plans_ " means the 2017 Stock Incentive Plan,  the 2008
Stock Incentive Plan, the 1995 Non Employee Directors' Incentive Plan and the
1992 Long-Term Incentive Plan, in each case as amended from time to time, and
any other plan or arrangement of the Company or any of its Subsidiaries
providing  for the grant of compensatory equity-based awards.

 


 

 

" _Company Stock Price_ " means the average of the volume  weighted averages
of the trading price of Company Common Stock on Nasdaq (as reported by
Bloomberg L.P. or, if not reported thereby, by another authoritative source
mutually selected by Parent and the Company in good faith) on each of the
three (3)  consecutive trading days ending on the last trading day prior to
the Closing.

 


 

 

" _Consent_ " means any consent, approval, waiver, license,  permit,
variance, exemption, franchise, clearance, authorization, acknowledgment,
Order or other confirmation.

 


 

 

" _Contract_ " means any legally binding contract, agreement,  obligation,
understanding or instrument, lease, license or other legally binding
commitment or undertaking of any nature.

 


 

 

" _Covered Product_ " means each of the Company Products listed  on _Section
1.01(a)(1)_ of the Company Disclosure Schedule.

 


 

 

 

6  

" _Covered Rights_ " means, with respect to a Company Product,  the right to
research, develop, manufacture, have manufactured, supply, test, distribute,
market, promote, license, offer for sale, sell, import, export, commercialize
or otherwise exploit such Company Product in any jurisdiction.

 


 

 

" _Credit Agreement_ " means that certain Amended and Restated  Credit
Agreement, dated as of April 25, 2018, by and among the Company, the Lenders
party thereto and Citibank, N.A. as Administrative Agent.

 


 

 

" _Environmental Law_ " means any Applicable Law relating to  (i) the
protection, preservation or restoration of the environment (including air,
surface water, groundwater, drinking water supply, surface land, subsurface
land, plant and animal life or any other natural resource), or (ii) the
exposure to, or  the use, storage, recycling, treatment, generation,
transportation, processing, handling, labeling, production, release or
disposal of Hazardous Substances.

 


 

 

" _Environmental Permits_ " means all permits, licenses,  franchises,
consents (including consents required by Contract), variances, exemptions,
orders, certificates, approvals and other similar authorizations of
Governmental Authorities required by Environmental Law and affecting, or
relating to, the  business of the Company or any of its Subsidiaries, or the
business of Parent or any of its Subsidiaries, as applicable.

 


 

 

" _Equity Award Exchange Ratio_ " means the sum, rounded to the  nearest one
hundredth, equal to (i) the Exchange Ratio, _plus_ (ii) the quotient  of (A)
the Cash Consideration, _divided by_ (B) the Parent Stock Price.

 


 

 

" _Equity Securities_ " means, with respect to any Person, (i)  any shares of
capital stock or other voting securities of, or other ownership interest in,
such Person, (ii) any securities of such Person convertible into or
exchangeable for shares of capital stock or other voting securities of, or
other  ownership interests in, such Person or any of its Subsidiaries, (iii)
any warrants, calls, options or other rights to acquire from such Person, or
other obligations of such Person to issue, any capital stock or other voting
securities of, or other  ownership interests in, or securities convertible
into or exchangeable for capital stock or other voting securities of, or other
ownership interests in, such Person or any of its Subsidiaries, or (iv) any
restricted shares, stock appreciation  rights, performance units, contingent
value rights, "phantom" stock or similar securities or rights issued by or
with the approval of such Person that are derivative of, or provide economic
benefits based, directly or indirectly, on the value or  price of (A) any
capital stock or other voting securities of, (B) other ownership interests in,
or (C) any business, products or assets of, such Person or any of its
Subsidiaries.

 


 

 

" _ERISA_ " means the Employee Retirement Income Security Act  of 1974.

 


 

 

" _ERISA Affiliate_ " means, with respect to any entity, any  other entity
that, together with such entity, would be treated as a single employer under
Section 414 of the Code.

 


 

 

" _FCPA_ " means the Foreign Corrupt Practices Act of 1977.

 


 

 

 

7  

" _Filing_ " means any registration, petition, statement,  application,
schedule, form, declaration, notice, notification, report, submission or other
filing.

 


 

 

" _Financing Sources_ " means the Persons that have entered or  will enter
into commitment letters, credit agreements or other agreements with Parent in
connection with the Debt Financing (including any Persons providing
Alternative Financing and including, for purposes of _Section 6.03_ , any
Persons  providing any alternate permanent financing referred to in the Debt
Commitment Letter) and any joinder agreements, indentures or credit agreements
entered into pursuant thereto, including the agents, arrangers, lenders and
other entities that have  committed to provide or arrange all or part of the
Debt Financing, and their respective general or limited partners, direct or
indirect shareholders, managers, members, Affiliates, Representatives,
successors and assigns; provided that neither  Parent nor any Affiliate of
Parent shall be a Financing Source.

 


 

 

" _GAAP_ " means United States generally accepted accounting  principles.

 


 

 

" _Governmental Authority_ " means any transnational, domestic  or foreign
federal, state or local governmental, regulatory or administrative authority,
department, court, agency, commission or official, including any political
subdivision thereof, or any non-governmental self-regulatory agency,
commission or  authority and any arbitral tribunal.

 


 

 

" _Government Official_ " means (i) any official, officer,  employee or
representative of, or any Person acting in an official capacity for or on
behalf of, any Governmental Authority, (ii) any candidate for political office
or (iii) any political party or party official.

 


 

 

" _Group_ " means a "group" as defined in Section 13(d) of the  1934 Act.

 


 

 

" _Hatch-Waxman Act_ " means the Drug Price Competition and  Patent Term
Restoration Act of 1984.

 


 

 

" _Hazardous Substance_ " means any substance, material or  waste that is
listed, defined, designated or classified as hazardous, toxic, radioactive,
dangerous or a "pollutant" or "contaminant" or words of similar meaning under
any Environmental Law or that is otherwise regulated by any Governmental 
Authority with jurisdiction over the environment or natural resources,
including petroleum or any derivative or byproduct thereof, radon, radioactive
material, asbestos or asbestos-containing material, urea formaldehyde, foam
insulation or  polychlorinated biphenyls.

 


 

 

" _HSR Act_ " means the Hart-Scott-Rodino Antitrust  Improvements Act of
1976.

 


 

 

" _Indentures_ " means, collectively:

 


 

(i) that certain  indenture, dated as of October 7, 2010, relating to the
Company's 3.950% Senior Notes due 2020 and 5.700% Senior Notes due 2040;

 


 

(ii) that  certain indenture, dated as of August 9, 2012, relating to the
Company's 3.250% Senior Notes due 2022;

 


 

 

 

 

8  

(iii) that certain indenture dated as of August 6, 2013, relating to the
Company's 4.000% Senior Notes due 2023 and 5.250% Senior Notes due 2043;

 


 

(iv) that  certain indenture, dated as of May 15, 2014, relating to the
Company's 2.250% Senior Notes due 2019, 3.625% Senior Notes due 2024 and
4.625% Senior Notes due 2044;

 

 


 

(v) that  certain indenture, dated as of August 12, 2015, relating to the
Company's 2.875% Senior Notes due 2020, 3.550% Senior Notes due 2022, 3.875%
Senior Notes due 2025 and 5.000% Senior Notes due 2045;

 


 

 

 

 

(vi) that  certain indenture, dated November 9, 2017, relating to the
Company's 2.750% Senior Notes due 2023, 3.450% Senior Notes due 2027 and
4.350% Senior Notes due 2047;

 

 


 

(vii) that  certain indenture, dated as of February 2018, relating to the
Company's 2.875% Senior Notes due 2021, 3.250% Senior Notes due 2023, 3.900%
Senior Notes due 2028 and 4.550% Senior Notes due 2048; and

 


 

(viii) that  certain indenture, dated as of August 10, 2017, relating to the
Company's 2.250% Senior Notes due 2021.

 

 


 

 

 

 

" _Intellectual Property_ " means any and all of the following,  whether or
not registered, and all rights therein and associated therewith, arising in
the United States or any other jurisdiction throughout the world: (i)
trademarks, service marks, trade names, trade dress, logos, slogans, Internet
domain names,  Internet account names (including social networking and media
names) and other indicia of origin, together with all goodwill associated
therewith or symbolized thereby, and all registrations and applications
relating to the foregoing; (ii) patents  and pending patent applications, and
all divisions, continuations, continuations-in-part, reissues and
reexaminations, and any extensions and counterparts thereof; (iii) works of
authorship (whether or not copyrightable), registered and  unregistered
copyrights (including those in Software), all registrations and applications
to register the same, and all renewals, extensions, reversions and
restorations thereof, including moral rights of authors, and database rights;
(iv) trade  secrets, rights in technology, confidential or proprietary
information and other know-how, including inventions (whether or not
patentable or reduced to practice), concepts, methods, processes, protocols,
assays, formulations, formulae, technical,  research, clinical and other
data, databases, designs, specifications, schematics, drawings, algorithms,
models and methodologies; (v) rights in Software; and (vi) other similar types
of proprietary rights or other intellectual property.

 


 

 

" _In-the-Money Option_ " means each Company Stock Option that  is not an
Out-of-the-Money Option.

 


 

 

" _IT Assets_ " means any and all computers, Software,  firmware, middleware,
servers, workstations, routers, hubs, switches, data communications lines and
other information technology equipment, and all associated documentation,
owned by, or licensed or leased to, the Company or any of its  Subsidiaries,
or Parent or any of its Subsidiaries, as applicable.

 


 

 

 

9  

" _Key Covered Product_ " means each Company Product listed on  _Section
1.01(a)(3)_ of the Company Disclosure Schedule.

 


 

 

" _knowledge_ " means (i) with respect to the Company, the  actual knowledge
of those executive officers of the Company set forth in _Section 1.01 (b)_ of
the Company Disclosure Schedule and (ii) with respect to Parent, the actual 
knowledge of those executive officers of Parent set forth in _Section 1.01_ of
the Parent Disclosure Schedule. None of the individuals set forth in _Section
1.01 (b)_  of the Company Disclosure Schedule or _Section 1.01_ of the Parent
Disclosure Schedule shall have any personal liability or obligations regarding
such knowledge.

 


 

 

" _Licensed Intellectual Property_ " means any and all  Intellectual Property
owned by a Third Party and licensed (including sublicensed) to the Company or
any of its Subsidiaries, or Parent or any of its Subsidiaries, as applicable.

 


 

 

" _Lien_ " means, with respect to any property or asset, any  mortgage, lien,
pledge, charge, security interest or encumbrance of any kind in respect of
such property or asset (excluding in each case any license to, or covenant not
to sue in respect of, Intellectual Property).

 


 

 

" _Major Subsidiary_ " means, with respect to any Person, each  Subsidiary of
such Person that is a "significant subsidiary" (as defined in Regulation S-X)
of such Person.

 


 

 

" _NYSE_ " means the New York Stock Exchange.

 


 

 

" _Order_ " means any order, writ, decree, judgment, award,  injunction,
ruling, settlement or stipulation issued, promulgated, made, rendered or
entered into by or with any Governmental Authority or arbitrator (in each
case, whether temporary, preliminary or permanent).

 


 

 

" _Out-of-the-Money Option_ " means each Company Stock Option  for which the
per share exercise price as of immediately prior to the Effective Time is
equal to, or exceeds, the Company Stock Price.

 


 

 

" _Out-of-the-Money Option Exchange Ratio_ " means the  quotient, rounded to
the nearest one hundredth, of (i) the Company Stock Price, _divided by_ (ii)
the Parent Stock Price.

 


 

 

" _Owned Intellectual Property_ " means, with respect to any  Person, any and
all Intellectual Property owned or purported to be owned by such Person or any
of its Subsidiaries.

 


 

 

 

10  

" _Parent Acquisition Proposal_ " means any indication of  interest, proposal
or offer from any Person or Group, other than the Company and its
Subsidiaries, relating to any (i) direct or indirect acquisition (whether in a
single transaction or a series of related transactions) of assets of Parent or
any  of its Subsidiaries (including securities of Subsidiaries) equal to
twenty percent (20%) or more of the consolidated assets of Parent, or to which
twenty percent (20%) or more of the revenues or earnings of Parent on a
consolidated basis are  attributable for the most recent fiscal year in which
audited financial statements are then available, (ii) direct or indirect
acquisition or issuance (whether in a single transaction or a series of
related transactions) of twenty percent (20%) or  more of any class of equity
or voting securities of Parent, (iii) tender offer or exchange offer that, if
consummated, would result in such Person or Group beneficially owning twenty
percent (20%) or more of any class of equity or voting securities  of Parent,
or (iv) merger, consolidation, share exchange, business combination, joint
venture, reorganization, recapitalization, liquidation, dissolution or similar
transaction or series of related transactions involving Parent or any of its 
Subsidiaries, under which such Person or Group or, in the case of clause (B),
the stockholders or equityholders of any such Person or Group would, directly
or indirectly, (A) acquire assets equal to twenty percent (20%) or more of the
consolidated  assets of Parent, or to which twenty percent (20%) or more of
the revenues or earnings of Parent on a consolidated basis are attributable
for the most recent fiscal year in which audited financial statements are then
available, or (B) immediately  after giving effect to such transaction(s),
beneficially own twenty percent (20%) or more of any class of equity or voting
securities of Parent or the surviving or resulting entity in such
transaction(s).

 


 

 

" _Parent Balance Sheet_ " means the unaudited consolidated  balance sheet of
Parent and its Subsidiaries as of September 30, 2018, and the footnotes to
such consolidated balance sheet, in each case set forth in Parent's report on
Form 10-Q for the fiscal quarter ended September 30, 2018.

 


 

 

" _Parent Balance Sheet Date_ " means September 30, 2018.

 


 

 

" _Parent Common Stock_ " means the common stock, par value  $0.10 per share,
of Parent.

 


 

 

" _Parent Disclosure Schedule_ " means the Parent Disclosure  Schedule
delivered to the Company on the date of this Agreement.

 


 

 

" _Parent Employee Plan_ " means any (i) "employee benefit  plan" as defined
in Section 3(3) of ERISA, (ii) compensation, employment, consulting,
severance, termination protection, change in control, transaction bonus,
retention or similar plan, agreement, arrangement, program or policy or (iii)
other plan,  agreement, arrangement, program or policy providing for
compensation, bonuses, profit-sharing, equity or equity-based compensation or
other forms of incentive or deferred compensation, vacation benefits,
insurance (including any self-insured  arrangement), medical, dental, vision,
prescription or fringe benefits, life insurance, relocation or expatriate
benefits, perquisites, disability or sick leave benefits, employee assistance
program, workers' compensation, supplemental unemployment  benefits or post-
employment or retirement benefits (including compensation, pension, health,
medical or insurance benefits), in each case whether or not written (A) that
is sponsored, maintained, administered, contributed to or entered into by 
Parent or any of its Subsidiaries for the current or future benefit of any
director, officer, or employee (including any former director, officer, or
employee) of Parent or any of its Subsidiaries or (B) for which Parent or any
of its Subsidiaries  has any direct or indirect liability and, in each case,
other than any benefit or compensation plan, program or other arrangement
maintained by a Governmental Authority.

 


 

 

" _Parent Intellectual Property_ " means the Owned Intellectual  Property and
the Licensed Intellectual Property, in each case, of Parent and its
Subsidiaries.

 


 

 

 

11  

" _Parent Material Adverse Effect_ " means any event, change,  effect,
development or occurrence that, individually or together with any other event,
change, effect, development or occurrence, has had or would reasonably be
expected to have a material adverse effect on the financial condition,
business or  results of operations of Parent and its Subsidiaries, taken as a
whole; _provided_ that        no event, change, effect, development or
occurrence to the extent resulting from, arising out of, or relating to any of
the following shall be deemed to constitute a Parent Material Adverse Effect
or shall be taken into account in determining  whether there has been, or
would reasonably be expected to be, a Parent Material Adverse Effect: (i) any
changes in general United States or global economic conditions, (ii) any
changes in conditions generally affecting the industries in which  Parent or
any of its Subsidiaries operates, (iii) any decline, in and of itself, in the
market price or trading volume of Parent Common Stock (it being understood and
agreed that the foregoing shall not preclude the Company from asserting that
any  facts, events, developments or occurrences giving rise to or
contributing to such decline that are not otherwise excluded from the
definition of Parent Material Adverse Effect should be deemed to constitute a
Parent Material Adverse Effect or  should be taken into account in
determining whether there has been, or would reasonably be expected to be, a
Parent Material Adverse Effect), (iv) any changes in regulatory, legislative
or political conditions or in securities, credit, financial,  debt or other
capital markets, in each case in the United States or any foreign
jurisdiction, (v) any failure, in and of itself, by Parent or any of its
Subsidiaries to meet any internal or published projections, forecasts,
estimates or  predictions, revenues, earnings or other financial or operating
metrics for any period (it being understood and agreed that the foregoing
shall not preclude the Company from asserting that any facts, events,
developments or occurrences giving rise  to or contributing to such failure
that are not otherwise excluded from the definition of Parent Material Adverse
Effect should be deemed to constitute a Parent Material Adverse Effect or
should be taken into account in determining whether there  has been, or would
reasonably be expected to be, a Parent Material Adverse Effect), (vi) the
execution and delivery of this Agreement, the public announcement or the
pendency of this Agreement or the pendency or consummation of the
transactions  contemplated by this Agreement (including the Merger), the
taking of any action required or expressly contemplated by this Agreement or
the identity of, or any facts or circumstances relating to the Company or any
of its Subsidiaries, including the  impact of any of the foregoing on the
relationships, contractual or otherwise, of Parent or any of its Subsidiaries
with Governmental Authorities, customers, suppliers, partners, officers,
employees or other material business relations (it being  understood and
agreed that the foregoing shall not apply with respect to any representation
or warranty that is expressly intended to address the consequences of the
execution, delivery or performance of this Agreement or the consummation of
the  transactions contemplated hereby (including _Section 5.04_ (c)) or with
respect to the condition to Closing contained in _Section 9.03(b)_ , to the
extent it relates to such representations and warranties), (vii) any
adoption,  implementation, promulgation, repeal, modification, amendment,
authoritative interpretation, change or proposal of any Applicable Law of or
by any Governmental Authority, (viii) any changes or prospective changes in
GAAP (or authoritative  interpretations thereof), (ix) any changes in
geopolitical conditions, the outbreak or escalation of hostilities, any acts
of war, sabotage, cyberattack or terrorism, or any escalation or worsening of
any such acts of war, sabotage, cyberattack or  terrorism threatened or
underway as of the date of this Agreement, (x) the taking of any action at the
written request of or with the written consent of the Company, (xi) any
reduction in the credit rating of Parent or any of its Subsidiaries (it 
being understood and agreed that the foregoing shall not preclude the Company
from asserting that any facts, events, developments or occurrences giving rise
to or contributing to such reduction that are not otherwise excluded from the
definition of  Parent Material Adverse Effect should be deemed to constitute
a Parent Material Adverse Effect or should be taken into account in
determining whether there has been, or would reasonably be expected to be, a
Parent Material Adverse Effect), (xii)  any epidemic, plague, pandemic or
other outbreak of illness or public health event, hurricane, earthquake, flood
or other natural disasters, acts of God or any change resulting from weather
conditions, (xiii) any claims, actions, suits or  proceedings arising from
allegations of a breach of fiduciary duty or violation of Applicable Law
relating to this Agreement or the transactions contemplated hereby (including
the Merger), or (xiv) any regulatory or clinical changes, effects, 
developments or occurrences relating to any Parent Pipeline Product (including
(A) any suspension, rejection, refusal of, request to refile or any delay in
obtaining or making any regulatory application or filing relating to any
Parent Pipeline  Product, (B) any negative regulatory actions, requests,
recommendations or decisions of any Governmental Authority relating to any
Parent Pipeline Product or any other regulatory or clinical development
relating to any Parent Pipeline Product,  (C) any clinical studies, tests or
results or announcements thereof with respect to any Parent Pipeline Product,
and (D) any delay, hold or termination of any clinical trial or any delay,
hold or termination of any planned application for marketing  approval with
respect to any Parent Pipeline Product), except in the case of each of clauses
(i), (ii), (iv), (vii), (viii), (ix) or (xii), to the extent that any such
event, change, effect, development or occurrence has a disproportionate
adverse  effect on Parent and its Subsidiaries, taken as a whole, relative to
the adverse effect such event, change, effect, development or occurrence has
on other companies operating in the industries in which Parent and its
Subsidiaries operate.

 


 

 

 

12  

" _Parent Pipeline Product_ " means any Parent Product that, as  of the date
of this Agreement, is not being sold or distributed by or on behalf of Parent
or any of its Subsidiaries.

 


 

 

" _Parent Product_ " means each product or product candidate  that is being
researched, tested, developed, commercialized, manufactured, sold or
distributed by or on behalf of Parent or any of its Subsidiaries.

 


 

 

" _Parent Stock Price_ " means the average of the volume  weighted averages
of the trading price of Parent Common Stock on the NYSE (as reported by
Bloomberg L.P. or, if not reported therein, in another authoritative source
mutually selected by Parent and the Company in good faith) on each of the five
(5)  consecutive trading days ending on the trading day that is two (2)
trading days prior to the Closing Date.

 


 

 

" _PBGC_ " means the Pension Benefit Guaranty Corporation.

 


 

 

" _Permitted Lien_ " means (i) any Liens for utilities or Taxes  not yet due
and payable or which are being contested in good faith by appropriate
proceedings and with respect to which adequate reserves have been established
in accordance with GAAP, (ii) carriers', warehousemen's, mechanics',
materialmen's,  repairmen's or other similar Liens, (iii) pledges or deposits
in connection with workers' compensation, unemployment insurance and other
social security legislation, (iv) gaps in the chain of title evident from the
records of the applicable  Governmental Authority maintaining such records,
easements, rights-of-way, covenants, restrictions and other encumbrances of
record as of the date of this Agreement, (v) easements, rights-of-way,
covenants, restrictions and other encumbrances  incurred in the ordinary
course of business that do not materially detract from the value or the use of
the property subject thereto, (vi) statutory landlords' liens and liens
granted to landlords under any lease, (vii) any purchase money security 
interests, equipment leases or similar financing arrangements, (viii) any
Liens which are disclosed on the Company Balance Sheet (in the case of Liens
applicable to the Company or any of its Subsidiaries) or the Parent Balance
Sheet (in the case of  Liens applicable to Parent or any of its
Subsidiaries), or the notes thereto, or (ix) any Liens that are not material
to the Company and its Subsidiaries or Parent and its Subsidiaries, as
applicable, taken as a whole.

 


 

 

 

13  

" _Person_ " means any individual, corporation, partnership,  limited
liability company, association, trust or other entity or organization,
including a government or political subdivision or an agency or
instrumentality of such government or political subdivision.

 


 

 

" _Representatives_ " means, with respect to any Person, its  officers,
directors, employees, investment bankers, attorneys, accountants, consultants
and other agents, advisors and representatives.

 


 

 

" _Sanctioned Country_ " means any of Crimea, Cuba, Iran, North  Korea,
Sudan, and Syria.

 


 

 

" _Sanctioned Person_ " means any Person with whom dealings are  restricted
or prohibited under any Sanctions Laws, including the Sanctions Laws of the
United States, the United Kingdom, the European Union or the United Nations,
including (i) any Person identified in any list of Sanctioned Persons
maintained by  (A) the United States Department of Treasury, Office of
Foreign Assets Control, the United States Department of Commerce, Bureau of
Industry and Security or the United States Department of State, (B) Her
Majesty's Treasury of the United Kingdom,  (C) any committee of the United
Nations Security Council, or (D) the European Union, (ii) any Person located,
organized, or resident in, organized in, or a Governmental Authority or
government instrumentality of, any Sanctioned Country and (iii)  any Person
directly or indirectly fifty percent (50%) or more owned or controlled by, or
acting for the benefit or on behalf of, a Person described in (i) or (ii).

 


 

 

" _Sanctions Laws_ " means all Applicable Laws concerning  economic
sanctions, including embargoes, export restrictions, the ability to make or
receive international payments, the freezing or blocking of assets of targeted
Persons, the ability to engage in transactions with specified Persons or
countries  or the ability to take an ownership interest in assets of
specified Persons or located in a specified country, including any Applicable
Laws threatening to impose economic sanctions on any person for engaging in
proscribed behavior.

 


 

 

" _Sarbanes-Oxley Act_ " means the Sarbanes-Oxley Act of 2002.

 


 

 

" _SEC_ " means the U.S. Securities and Exchange Commission.

 


 

 

" _Severance Pay Plans_ " means the severance plans set forth  on _Section
7.05(a)_ of the Company Disclosure Schedule.

 


 

 

" _Software_ " means all (i) computer programs and other  software including
any and all software implementations of algorithms, models, methodologies,
assemblers, applets, compilers, development tools, design tools and user
interfaces, whether in source code or object code form, (ii) databases and 
compilations, including all data and collections of data, whether machine
readable or otherwise, and (iii) updates, upgrades, modifications,
improvements, enhancements, derivative works, new versions, new releases and
corrections to or based on any  of the foregoing.

 


 

 

 

14  

" _Subsidiary_ " means, with respect to any Person, any entity  of which
securities or other ownership interests having ordinary voting power to elect
a majority of the board of directors or other persons performing similar
functions are directly or indirectly owned by such Person. For purposes of
this  Agreement, a Subsidiary shall be considered a "wholly owned Subsidiary"
of a Person as long as such Person directly or indirectly owns all of the
securities or other ownership interests (excluding any securities or other
ownership interests held by  an individual director or officer required to
hold such securities or other ownership interests pursuant to Applicable Law)
of such Subsidiary.

 


 

 

" _Tax_ " means any income, gross receipts, franchise, sales,  use, ad
valorem, property, payroll, withholding, excise, severance, transfer,
employment, estimated, alternative or add-on minimum, value added, stamp,
occupation, premium, environmental or windfall profits taxes, and any other
taxes, charges,  fees, levies, imposts, customs, duties, licenses or other
assessments, together with any interest, penalties and additions to tax
(including penalties for failure to file or late filing of any tax return,
report or other filing, and any interest in  respect of such penalties,
additions to tax or additional amounts imposed by any federal, state, local,
non-U.S. or other Taxing Authority).

 


 

 

" _Tax Return_ " means any report, return, document, statement,  declaration
or other information or filing supplied or required to be supplied to any
Taxing Authority with respect to Taxes, including information returns, claims
for refunds, any documents with respect to or accompanying payments of
estimated  Taxes or with respect to or accompanying requests for the
extension of time in which to file any such report, return, document,
declaration or other information.

 


 

 

" _Tax Sharing Agreement_ " means any existing agreement  binding any Person
or any of its Subsidiaries that provides for the allocation, apportionment,
sharing or assignment of any Tax liability or benefit, or the transfer or
assignment of income, revenues, receipts, or gains for the purpose of 
determining any Person's Tax liability, other than agreements entered into in
the ordinary course of business that do not have as a principal purpose
addressing Tax matters.

 


 

 

" _Taxing Authority_ " means any Governmental Authority  responsible for the
imposition or collection of any Tax.

 


 

 

" _Third Party_ " means any Person or Group, other than the  Company or any
of its Affiliates, in the case of Parent, or Parent or any of its Affiliates,
in the case of the Company, and the Representatives of such Persons, in each
case, acting in such capacity.

 


 

 

" _Willful Breach_ " means a material breach of this Agreement  that is the
consequence of an act or omission by a party with the actual knowledge that
the taking of such act or failure to take such action would be a material
breach of this Agreement.

 


 

 

(b) Each of the following terms is defined in the Section set forth opposite
such term:

 


 

 

 

15    

        

Term

    | Section  
---|--- 
     

Affected Employees

    |  

7.05(a)

    
     

Agreement

    |  

Preamble

    
     

Alternative Financing

    |  

7.06(b)

    
     

Annual Incentive Plans

    |  

7.05(c)

    
     

Assumed In-the-Money Option

    |  

2.06(a)

    
     

Assumed Performance Unit Award

    |  

2.06(c)

    
     

Assumed Restricted Stock Award

    |  

2.06(d)

    
     

Assumed Restricted Unit Award

    |  

2.06(b)

    
     

Bankruptcy and Equity Exceptions

    |  

4.02(a)

    
     

Cash Consideration

    |  

2.03(a)

    
     

Certificate

    |  

2.03(b)

    
     

Certificate of Merger

    |  

2.02(a)

    
     

Claim Expenses

    |  

7.04(a)

    
     

Closing

    |  

2.01

    
     

Closing Date

    |  

2.01

    
     

Company

    |  

Preamble

    
     

Company Additional Amounts

    |  

10.03(f)

    
     

Company Adverse Recommendation Change

    |  

6.02(a)

    
     

Company Approval Time

    |  

6.02(b)

    
     

Company Bankers

    |  

4.28

    
     

Company Board Recommendation

    |  

4.02(b)

    
     

Company Fee Reimbursement

    |  

10.03(d)

    
     

Company Indenture Officers' Certificate

    |  

6.04

    
     

Company Intervening Event

    |  

6.02(g)

    
     

Company Material Contract

    |  

4.16(a)

    
     

Company Note Offers and Consent Solicitations

    |  

6.04

    
     

Company Opinion of Counsel

    |  

6.04

    
     

Company Organizational Documents

    |  

4.01

    
     

Company Permits

    |  

4.13

    
     

Company Preferred Stock

    |  

4.05(a)

    
     

Company PSU Award

    |  

2.06(c)

    
     

Company Record Date

    |  

8.04(a)

    
     

Company Regulatory Agency

    |  

4.15(a)

    
     

Company Regulatory Permits

    |  

4.15(a)

    
     

Company RSA

    |  

2.06(d)

    
     

Company RSA

    |  

2.06(d)

    
     

Company RSU Award

    |  

2.06(b)

    
     

Company SEC Documents

    |  

4.07(a)

    
     

Company Stock Option

    |  

2.06(a)

    
     

Company Stockholder Approval

    |  

4.02(a)

    
     

Company Stockholder Meeting

    |  

8.04(a)

    
     

Company Superior Proposal

    |  

6.02(f)

    
     

Company Supplemental Indenture

    |  

6.04

    
     

Company Termination Fee

    |  

10.03(a)

    
     

Compensation Continuation Period

    |  

7.05(a)

    
    


 

 

 

16         

Confidentiality Agreement

    |  

8.01(a)

    
---|--- 
     

Consent Solicitations

    |  

6.04

    
     

DandO Claim

    |  

7.04(a)

    
     

DandO Indemnified Parties

    |  

7.04(a)

    
     

DandO Indemnifying Parties

    |  

7.04(a)

    
     

Debt Commitment Letter

    |  

5.27(a)

    
     

Debt Commitment Letters

    |  

5.27(a)

    
     

Debt Financing

    |  

5.27(a)

    
     

Debt Offer Documents

    |  

6.04

    
     

DGCL

    |  

2.02(a)

    
     

Dissenting Shares

    |  

2.05

    
     

Dissenting Stockholders

    |  

2.05

    
     

EMA

    |  

4.15(d)

    
     

End Date

    |  

10.01(b)(i)

    
     

Exchange Agent

    |  

2.04(a)

    
     

Exchange Agent Agreement

    |  

2.04(a)

    
     

Exchange Fund

    |  

2.04(a)

    
     

Exchange Ratio

    |  

2.03(a)

    
     

Excluded Shares

    |  

2.03(a)

    
     

FDA

    |  

4.15(a)

    
     

FDCA

    |  

4.15(a)

    
     

Foreign Antitrust Laws

    |  

4.03

    
     

Incentive Plan Participant

    |  

7.05(c)

    
     

internal controls

    |  

4.07(f)

    
     

Joint Proxy Statement/Prospectus

    |  

8.03(a)

    
     

Lease

    |  

4.21

    
     

Market Based Units

    |  

5.05(a)

    
     

Maximum Premium

    |  

7.04(b)

    
     

Merger

    |  

2.02(b)

    
     

Merger Consideration

    |  

2.03(a)

    
     

Merger Effective Time

    |  

2.02(a)

    
     

Merger Sub

    |  

Preamble

    
     

Nasdaq

    |  

4.03

    
     

New Company Plans

    |  

7.05(b)

    
     

New CVR

    |  

2.03(a)

    
     

New CVR Agreement

    |  

Recitals

    
     

New CVR Certificate

    |  

2.02(d)

    
     

New CVR Trustee

    |  

Recitals

    
     

Offers to Exchange

    |  

6.04

    
     

Offers to Purchase

    |  

6.04

    
     

Parent

    |  

Preamble

    
     

Parent Additional Amounts

    |  

10.03(f)

    
     

Parent Adverse Recommendation Change

    |  

7.02(a)

    
     

Parent Approval Time

    |  

7.02(b)

    
     

Parent Board Recommendation

    |  

5.02(b)

    
     

Parent Convertible Preferred Stock

    |  

5.05(a)

    
    


 

 

 

17         

Parent Equity Awards

    |  

5.05(a)

    
---|--- 
     

Parent Fee Reimbursement

    |  

10.03(c)

    
     

Parent Intervening Event

    |  

7.02(g)

    
     

Parent Organizational Documents

    |  

5.01

    
     

Parent Permits

    |  

5.13

    
     

Parent Preferred Stock

    |  

5.05(a)

    
     

Parent Registered IP

    |  

5.19(a)

    
     

Parent Regulatory Agency

    |  

5.15(a)

    
     

Parent Regulatory Permits

    |  

5.15(a)

    
     

Parent Restricted Stock Units

    |  

5.05(a)

    
     

Parent SEC Documents

    |  

5.07(a)

    
     

Parent Share Issuance

    |  

5.02(a)

    
     

Parent Stock Options

    |  

5.05(a)

    
     

Parent Stockholder Approval

    |  

5.02(a)

    
     

Parent Stockholder Meeting

    |  

8.04(b)

    
     

Parent Superior Proposal

    |  

7.02(f)

    
     

Parent Termination Fee

    |  

10.03(b)

    
     

Performance Share Units

    |  

5.05(a)

    
     

PHSA

    |  

4.15(a)

    
     

principal executive officer

    |  

4.07(e)

    
     

principal financial officer

    |  

4.07(e)

    
     

Registration Statement

    |  

8.03(a)

    
     

Regulation S-K

    |  

4.11

    
     

Regulation S-X

    |  

6.01(l)

    
     

Scheduled Covered Product IP

    |  

4.20(a)

    
     

Share Consideration

    |  

2.03(a)

    
     

Surviving Corporation

    |  

2.02(b)

    
     

Transaction Litigation

    |  

8.08

    
     

Trust Indenture Act

    |  

5.03

    
     

U.S. Company Employee Plan

    |  

4.18(a)

    
     

Uncertificated Share

    |  

2.03(b)

    
     

Unvested Equity Award CVR Consideration

    |  

2.06(e)

    
     

Vesting Date

    |  

2.06(e)

    
    

 


 

 

 

18  

Section 1.02 _Other Definitional and Interpretative Provisions_. The following
rules of interpretation shall apply to this Agreement: (i) the words
"hereof",  "hereby", "herein" and "hereunder" and words of like import used
in this Agreement shall refer to this Agreement as a whole and not to any
particular provision of this Agreement; (ii) the table of contents and
captions in this Agreement are  included for convenience of reference only
and shall be ignored in the construction or interpretation hereof; (iii)
references to Articles, Sections and Exhibits are to Articles, Sections and
Exhibits of this Agreement unless otherwise specified;  (iv) all Exhibits and
schedules annexed to this Agreement or referred to in this Agreement,
including the Company Disclosure Schedule and the Parent Disclosure Schedule,
are incorporated in and made a part of this Agreement as if set forth in 
full in this Agreement; (v) any capitalized term used in any Exhibit or
schedules annexed to this Agreement, including the Company Disclosure Schedule
or the Parent Disclosure Schedule, but not otherwise defined therein shall
have the meaning set  forth in this Agreement; (vi) any singular term in this
Agreement shall be deemed to include the plural, and any plural term the
singular, and references to any gender shall include all genders; (vii)
whenever the words "include", "includes" or  "including" are used in this
Agreement, they shall be deemed to be followed by the words "without
limitation", whether or not they are in fact followed by those words or words
of like import; (viii) "writing", "written" and comparable terms refer  to
printing, typing and other means of reproducing words (including electronic
media) in a visible form; (ix) references to any Applicable Law shall be
deemed to refer to such Applicable Law as amended from time to time and to any
rules or  regulations promulgated thereunder; (x) references to any Contract
are to that Contract as amended, modified or supplemented from time to time in
accordance with the terms hereof and thereof; _provided_ that with respect to
any Contract listed on any  schedule annexed to this Agreement, including the
Company Disclosure Schedule or the Parent Disclosure Schedule, all such
amendments, modifications or supplements (other than such amendments,
modifications or supplements that are immaterial) must  also be listed in the
appropriate schedule; (xi) references to any Person include the successors and
permitted assigns of that Person; (xii) references "from" or "through" any
date mean, unless otherwise specified, "from and including" or  "through and
including", respectively; (xiii) references to "dollars" and "$" means U.S.
dollars; (xiv) the term "made available" and words of similar import mean that
the relevant documents, instruments or materials were (A) with respect to 
Parent, posted and made available to Parent on the Company due diligence data
site (or in any "clean room" or as otherwise provided on an "outside counsel
only" basis), or, with respect to the Company, posted or made available to the
Company on  the Parent due diligence data site (or in any "clean room" or as
otherwise provided on an "outside counsel only" basis), as applicable, in each
case, prior to the date hereof; or (B) filed or furnished to the SEC prior to
the date hereof; (xv)  the word "extent" in the phrase "to the extent" shall
mean the degree to which a subject or other theory extends and such phrase
shall not mean "if"; and (xvi) the parties hereto have participated jointly in
the negotiation and drafting of this  Agreement and, in the event an
ambiguity or question of intent or interpretation arises, this Agreement shall
be construed as jointly drafted by the parties hereto and no presumption or
burden of proof shall arise favoring or disfavoring any  party by virtue of
the authorship of any provision of this Agreement.

 


 

 

ARTICLE II 
  
  CLOSING; THE MERGER

 


 

 

Section 2.01 _Closing_. The closing of the Merger (the " _Closing_ ") shall
take place in New York City at the offices of Kirkland and Ellis LLP, 601
Lexington Avenue, New York, New York, 10022 at 10:00 a.m., Eastern time, on
the third (3rd) Business Day  after the date the conditions set forth in
_Article IX_ (other than conditions that by their nature are to be satisfied
at the Closing, but subject to the satisfaction or, to the extent permitted by
Applicable Law, waiver of such conditions  by the party or parties entitled
to the benefit thereof at the Closing) have been satisfied or, to the extent
permitted by Applicable Law, waived by the party or parties entitled to the
benefit thereof, or at such other place, at such other time  or on such other
date as Parent and the Company may mutually agree (the date on which the
Closing occurs, the " _Closing Date_ ").

 


 

 

 

19  

Section 2.02 _The Merger_.

 


 

 

(a) At the Closing, the Company shall file a certificate of merger (the "
_Certificate of Merger_ ")        with the Delaware Secretary of State
and make all other filings or recordings required by the General Corporation
Law of the State of Delaware (the " _DGCL_ ") in connection with the Merger.
The Merger shall become effective at such time (the " _Merger Effective Time_
") as the Certificate of Merger is duly filed with the Delaware Secretary of
State (or at such later time as Parent and the Company shall agree and is
specified in the Certificate of  Merger).

 


 

 

(b) At the Merger Effective Time, Merger Sub shall be merged with and into the
Company in accordance with the DGCL (the " _Merger_ "), whereupon the separate
existence of Merger Sub shall cease, and the Company shall survive as the
surviving corporation in the merger (the " _Surviving       
Corporation_ ").

 


 

 

(c) From and after the Merger Effective Time, the Surviving Corporation shall
possess all the rights, powers, privileges and franchises and be subject to
all of the obligations, liabilities, restrictions and disabilities of the
Company and  Merger Sub, all as provided under the DGCL.

 


 

 

(d) Each New CVR issued as part of the Merger Consideration hereunder will be
substantially in the form attached as Annex A to the New CVR Agreement (each,
a " _New CVR  Certificate_ ").

 


 

 

Section 2.03 _Conversion of Shares_. At the Merger Effective Time, by virtue
of the Merger and without any action on the part of Parent, Merger Sub, the
Company or  the holders of the Company Common Stock:

 


 

 

(a) other than (i) shares of Company Common Stock to be cancelled pursuant to
_Section 2.03(b)_ and (ii) Dissenting Shares (such shares together with the
shares of Company Common Stock to be cancelled pursuant to _Section 2.03(b)_
,  collectively, the " _Excluded Shares_ "), each share of Company Common
Stock outstanding immediately  prior to the Merger Effective Time shall be
converted into the right to receive (A) one (the " _Exchange Ratio_ ") share
of Parent Common Stock (the " _Share Consideration_ "), subject to _Section
2.08_   with respect to fractional shares, (B) $50.00 in cash without
interest (the " _Cash Consideration_ ")  and (C) one contingent value right
(a " _New CVR_ ") issued by Parent subject to and in accordance with  the New
CVR Agreement (the consideration contemplated by subclauses (A), (B) and (C)
together, the " _Merger Consideration_ ");

 


 

 

(b) (i) each share of Company Common Stock held by the Company as treasury
stock or owned by Parent or Merger Sub immediately prior to the Merger
Effective Time (other than any such shares owned by Parent or Merger Sub in a
fiduciary,  representative or other capacity on behalf of other Persons,
whether or not held in a separate account) shall be cancelled, and no
consideration shall be paid with respect thereto and (ii) each share of
Company Common Stock held by any wholly  owned Subsidiary of either the
Company or Parent (other than Merger Sub) immediately prior to the Merger
Effective Time (other than shares held in a fiduciary, representative or other
capacity on behalf of other Persons, whether or not held in a  separate
account) shall be converted into such number of fully paid and non-assessable
shares of common stock of the Surviving Corporation such that the ownership
percentage of any such Subsidiary in the Surviving Corporation immediately 
following the Merger Effective Time shall equal the ownership percentage of
such Subsidiary in the Company immediately prior to the Merger Effective Time;

 


 

 

 

20  

(c) each share of common stock of Merger Sub, par value $0.01 per share,
issued and outstanding immediately prior to the Merger Effective Time shall be
converted into and become one share of common stock, par value $0.01 per
share, of the  Surviving Corporation with the same rights, powers and
privileges as the shares so converted and shall constitute (together with any
share of common stock of the Surviving Corporation described in Section
2.03(b) _(ii)_ ) the only outstanding shares of capital stock of the Surviving
Corporation; and

 


 

 

(d) all outstanding shares of Company Common Stock shall no longer be
outstanding and shall automatically be cancelled and retired and shall cease
to exist, and (i) each share of Company Common Stock that was, immediately
prior to the Merger  Effective Time, represented by a certificate (each, a "
_Certificate_ ") and (ii) each uncertificated  share of Company Common Stock
which, immediately prior to the Merger Effective Time, was registered to a
holder on the stock transfer books of the Company (an "
_Uncertificated        Share_ ") shall (in each case, other than with
respect to Excluded Shares) thereafter represent only the right to receive (A)
the Merger Consideration and (B) with respect  to the Share Consideration,
the right to receive (1) any dividends or other distributions pursuant to
_Section 2.04(f)_ and (2) any cash in lieu of any fractional shares of Parent
Common Stock pursuant to _Section 2.08_ , in each case  to be issued or paid
in accordance with _Section 2.04_ , without interest.

 


 

 

Section 2.04 _Surrender and Payment_.

 


 

 

(a) Prior to the Merger Effective Time, Parent shall appoint a commercial bank
or trust company reasonably acceptable to the Company (the " _Exchange Agent_
") and enter into an exchange agent agreement with the Exchange Agent
reasonably acceptable to the Company (the " _Exchange        Agent
Agreement_ ") for the purpose of exchanging (i) Certificates or (ii)
Uncertificated Shares for the Merger Consideration payable in respect of the
shares of Company  Common Stock. As of the Merger Effective Time, Parent
shall deposit with the Exchange Agent, for the benefit of the holders of
shares of Company Common Stock, for exchange in accordance with this _Section
2.04_ through the Exchange Agent,  (x) certificates (or evidence of shares in
book-entry form) representing the shares of Parent Common Stock issuable
pursuant to _Section 2.03(a)_ in exchange for outstanding shares of Company
Common Stock, (y) cash sufficient to pay the  aggregate Cash Consideration
payable pursuant to _Section 2.03(a)_ and (z) New CVR Certificates
representing the New CVRs issuable pursuant to _Section 2.03(a)_ and the New
CVR Agreement. Parent agrees to make available, directly or indirectly, to the
Exchange Agent from time to time as needed additional cash sufficient to pay
any dividends or  other distributions to which such holders are entitled
pursuant to _Section 2.04(f)_ and cash in lieu of any fractional share of
Parent Common Stock to which such holder is entitled pursuant to _Section
2.08_. Promptly after the  Merger Effective Time (and in no event more than
two (2) Business Days following the Closing Date), Parent shall send, or shall
cause the Exchange Agent to send, to each holder of shares of Company Common
Stock at the Merger Effective Time a  letter of transmittal and instructions
(which shall be in a form reasonably acceptable to the Company and
substantially finalized prior to the Merger Effective Time and which shall
specify that delivery shall be effected, and risk of loss and  title shall
pass, only upon proper delivery of the Certificates or transfer of the
Uncertificated Shares to the Exchange Agent) for use in such exchange. All
certificates (or evidence of shares in book-entry form) representing shares of
Parent  Common Stock and New CVR Certificates and cash deposited with the
Exchange Agent pursuant to this _Section 2.04_ shall be referred to in this
Agreement as the " _Exchange       Fund_ ". Parent shall cause the
Exchange Agent to deliver the Merger Consideration contemplated to be issued
or paid pursuant to this Article II out of the Exchange Fund.   The Exchange
Fund shall not be used for any other purpose. The Exchange Agent shall invest
any cash included in the Exchange Fund as directed by Parent; _provided_ that
such cash shall only be invested in the manner provided in the Exchange Agent
Agreement; and  _provided_ , _further_ , that no such investment or losses
thereon shall affect the Merger Consideration payable to holders of Company
Common Stock entitled to receive such consideration or cash in lieu of 
fractional interests; _provided_ , _further_ , that to the extent necessary to
pay the Merger Consideration, Parent shall promptly cause to be provided
additional funds to the Exchange Agent for the  benefit of holders of Company
Common Stock entitled to receive such consideration in the amount of any such
losses. Any interest and other income resulting from such investments shall be
the property of, and paid to, Parent upon termination of  the Exchange Fund.

 


 

 

 

21  

(b) Each holder of shares of Company Common Stock that have been converted
into the right to receive the Merger Consideration shall be entitled to
receive, upon (i) surrender to the Exchange Agent of a Certificate, together
with a properly  completed and duly executed letter of transmittal, or (ii)
receipt of an "agent's message" by the Exchange Agent (or such other evidence,
if any, of transfer as the Exchange Agent may reasonably request) in the case
of a book-entry transfer of  Uncertificated Shares, the Merger Consideration
in respect of each share of the Company Common Stock represented by such
Certificate or Uncertificated Share (including cash in lieu of any fractional
shares of Parent Common Stock and any dividends  and distributions with
respect to the Share Consideration as contemplated by _Section 2.08_ and
_Section 2.04(f)_ ). The shares of Parent Common Stock constituting the Share
Consideration, at Parent's option, shall be in  uncertificated book-entry
form, unless a physical certificate is requested by a holder of shares of
Company Common Stock or is otherwise required under Applicable Law.

 


 

 

(c) If any portion of the Merger Consideration (or cash in lieu of any
fractional shares of Parent Common Stock or any dividends and distributions
with respect to the Share Consideration as contemplated by _Section 2.08_ or
_Section  2.04(f)_ ) is to be paid to a Person other than the Person in whose
name the surrendered Certificate or the transferred Uncertificated Share is
registered, it shall be a condition to such payment that (i) either such
Certificate shall be  properly endorsed or shall otherwise be in proper form
for transfer or such Uncertificated Share shall be properly transferred and
(ii) the Person requesting such payment shall pay to the Exchange Agent any
transfer or similar Taxes required as a  result of such payment to a Person
other than the registered holder of such Certificate or Uncertificated Share
or establish to the satisfaction of the Exchange Agent that such transfer or
similar Taxes have been paid or are not payable.

 


 

 

 

22  

(d) Upon the Merger Effective Time, there shall be no further registration of
transfers of shares of Company Common Stock thereafter on the records of the
Company. If, after the Merger Effective Time, Certificates or Uncertificated
Shares  are presented to Parent, the Surviving Corporation or the Exchange
Agent for any reason, they shall be cancelled and exchanged for the Merger
Consideration (and cash in lieu of any fractional shares of Parent Common
Stock and any dividends and  distributions with respect to the Share
Consideration as contemplated by _Section 2.08_ and _Section 2.04(f)_ ) with
respect thereto in accordance with the procedures set forth in, or as
otherwise contemplated by, this _Article II_   (including this _Section 2.04_
).

 


 

 

(e) Any portion of the Exchange Fund that remains unclaimed by the holders of
shares of Company Common Stock twelve (12) months following the Closing Date
shall be delivered to Parent or as otherwise instructed by Parent, and any
such holder  who has not exchanged shares of Company Common Stock for the
Merger Consideration in accordance with this _Section 2.04_ prior to that time
shall thereafter look only to Parent for payment of the Merger Consideration
(and cash in lieu of  any fractional shares of Parent Common Stock and any
dividends and distributions with respect to the Share Consideration as
contemplated by _Section 2.08_ and _Section 2.04(f)_ ), without any interest
thereon. Notwithstanding the  foregoing, Parent and its Subsidiaries
(including the Surviving Corporation and its Subsidiaries) shall not be liable
to any holder of shares of Company Common Stock for any amounts properly paid
to a public official in compliance with applicable  abandoned property,
escheat or similar laws. Any amounts remaining unclaimed by holders of shares
of Company Common Stock immediately prior to such time when the amounts would
otherwise escheat to or become property of any Governmental Authority  shall
become, to the extent permitted by Applicable Law, the property of Parent free
and clear of any claims or interest of any Person previously entitled thereto.

 


 

 

(f) Following the surrender of any Certificates, along with the delivery of a
properly completed and duly executed letter of transmittal, or the transfer of
any Uncertificated Shares, in each case as provided in this _Section 2.04_ , 
Parent shall pay, or cause to be paid, without interest, to the Person in
whose name the shares of Parent Common Stock constituting the Share
Consideration have been registered, (i) in connection with the payment of the
Share Consideration, (x)  the amount of any cash payable in lieu of
fractional shares to which such Person is entitled pursuant to _Section 2.08_
, and (y) the aggregate amount of all dividends or other distributions payable
with respect to such shares of Parent  Common Stock with a record date on or
after the Merger Effective Time that were paid prior to the time of such
surrender or transfer, and (ii) at the appropriate payment date after the
payment of the Merger Consideration, the amount of all  dividends or other
distributions payable with respect to whole shares of Parent Common Stock
constituting the Share Consideration with a record date on or after the Merger
Effective Time and prior to the time of such surrender or transfer and  with
a payment date subsequent to the time of such surrender or transfer. No
dividends or other distributions with respect to shares of Parent Common Stock
constituting the Share Consideration, and no cash payment in lieu of
fractional shares  pursuant to _Section 2.08_ , shall be paid to the holder
of any Certificates not surrendered or of any Uncertificated Shares not
transferred until such Certificates are surrendered and the holder thereof
delivers a properly completed and  duly executed letter of transmittal or
such Uncertificated Shares are transferred, as the case may be, as provided in
this _Section 2.04_.

 


 

 

 

23  

(g) The payment of any transfer, documentary, sales, use, stamp, registration,
value added and other Taxes and fees (including any penalties and interest)
incurred by a holder of Company Common Stock in connection with the Merger,
and the  filing of any related Tax Returns and other documentation with
respect to such Taxes and fees, shall be the responsibility solely of such
holder.

 


 

 

Section 2.05 _Dissenting Shares_. Notwithstanding anything in this Agreement
to the contrary, shares of Company Common Stock that are issued and
outstanding  immediately prior to the Merger Effective Time and that are held
by a stockholder who is entitled to demand and properly demands appraisal of
such shares pursuant to, and who complies in all respects with, the provisions
of Section 262 of the  DGCL (such stockholders, the " _Dissenting
Stockholders_ " and, such shares of Company Common Stock,  the " _Dissenting
Shares_ "), shall not be converted into or be exchangeable for the right to
receive  the Merger Consideration, but instead such holder shall be entitled
to payment of the fair value of such Dissenting Shares in accordance with the
provisions of Section 262 of the DGCL (and, at the Merger Effective Time, such
Dissenting Shares  shall no longer be outstanding and shall automatically be
cancelled and shall cease to exist, and such holder shall cease to have any
rights with respect thereto, except the right to receive the fair value of
such Dissenting Shares in accordance  with the provisions of Section 262 of
the DGCL), unless and until such holder shall have failed to perfect or shall
have effectively waived, withdrawn or lost rights to appraisal under the DGCL.
If any Dissenting Stockholders shall have failed  to perfect or shall have
effectively waived, withdrawn or lost such rights, the Dissenting Shares held
by such Dissenting Stockholder shall thereupon be deemed to have been
converted, as of the Merger Effective Time, into the right to receive the 
Merger Consideration as provided in _Section 2.03(a)_ (and cash in lieu of any
fractional shares of Parent Common Stock and any dividends and distributions
with respect thereto as contemplated by _Section 2.04(f)_ and _Section 2.08_
),       without interest. The Company shall give Parent prompt notice
of any written demands for appraisal of any shares of Company Common Stock,
attempted withdrawals of such demands and any other instruments served
pursuant to the DGCL and received by  the Company relating to stockholders'
rights of appraisal in accordance with the provisions of Section 262 of the
DGCL, and Parent shall have the opportunity to participate in all negotiations
and proceedings with respect to all such demands.   The Company shall not,
except with the prior written consent of Parent, make any payment with respect
to, settle or offer or agree to settle any such demands. Any portion of the
Merger Consideration made available to the Exchange Agent pursuant  to
_Section 2.04_ to pay for shares of Company Common Stock for which appraisal
rights have been perfected shall be returned to Parent upon demand.

 


 

 

Section 2.06 _Company Equity Awards._

 


 

 

(a) _Company Stock Options_. At the Merger Effective Time, each compensatory
option to purchase shares of Company Common Stock under any Company Stock Plan
that is  outstanding and unexercised immediately prior to the Merger
Effective Time (each, a " _Company Stock Option_ "), whether or not vested
shall, by virtue of the Merger and without further action on the part of the
holder thereof be:

 


 

 

 

24  

 

(i) if such  Company Stock Option is an In-the-Money Option, assumed by
Parent and converted into (A) an option (an " _Assumed In-the-Money Option_ ")
to purchase, on the same  terms and conditions (including applicable vesting,
exercise and expiration provisions and any terms and conditions relating to
accelerated vesting upon a termination of the holder's employment in
connection with or following the Merger) as  applied to each such Company
Stock Option immediately prior to the Merger Effective Time, shares of Parent
Common Stock, except that the number of shares of Parent Common Stock, rounded
down to the nearest whole number of shares, subject to such  Assumed In-the-
Money Option shall equal the product of (1) the number of shares of Company
Common Stock that were subject to such Company Stock Option immediately prior
to the Merger Effective Time, _multiplied by_ (2) the Equity Award Exchange
Ratio, and the per-share exercise price, rounded up to the nearest whole cent,
shall equal the quotient of (x) the exercise price per share of Company 
Common Stock at which such Company Stock Option was exercisable immediately
prior to the Merger Effective Time, _divided by_ (y) the Equity Award
Exchange  Ratio, and (B) the right to receive (1) if such In-the-Money Option
was vested prior to the Merger Effective Time, one New CVR for each share of
Company Common Stock underlying such In-the-Money Option immediately prior to
the Merger Effective  Time to be delivered within five (5) Business Days
following the Merger Effective Time or (2) if such In-the-Money Option was not
vested immediately prior to the Merger Effective Time, immediately upon, and
subject to, the vesting of the Assumed  In-the-Money Option, the Unvested
Equity Award CVR Consideration (as defined in _Section 2.06(e)_ below); or

 


 

(ii) if such  Company Stock Option is an Out-of-the-Money Option, assumed by
Parent and converted into an option (an " _Assumed Out-of-the-Money Stock
Option_ ") to purchase,  on the same terms and conditions (including
applicable vesting, exercise and expiration provisions and any terms and
conditions relating to accelerated vesting upon a termination of the holder's
employment in connection with or following the  Merger) as applied to each
such Company Stock Option immediately prior to the Merger Effective Time,
shares of Parent Common Stock, except that the number of shares of Parent
Common Stock, rounded down to the nearest whole number of shares,  subject to
such Assumed Out-of-the-Money Stock Option shall equal the product of (1) the
number of shares of Company Common Stock that were subject to such Company
Stock Option immediately prior to the Merger Effective Time, _multiplied by_
(2) the Out-of-the-Money Option Exchange Ratio, and the per-share exercise
price, rounded up to the nearest whole cent, shall equal the quotient of  (x)
the exercise price per share of Company Common Stock at which such Company
Stock Option was exercisable immediately prior to the Merger Effective Time,
_divided by_   (y) the Out-of-the-Money Option Exchange Ratio;

 


 

 

 

 

_provided_ that each Company Stock Option that is an "incentive stock option"
(as defined in Section 422 of the Code) shall be adjusted in accordance with
the requirements of Section 424 of the Code, and each Company  Stock Option
shall be adjusted in a manner that complies with Section 409A of the Code.

 


 

 

 

25  

(b) _Company Restricted Stock Units_. At the Merger Effective Time, each
restricted stock unit award with respect to shares of Company Common Stock
outstanding under  any Company Stock Plan that vests solely based on the
passage of time (each, a " _Company RSU Award_ ")  shall, by virtue of the
Merger and without further action on the part of the holder thereof, be
assumed by Parent and shall be converted into (i) a restricted unit award
(each, an " _Assumed Restricted Unit Award_ ") that settles in a number of
shares of Parent Common Stock equal to the number of shares of Company Common
Stock underlying the  Company RSU Award _multiplied by_ the Equity Award
Exchange Ratio, rounded up to the nearest whole  number of shares, and (ii)
the right to receive, immediately upon, and subject to, the vesting of the
Assumed Restricted Unit Award, the Unvested Equity Award CVR Consideration.
Each Assumed Restricted Unit Award shall continue to have, and  shall be
subject to, the same terms and conditions as applied to the corresponding
Company RSU Award immediately prior to the Merger Effective Time (including
any terms and conditions relating to accelerated vesting upon a termination of
the  holder's employment in connection with or following the Merger).

 


 

 

(c) _Company Performance-Based Restricted Stock Units_. At the Merger
Effective Time, each restricted stock unit award with respect to shares of
Company Common Stock  outstanding under any Company Stock Plan that vests
based on the achievement of performance goals (each, a " _Company PSU Award_
") shall, by virtue of the Merger and without further action on the part of
the holder thereof, be assumed by Parent and shall be converted into (i) a
restricted stock unit award (each, an " _Assumed Performance Unit Award_ ")
that settles in a number of shares of Parent Common Stock equal to the
product  of the number of shares of Company Common Stock underlying the
Company PSU Award (with such number of shares determined __ by deeming the
applicable performance goals to be achieved at the greater of (A) the target
level and (B) the actual level of achievement through the end of the calendar
quarter immediately _preceding_ the quarter in which the Merger Effective Time
occurs as determined by the Management Compensation and Development 
Committee of the Board of Directors of the Company prior to the Merger
Effective Time) _multiplied by_ the Equity Award Exchange Ratio, rounded up to
the nearest whole number of shares, and (ii) the right to receive, immediately
upon, and subject to, the vesting of the Assumed Performance Unit Award, the
Unvested Equity Award CVR  Consideration. Each Assumed Performance Unit Award
shall continue to have, and shall be subject to, the same terms and conditions
as applied to the corresponding Company PSU Award (other than performance-
based vesting conditions) immediately  prior to the Merger Effective Time
(including any terms and conditions relating to accelerated vesting upon a
termination of the holder's employment in connection with or following the
Merger).

 


 

 

(d) _Company Restricted Stock Awards_. At the Merger Effective Time, each
restricted stock award with respect to shares of Company Common Stock
outstanding under any  Company Stock Plan that vests based on the passage of
time and/or the achievement of performance goals (each, a " _Company RSA_ ")
shall, by virtue of the Merger and without further action on the part of the
holder thereof, be assumed by Parent and shall be converted into (i) a
restricted stock award (each, an " _Assumed Restricted Stock Award_ ") that
settles in a number of shares of Parent Common Stock equal to the number  of
shares of Company Common Stock underlying the Company RSA _multiplied by_ the
Equity Award  Exchange Ratio, rounded up to the nearest whole number of
shares, and (ii) the right to receive, immediately upon, and subject to, the
vesting of the Assumed Restricted Stock Award, the Unvested Equity Award CVR
Consideration. Each Assumed  Restricted Stock Award shall continue to have,
and shall be subject to, the same terms and conditions as applied to the
corresponding Company RSA immediately prior to the Merger Effective Time
(including any terms and conditions relating to  accelerated vesting upon a
termination of the holder's employment in connection with or following the
Merger).

 


 

 

 

26  

(e) _Unvested Equity Award CVR Consideration_. With respect to each In-the-
Money Option that is unvested as of immediately prior to the Merger Effective
Time, each  Company RSU Award, each Company PSU Award, and each Company RSA,
the " _Unvested Equity Award CVR Consideration_ " means either (i) if the
Vesting Date (as defined below) occurs prior to the Milestone Payment Record
Date (as defined in the New CVR Agreement) and prior to the Termination Date
(as defined in the New CVR Agreement), one New CVR in  respect of each share
of Company Common Stock underlying such In-the-Money Option, Company RSU
Award, Company PSU Award, or Company RSA, as applicable, immediately prior to
the Merger Effective Time, (ii) if the Vesting Date occurs on or after  the
Milestone Payment Record Date, a cash payment equal to the Milestone Payment
(as defined in the New CVR Agreement) in respect of each share of Company
Common Stock underlying such In-the-Money Option, Company RSU Award, Company
PSU Award, or  Company RSA, as applicable, immediately prior to the Merger
Effective Time, or (iii) if the Vesting Date occurs on or after the
Termination Date and the Milestone (as defined in the New CVR Agreement) was
not achieved prior to the Termination  Date, no additional consideration. As
used in this _Section 2.06(e)_ , " _Vesting Date_ " means  the date on which
the Assumed In-the-Money Option, Assumed Restricted Unit Award, Assumed
Performance Unit Award, or Assumed Restricted Stock Award that was issued in
exchange for the applicable In-the-Money Option, Company RSU Award, Company
PSU  Award, or Company RSA, as applicable, becomes vested. For purposes of
this _Section 2.06(e)_ , the number of shares of Company Common Stock
underlying each Company PSU Award immediately prior to the Merger Effective
Time will be determined  in accordance with _Section 2.06(c)(i)_.

 


 

 

(f) _Reservation of Shares_. As soon as practicable following the Closing Date
(but in no event more than five (5) Business Days following the Closing Date),
Parent  shall file a registration statement on Form S-8 (or any successor
form) or, if required, Form S-3 (or any successor form), with respect to the
issuance of (i) the shares of Parent Common Stock subject to the Assumed In-
the-Money Options, the  Assumed Out-of-the-Money Options, the Assumed
Restricted Unit Awards, the Assumed Performance Unit Awards, and the Assumed
Restricted Stock Awards, and (ii) the New CVRs to holders of Assumed In-the-
Money Options that are unvested as of  immediately prior to the Merger
Effective Time, Assumed Restricted Unit Awards, Assumed Performance Unit
Awards, and Assumed Restricted Stock Awards, and shall use its reasonable best
efforts to maintain the effectiveness of such registration  statement or
registration statements (and maintain the current status of the prospectus or
prospectuses contained therein) for so long as the Assumed In-the-Money
Options, the Assumed Out-of-the-Money Options, the Assumed Restricted Unit
Awards,  the Assumed Performance Unit Awards, and the Assumed Restricted
Stock Awards remain outstanding.

 


 

 

(g) _Board Actions_. Prior to the Merger Effective Time, the Board of
Directors of the Company (and/or the Management Compensation and Development
Committee of the  Board of Directors of the Company) and the Board of
Directors of Parent (and/or the Compensation and Management Development
Committee of the Board of Directors of Parent) shall adopt such resolutions as
are necessary to give effect to the  transactions contemplated by this
_Section 2.06_.

 


 

 

Section 2.07 _Adjustments_. Without limiting or affecting any of the
provisions of _Section 6.01_ or _Section 7.01_ , if, during the period between
the  date of this Agreement and the Merger Effective Time, any change in the
outstanding shares of capital stock of the Company or Parent shall occur as a
result of any reclassification, recapitalization, stock split (including
reverse stock split),  merger, combination, exchange or readjustment of
shares, subdivision or other similar transaction, or any stock dividend
thereon with a record date during such period, the Merger Consideration and
any other amounts payable pursuant to this  Agreement shall be appropriately
adjusted to eliminate the effect of such event on the Merger Consideration or
any such other amounts payable pursuant to this Agreement.

 


 

 

 

27  

 

 

Section 2.08 _Fractional Shares_. Notwithstanding anything in this Agreement
to the contrary, no fractional shares of Parent Common Stock or fractional New
CVRs shall be  issued in the Merger. Each holder of shares of Company Common
Stock who would otherwise have been entitled to receive as a result of the
Merger a fraction of a share of Parent Common Stock or a fractional New CVR
(after aggregating all shares  represented by the Certificates and
Uncertificated Shares delivered by such holder), as the case may be, shall
receive, in lieu thereof, cash (without interest) in an amount (rounded down
to the nearest cent) representing such holder's  proportionate interest in
the net proceeds from the sale by the Exchange Agent on behalf of all such
holders of shares of Parent Common Stock or New CVRs, respectively, that would
otherwise be issued.

 

 


 

 

 

 

Section 2.09 _Withholding Rights_. Each of the Exchange Agent, Parent and the
Surviving Corporation shall be entitled to deduct and withhold from the
consideration otherwise payable pursuant to  this Agreement such amounts as
it is required to deduct and withhold with respect to the making of such
payment under any provision of any Applicable Law, including federal, state,
local or non-U.S. Tax law. If the Exchange Agent, Parent or  the Surviving
Corporation, as the case may be, so withholds and pays over all amounts so
withheld to the appropriate Taxing Authority, such amounts shall be treated
for all purposes of this Agreement as having been paid to the Person in 
respect of which the Exchange Agent, Parent or the Surviving Corporation, as
the case may be, made such deduction and withholding.

 


 

 

Section 2.10 _Lost Certificates_. If any Certificate shall have been lost,
stolen or destroyed, upon the making of an affidavit of that fact by the
Person claiming such Certificate to be lost,  stolen or destroyed and, if
reasonably required by the Surviving Corporation or the Exchange Agent, the
posting by such Person of a customary bond issued for lost, stolen or
destroyed stock certificates, in such reasonable amount as the  Surviving
Corporation or the Exchange Agent may direct, as indemnity against any claim
that may be made against the Surviving Corporation or the Exchange Agent, with
respect to such Certificate, the Exchange Agent will, if such holder has 
otherwise delivered a properly completed and duly executed letter of
transmittal, issue, in exchange for such lost, stolen or destroyed
Certificate, the Merger Consideration to be paid in respect of the shares of
Company Common Stock  represented by such Certificate, as contemplated by
this _Article II_ (including _Section 2.04_ ).

 


 

 

Section 2.11 _Further Assurances_. At and after the Merger Effective Time, the
officers and directors of the Surviving Corporation shall be authorized to
execute and deliver, in the name and on  behalf of the Company, any of its
Subsidiaries or Merger Sub, any deeds, bills of sale, assignments or
assurances and to take and do, in the name and on behalf of the Company, any
of its Subsidiaries or Merger Sub, any other actions and  things to vest,
perfect or confirm of record or otherwise in the Surviving Corporation any and
all right, title and interest in, to and under any of the rights, properties
or assets of the Company acquired or to be acquired by the Surviving 
Corporation as a result of, or in connection with, the Merger.

 


 

 

 

28  

ARTICLE III 
  
  ORGANIZATIONAL DOCUMENTS; DIRECTORS AND OFFICERS 
  
 

 

Section 3.01 _Certificate of Incorporation and Bylaws of the Surviving
Corporation_. (a) The certificate of incorporation of Merger Sub, as in effect
immediately prior to the Merger Effective Time,  shall be the certificate of
incorporation of the Surviving Corporation from and after the Merger Effective
Time until thereafter amended as provided therein or by Applicable Law and (b)
the bylaws of Merger Sub, as in effect immediately prior  to the Merger
Effective Time, shall be the bylaws of the Surviving Corporation from and
after the Merger Effective Time until thereafter amended as provided therein,
in the certificate of incorporation of the Surviving Corporation or by 
Applicable Law, except in each case that the name of the corporation reflected
therein shall be "Celgene Corporation".

 


 

 

Section 3.02 _Directors and Officers of the Surviving Corporation_. From and
after the Merger Effective Time, until their respective successors are duly
elected or appointed and qualified in  accordance with Applicable Law, (a)
the directors of Merger Sub immediately prior to the Merger Effective Time
shall be the directors of the Surviving Corporation and (b) the officers of
the Company immediately prior to the Merger Effective  Time shall be the
officers of the Surviving Corporation.

 


 

 

ARTICLE IV 
  
  REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 


 

 

Subject to Section 11.05, except (i) as  disclosed in any publicly available
Company SEC Document or (ii) as set forth in the Company Disclosure Schedule,
the Company represents and warrants to Parent that:

 


 

 

Section 4.01 _Corporate Existence and Power_. The Company is a corporation
duly incorporated, validly existing and in good standing under the laws of the
State of Delaware. The Company has all  requisite corporate power and
authority required to own or lease all of its properties or assets and to
carry on its business as now conducted. The Company is duly qualified to do
business and is in good standing in each jurisdiction where  such
qualification is necessary, except for those jurisdictions where failure to be
so qualified or in good standing has not had and would not reasonably be
expected to have, individually or in the aggregate, a Company Material
Adverse  Effect. Prior to the date of this Agreement, the Company has made
available to Parent true and complete copies of the certificate of
incorporation and bylaws of the Company as in effect on the date of this
Agreement (the " _Company Organizational Documents_ ").

 


 

 

 

29  

Section 4.02 _Corporate Authorization_.

 


 

 

(a) The execution, delivery and performance by the  Company of this Agreement
and the consummation by the Company of the transactions contemplated by this
Agreement are within the corporate powers and authority of the Company and,
except for the Company Stockholder Approval, have been duly  authorized by
all necessary corporate action on the part of the Company. The affirmative
vote of the holders of at least a majority of the outstanding shares of
Company Common Stock adopting this Agreement is the only vote of the holders
of  any of the Company's capital stock necessary in connection with the
consummation of the Merger (the " _Company Stockholder Approval_ "). This
Agreement has  been duly executed and delivered by the Company and (assuming
due authorization, execution and delivery by Parent and Merger Sub)
constitutes a valid, legal and binding agreement of the Company enforceable
against the Company in accordance  with its terms (subject to applicable
bankruptcy, insolvency, reorganization, moratorium and similar laws affecting
creditors' rights and remedies generally, and subject to general principles of
equity, regardless of whether enforcement is  sought in a proceeding at law
or in equity (collectively, the " _Bankruptcy and Equity Exceptions_ ")).

 


 

 

(b) At a meeting duly called and held, the Board of  Directors of the Company
unanimously adopted resolutions (i) determining that this Agreement and the
transactions contemplated hereby (including the Merger) are fair to and in the
best interests of the Company and its stockholders, (ii)  approving, adopting
and declaring advisable this Agreement and the transactions contemplated
hereby (including the Merger), (iii) directing that the adoption of this
Agreement be submitted to a vote at a meeting of the Company's stockholders, 
and (iv) recommending adoption of this Agreement by the Company's stockholders
(such recommendation, the " _Company Board Recommendation_ "). Except as 
permitted by Section 6.02, the Board of Directors of the Company has not
subsequently rescinded, modified or withdrawn any of the foregoing
resolutions.

 


 

 

Section 4.03 _Governmental Authorization_. The execution, delivery and
performance by the Company of this Agreement and the consummation by the
Company of the transactions contemplated hereby  require no action by or in
respect of, Consents of, or Filings with, any Governmental Authority other
than (a) the filing of the Certificate of Merger with the Delaware Secretary
of State and appropriate documents with the relevant  authorities of other
states in which the Company is qualified to do business, (b) compliance with
any applicable requirements of the HSR Act, (c) compliance with and Filings
under any applicable Antitrust Laws of any non-U.S. jurisdictions 
(collectively, " _Foreign Antitrust Laws_ "), (d) compliance with any
applicable requirements of the 1933 Act, the 1934 Act and any other applicable
U.S. state  or federal securities laws or pursuant to the rules of the NASDAQ
Global Select Market and NASDAQ Global Market (collectively, " _Nasdaq_ "),
and (e) any other  actions, Consents or Filings the absence of which has not
had and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect.

 


 

 

Section 4.04 _Non-contravention_. The execution, delivery and performance by
the Company of this Agreement and the consummation of the transactions
contemplated hereby do not and will not (a)  contravene, conflict with, or
result in any violation or breach of any provision of the Company
Organizational Documents, (b) assuming compliance with the matters referred to
in _Section 4.03_ and receipt of the Company Stockholder Approval, contravene,
conflict with or result in any violation or breach of any provision of any
Applicable Law, (c) assuming compliance with the matters  referred to in
_Section 4.03_ and receipt of the Company Stockholder Approval, require any
Consent or other action by any Person under, constitute a  default, or an
event that, with or without notice or lapse of time or both, would constitute
a default, under, or cause or permit the termination, cancellation,
acceleration or other change of any right or obligation or the loss of any 
benefit to which the Company or any of its Subsidiaries is entitled under, any
provision of any Company Permit or any Contract binding upon the Company or
any of its Subsidiaries, or (d) result in the creation or imposition of any
Lien on any  asset of the Company or any of its Subsidiaries, except, in the
case of each of clauses (b) through (d), as has not had and would not
reasonably be expected to have, individually or in the aggregate, a Company
Material Adverse Effect.

 


 

 

 

30  

Section 4.05 _Capitalization_.

 


 

 

(a) The authorized capital stock of the Company  consists of (i)
1,150,000,000 shares of Company Common Stock and (ii) 5,000,000 shares of
preferred stock, par value $0.01 per share (" _Company Preferred Stock_ ").
       As of December 31, 2018, there were outstanding (A) 700,238,758
shares of Company Common Stock (of which 17,065 shares of Company Common Stock
were subject to Company RSAs), (B) no shares of Company Preferred Stock, (C)
Company Stock Options  to purchase an aggregate of 71,139,116 shares of
Company Common Stock, (D) 11,676,491 shares of Company Common Stock were
subject to outstanding Company RSU Awards, (E) 652,837 shares of Company
Common Stock were subject to outstanding  Company PSU Awards, determined
assuming target performance levels were achieved, (F) 27,623,841 additional
shares of Company Common Stock were reserved for issuance pursuant to the
Company Stock Plans and (G) 43,273,855 Abraxis CVRs subject  to, and having
the terms set forth in, the Abraxis CVR Agreement. Except as set forth in this
Section _4.05(a)_ and for changes since December 31, 2018  resulting from (x)
the exercise or vesting and settlement of Company Equity Awards outstanding on
such date or issued on or after such date to the extent permitted by _Section
6.01_ , or (y) the issuance of Equity Securities of the Company on or after
the date hereof to the extent permitted by _Section  6.01_ , there are no
issued, reserved for issuance or outstanding Equity Securities of the Company.

 


 

 

(b) All outstanding shares of capital stock of the  Company have been, and
all shares that may be issued pursuant to any Company Stock Plan will be, when
issued in accordance with the respective terms thereof, duly authorized and
validly issued, fully paid and nonassessable and free of  preemptive rights.
No Subsidiary of the Company owns any shares of capital stock of the Company
(other than any such shares owned by Subsidiaries of the Company in a
fiduciary, representative or other capacity on behalf of other Persons, 
whether or not held in a separate account). There are no outstanding bonds,
debentures, notes or other indebtedness of the Company having the right to
vote (or convertible into, or exchangeable for, securities having the right to
vote) on  any matters on which stockholders of the Company have the right to
vote. There are no outstanding obligations of the Company or any of its
Subsidiaries to repurchase, redeem or otherwise acquire any Equity Securities
of the Company. Neither  the Company nor any of its Subsidiaries is a party
to any agreement with respect to the voting of any Equity Securities of the
Company.

 


 

 

 

31  

Section 4.06 _Subsidiaries_.

 


 

 

(a) Each Major Subsidiary of the Company is a  corporation or other entity
duly incorporated or organized, validly existing and in good standing (except
to the extent such concept is not applicable under Applicable Law of such
Subsidiary's jurisdiction of incorporation, formation or  organization, as
applicable) under the laws of its jurisdiction of incorporation, formation or
organization, as applicable, and has all corporate or other organizational
powers and authority, as applicable, required to own, lease and operate  its
properties and assets and to carry on its business as now conducted, except
for those jurisdictions where failure to be so organized, validly existing and
in good standing or to have such power or authority has not had and would
not  reasonably be expected to have, individually or in the aggregate, a
Company Material Adverse Effect. Each such Major Subsidiary is duly qualified
to do business and is in good standing in each jurisdiction where such
qualification is  necessary, except for those jurisdictions where failure to
be so qualified or in good standing has not had and would not reasonably be
expected to have, individually or in the aggregate, a Company Material Adverse
Effect.

 


 

 

(b) All of the issued and outstanding capital stock  or other Equity
Securities of each Subsidiary of the Company have been validly issued and are
fully paid and nonassessable (except to the extent such concepts are not
applicable under Applicable Law of such Subsidiary's jurisdiction of 
incorporation, formation or organization, as applicable) and are owned by the
Company, directly or indirectly, free and clear of any Lien (other than any
restrictions imposed by Applicable Law) and free of preemptive rights, rights
of first  refusal, subscription rights or similar rights of any Person and
transfer restrictions (other than transfer restrictions under Applicable Law
or under the organizational documents of such Subsidiary). There are no
outstanding obligations of  the Company or any of its Subsidiaries to
repurchase, redeem or otherwise acquire any Equity Securities of any
Subsidiary of the Company. Except for the capital stock or other Equity
Securities of its Subsidiaries and publicly traded  securities held for
investment which do not exceed five percent (5%) of the outstanding securities
of any entity, the Company does not own, directly or indirectly, any capital
stock or other Equity Securities of any Person. 
  
 

 

Section 4.07 _SEC Filings and the Sarbanes-Oxley Act_.

 


 

 

(a) The Company has timely filed with or furnished  to the SEC all reports,
schedules, forms, statements, prospectuses, registration statements and other
documents required to be filed with or furnished to the SEC by the Company
since January 1, 2017 (collectively, together with any exhibits  and
schedules thereto and other information incorporated therein, the " _Company
SEC Documents_ "). No Subsidiary of the Company is required to file any 
report, schedule, form, statement, prospectus, registration statement or other
document with the SEC.

 


 

 

(b) As of its filing date ( or, if amended or  superseded by a filing prior
to the date of this Agreement, on the date of such amended or superseding
filing), the Company SEC Documents filed or furnished prior to the date of
this Agreement complied, and each Company SEC Document filed or  furnished
subsequent to the date of this Agreement (assuming, in the case of the Joint
Proxy Statement/Prospectus, that the representation and warranty set forth in
_Section       5.09_ is true and correct) will comply, in all material
respects with the applicable requirements of Nasdaq, the 1933 Act, the 1934
Act and the Sarbanes-Oxley Act, as the case may be.

 


 

 

 

32  

(c) As of its filing date (or, if amended or  superseded by a filing prior to
the date of this Agreement, on the date of such amended or superseding
filing), each Company SEC Document filed or furnished prior to the date of
this Agreement did not, and each Company SEC Document filed or  furnished
subsequent to the date of this Agreement (assuming, in the case of the Joint
Proxy Statement/Prospectus, that the representation and warranty set forth in
Section        5.09 is true and correct) will not, contain any untrue
statement of a material fact or omit to state any material fact necessary in
order to make the statements made therein, in light of the circumstances under
which they were made,  not misleading.

 


 

 

(d) The Company is, and since January 1, 2017 has  been, in compliance in all
material respects with (i) the applicable provisions of the Sarbanes-Oxley Act
and (ii) the applicable listing and corporate governance rules and regulations
of Nasdaq.

 


 

 

(e) Except as has not had and would not reasonably  be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, the
Company and its Subsidiaries have established and maintain disclosure controls
and procedures (as defined in Rule 13a-15 under the 1934 Act)  designed to
ensure that material information relating to the Company, including its
consolidated Subsidiaries, is made known to the Company's principal executive
officer and its principal financial officer by others within those entities, 
including during the periods in which the periodic reports required under the
1934 Act are being prepared. For purposes of this Agreement, " _principal
executive  officer_ " and " _principal financial officer_ " shall have the
meanings given to such terms in the Sarbanes-Oxley Act.

 


 

 

(f) Except as has not had and would not reasonably  be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, the
Company and its Subsidiaries have established and maintain a system of
internal controls over financial reporting (as defined in Rule 13a-15 under 
the 1934 Act) (" _internal controls_ ") designed to provide reasonable
assurance regarding the reliability of the Company's financial reporting and
the  preparation of the Company's financial statements for external purposes
in accordance with GAAP, and the Company's principal executive officer and
principal financial officer have disclosed, based on their most recent
evaluation of such  internal controls prior to the date of this Agreement, to
the Company's auditors and the audit committee of the Board of Directors of
the Company (i) all significant deficiencies and material weaknesses in the
design or operation of internal  controls which are reasonably likely to
adversely affect the Company's ability to record, process, summarize and
report financial information and (ii) any fraud, whether or not material, that
involves management or other employees who have a  significant role in
internal controls. The Company has made available to Parent prior to the date
of this Agreement a true and complete (in all material respects) summary of
any disclosure of the type described in the preceding sentence made  by
management to the Company's auditors and audit committee during the period
beginning January 1, 2017 and ending as of the date hereof.

 


 

 

(g) Since January 1, 2017, each of the principal  executive officer and
principal financial officer of the Company (or each former principal executive
officer and principal financial officer of the Company, as applicable) has
made all certifications required by Rules 13a-14 and 15d-14 under  the 1934
Act and Sections 302 and 906 of the Sarbanes-Oxley Act and any related rules
and regulations promulgated by the SEC and Nasdaq, and the statements
contained in any such certifications are true and complete in all material
respects as  of the date on which they were made.

 


 

 

 

33  

Section 4.08 _Financial Statements and Financial Matters_.

 


 

 

(a) The audited consolidated financial statements  and unaudited consolidated
interim financial statements of the Company included or incorporated by
reference in the Company SEC Documents present fairly in all material
respects, in conformity with GAAP applied on a consistent basis during  the
periods presented (except as may be indicated in the notes thereto), the
consolidated financial position of the Company and its Subsidiaries as of the
dates thereof and their consolidated results of operations and cash flows for
the  periods then ended (subject to normal and recurring year-end audit
adjustments in the case of any unaudited interim financial statements). Such
consolidated financial statements have been prepared in all material respects
from the books and  records of the Company and its Subsidiaries.

 


 

 

(b) From January 1, 2017 to the date of this  Agreement, the Company has not
received written notice from the SEC or any other Governmental Authority
indicating that any of its accounting policies or practices are or may be the
subject of any review, inquiry, investigation or challenge  by the SEC or any
other Governmental Authority.

 


 

 

Section 4.09 _Disclosure Documents_. The information relating to the Company
and its Subsidiaries that is provided by the Company, any of its Subsidiaries
or any of their respective Representatives  for inclusion or incorporation by
reference in the Registration Statement or the Joint Proxy
Statement/Prospectus will not (a) in the case of the Registration Statement,
at the time the Registration Statement or any amendment or supplement 
thereto becomes effective and at the time of the Company Stockholder Meeting
and the Parent Stockholder Meeting, and (b) in the case of the Joint Proxy
Statement/Prospectus, at the time the Joint Proxy Statement/Prospectus or any
amendment or  supplement thereto is first mailed to the stockholders of the
Company and the stockholders of Parent and at the time of the Company
Stockholder Meeting and the Parent Stockholder Meeting, contain any untrue
statement of a material fact or  omit to state any material fact necessary in
order to make the statements made therein, in light of the circumstances under
which they were made, not misleading. Notwithstanding the foregoing provisions
of this _Section 4.09_ , no representation or warranty is made by the Company
with respect to information or statements made or incorporated by reference in
the Registration Statement or  the Joint Proxy Statement/Prospectus which
were not supplied by or on behalf of the Company.

 


 

 

Section 4.10 _Absence of Certain Changes_.

 


 

 

(a) (i) Since the Company Balance Sheet Date through  the date of this
Agreement, except in connection with or related to the process in connection
with which the Company and its Representatives discussed and negotiated this
Agreement and the transactions contemplated hereby, the business of the 
Company and its Subsidiaries has been conducted in all material respects in
the ordinary course of business consistent with past practice and (ii) since
the Company Balance Sheet Date, there has not been any event, change, effect,
development  or occurrence that has had or would reasonably be expected to
have, individually or in the aggregate, a Company Material Adverse Effect.

 


 

 

 

34  

(b) Since the Company Balance Sheet Date through the  date of this Agreement,
there has not been any action taken by the Company or any of its Subsidiaries
that, if taken during the period from the date of this Agreement through the
Merger Effective Time without Parent's consent, would  constitute a breach of
clause (b), (c)(iii), (f), (h), (l) or (m) of Section 6.01 (or solely with
respect to the foregoing clauses, clause (o) of Section 6.01).

 


 

 

Section 4.11 _No Undisclosed Material Liabilities_. There are no liabilities
or obligations of the Company or any of its Subsidiaries of any kind
whatsoever, whether accrued, contingent, absolute,  determined, determinable
or otherwise, that would be required by GAAP to be reflected on the
consolidated balance sheet of the Company and its Subsidiaries, other than (a)
liabilities or obligations disclosed and provided for in the Company  Balance
Sheet or in the notes thereto, (b) liabilities or obligations incurred in the
ordinary course of business consistent with past practice since the Company
Balance Sheet Date, (c) liabilities arising in connection with the
transactions  contemplated hereby, or (d) other liabilities or obligations
that have not had and would not reasonably be expected to have, individually
or in the aggregate, a Company Material Adverse Effect. There are no off-
balance sheet arrangements of  any type pursuant to any off-balance sheet
arrangement required to be disclosed pursuant to Item 303(a)(4) of Regulation
S-K promulgated under the 1933 Act (" _Regulation       S-K_ ") that
have not been so described in the Company SEC Documents.

 


 

 

Section 4.12 _Litigation_. There is no claim, action, proceeding or suit or,
to the knowledge of the Company, investigation pending or, to the knowledge of
the Company, threatened (in the case of  clause (b) below, as of the date
hereof) against the Company, any of its Subsidiaries, any present or former
officers, directors or employees of the Company or any of its Subsidiaries in
their respective capacities as such, or any of the  respective properties or
assets of the Company or any of its Subsidiaries, before (or, in the case of
threatened claims, actions, suits, investigations or proceedings, that would
be before) any Governmental Authority (a) that has had or would  reasonably
be expected to have, individually or in the aggregate, a Company Material
Adverse Effect or (b) that, as of the date of this Agreement, in any manner
challenges or seeks to prevent, enjoin, alter or materially delay the Merger
or  any of the other transactions contemplated hereby. There is no Order
outstanding against the Company, any of its Subsidiaries, any present or
former officers, directors or employees of the Company or any of its
Subsidiaries in their  respective capacities as such, or any of the
respective properties or assets of any of the Company or any of its
Subsidiaries, that has had or would reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse  Effect or that,
as of the date of this Agreement, would reasonably be expected to prevent,
enjoin, alter or materially delay the Merger or any of the other transactions
contemplated hereby.

 


 

 

Section 4.13 _Permits_. Except as has not had and would not reasonably be
expected to have, individually or in the aggregate, a Company Material Adverse
Effect, the Company and each of its  Subsidiaries hold all governmental
licenses and Consents necessary for the operation of its respective businesses
(the " _Company Permits_ "). The Company and  each of its Subsidiaries are,
and since January 1, 2017 have been, in compliance with the terms of the
Company Permits, except for failures to comply that have not had and would not
reasonably be expected to have, individually or in the  aggregate, a Company
Material Adverse Effect. There is no claim, action, proceeding or suit or, to
the knowledge of the Company, investigation pending, or, to the knowledge of
the Company, threatened that seeks, or, to the knowledge of the  Company, any
existing condition, situation or set of circumstances that would reasonably be
expected to result in, the revocation, cancellation, termination, non-renewal
or adverse modification of any Company Permit, except where such  revocation,
cancellation, termination, non-renewal or adverse modification has not had and
would not reasonably be expected to have, individually or in the aggregate, a
Company Material Adverse Effect.

 


 

 

 

35    

Section 4.14 _Compliance with Laws_. The Company and each of its Subsidiaries
are, and since January 1, 2017 have been, in compliance with all Applicable
Laws, except for failures to comply that have not  had and would not
reasonably be expected to have, individually or in the aggregate, a Company
Material Adverse Effect.

 

_ 
  _

 

Section 4.15 _Regulatory Matters_.

 


 

 

(a) Except as has not had and would not reasonably  be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, (i) each
of the Company and its Subsidiaries holds (A) all authorizations under  the
United States Food, Drug and Cosmetic Act of 1938, as amended (the " _FDCA_
"), the Public Health Service Act, as amended (the " _PHSA_ "),  and the
regulations of the United States Food and Drug Administration (the " _FDA_ ")
promulgated thereunder, and (B) authorizations of any applicable Governmental
Authority that are concerned with the quality, identity, strength, purity,
safety, efficacy, manufacturing, marketing, distribution, sale,  pricing,
import or export of any of the Company Products (any such Governmental
Authority, a " _Company Regulatory Agency_ ") necessary for the lawful
operating of the businesses of the Company and each of its Subsidiaries as 
currently conducted (the " _Company Regulatory Permits_ "); (ii) all such 
Company Regulatory Permits are valid and in full force and effect; and (iii)
the Company and its Subsidiaries are in compliance with the terms of all
Company Regulatory Permits. All Company Regulatory Permits are in full force
and effect,  except where the failure to be in full force and effect has not
had and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect.

 


 

 

(b) Neither the Company nor any of its Subsidiaries  are party to any
material corporate integrity agreements, monitoring agreements, consent
decrees, settlement orders, or similar agreements with or imposed by any
Company Regulatory Agency.

 


 

 

(c) All pre-clinical and clinical investigations in  respect of a Company
Product or Company Product candidate conducted or sponsored by the Company or
any of its Subsidiaries are being and, since January 1, 2017 have been,
conducted in compliance with all Applicable Laws administered or issued  by
the applicable Company Regulatory Agencies, including (i) FDA standards for
the design, conduct, performance, monitoring, auditing, recording, analysis
and reporting of clinical trials contained in Title 21 parts 50, 54, 56, 312,
314 and  320 of the Code of Federal Regulations, and (ii) any applicable
federal, state and provincial Applicable Laws restricting the collection, use
and disclosure of individually identifiable health information and personal
information, except, in  each case, for such noncompliance that has not had
and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect.

 


 

 

 

36  

(d) Except as has not had and would not reasonably  be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, during
the period beginning on January 1, 2017 and ending on the date hereof, neither
the Company nor any of its Subsidiaries has received any written  notice from
the FDA or the European Medicines Agency (the " _EMA_ ") or any foreign agency
with jurisdiction over the development, marketing, labeling, sale,  use
handling and control, safety, efficacy, reliability, or manufacturing of the
Company Products which would reasonably be expected to lead to the denial,
limitation, revocation, or rescission of any of the Company Regulatory Permits
or of  any application for marketing approval currently pending before the
FDA or such other Company Regulatory Agency.

 


 

 

(e) During the period beginning on January 1, 2017  and ending on the date
hereof, all reports, documents, claims, permits and notices required to be
filed, maintained or furnished to the FDA or any other Company Regulatory
Agency by the Company and its Subsidiaries have been so filed,  maintained or
furnished, except where failure to file, maintain or furnish such reports,
documents, claims, permits or notices have not had and would not reasonably be
expected to have, individually or in the aggregate, a Company Material 
Adverse Effect. All such reports, documents, claims, permits and notices were
true and complete in all material respects on the date filed (or were
corrected in or supplemented by a subsequent filing). Since January 1, 2017,
neither the  Company nor any of its Subsidiaries, nor, to the knowledge of
the Company, any officer, employee, agent or distributor of the Company or any
of its Subsidiaries, has made an untrue statement of a material fact or a
fraudulent statement to the  FDA or any other Company Regulatory Agency,
failed to disclose a material fact required to be disclosed to the FDA or any
other Company Regulatory Agency, or committed an act, made a statement, or
failed to make a statement, in each such  case, related to the business of
the Company or any of its Subsidiaries, that, at the time such disclosure was
made, would reasonably be expected to provide a basis for the FDA to invoke
its policy respecting "Fraud, Untrue Statements of  Material Facts, Bribery,
and Illegal Gratuities", set forth in 56 Fed. Reg. 46191 (September 10, 1991)
or for the FDA or any other Company Regulatory Agency to invoke any similar
policy, except for any act or statement or failure to make a  statement that
has not had and would not reasonably be expected to have, individually or in
the aggregate, a Company Material Adverse Effect. Except as has not had and
would not reasonably be expected to have, individually or in the  aggregate,
a Company Material Adverse Effect, since January 1, 2017, (i) neither the
Company nor any of its Subsidiaries, nor, to the knowledge of the Company, any
officer, employee, agent or distributor of the Company or any of its 
Subsidiaries, has been debarred or convicted of any crime or engaged in any
conduct for which debarment is mandated by 21 U.S.C.  335a(a) or any similar
Applicable Law or authorized by 21 U.S.C.  335a(b) or any similar Applicable
Law  applicable in other jurisdictions in which material quantities of any of
the Company Products or Company Product candidates are sold or intended by the
Company to be sold; and (ii) neither the Company nor any of its Subsidiaries,
nor, to the  knowledge of the Company, any officer, employee, agent or
distributor of the Company or any of its Subsidiaries, has been excluded from
participation in any federal health care program or convicted of any crime or
engaged in any conduct for  which such Person could be excluded from
participating in any federal health care program under Section 1128 of the
Social Security Act of 1935, as amended, or any similar Applicable Law or
program.

 


 

 

 

37  

(f) Except as has not had and would not reasonably  be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, as to
each Company Product or Company Product candidate subject to the FDCA and the
regulations of the FDA promulgated thereunder or any similar  Applicable Law
in any foreign jurisdiction in which material quantities of any of the Company
Products or Company Product candidates are sold or intended by the Company or
any of its Subsidiaries to be sold that is or has been developed, 
manufactured, tested, distributed or marketed by or on behalf of the Company
or any of its Subsidiaries, each such Company Product or Company Product
candidate is being or has been developed, manufactured, stored, distributed
and marketed in  compliance with all Applicable Laws, including those
relating to investigational use, marketing approval, current good
manufacturing practices, packaging, labeling, advertising, record keeping,
reporting, and security. There is no action or  proceeding pending or, to the
knowledge of the Company, threatened, including any prosecution, injunction,
seizure, civil fine, debarment, suspension or recall, in each case alleging
any violation applicable to any Company Product or Company  Product candidate
by the Company or any of its Subsidiaries of any Applicable Law, except as has
not had and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect.

 


 

 

(g) Except as has not had and would not reasonably  be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, during
the period beginning on January 1, 2017 and ending on the date hereof, neither
the Company nor any of its Subsidiaries have voluntarily or  involuntarily
initiated, conducted or issued, or caused to be initiated, conducted or
issued, any material recall, field corrections, market withdrawal or
replacement, safety alert, warning, "dear doctor" letter, investigator notice,
or other  notice or action to wholesalers, distributors, retailers,
healthcare professionals or patients relating to an alleged lack of safety,
efficacy or regulatory compliance of any Company Product. To the knowledge of
the Company, there are no  facts as of the date hereof which are reasonably
likely to cause, and neither the Company nor any of its Subsidiaries has
received any written notice from the FDA or any other Company Regulatory
Agency during the period beginning on January  1, 2017 and ending on the date
hereof regarding, (i) the recall, market withdrawal or replacement of any
Company Product sold or intended to be sold by the Company or its Subsidiaries
(other than recalls, withdrawals or replacements that are  not material to
the Company and its Subsidiaries, taken as a whole), (ii) a material change in
the marketing classification or a material change in the labeling of any such
Company Products, (iii) a termination or suspension of the  manufacturing,
marketing, or distribution of such Company Products, or (iv) a material
negative change in reimbursement status of a Company Product.

 


 

 

Section 4.16 _Material Contracts_.

 


 

 

(a) _Section 4.16(a)_ of the Company Disclosure Schedule sets forth a list as
of the date of this Agreement of each of the following Contracts (other than
any Contract that is a Company Employee Plan) to  which the Company or any of
its Subsidiaries is a party or by which it is bound (each such Contract listed
or required to be so listed, and each of the following Contracts to which the
Company or any of its Subsidiaries becomes a party or by  which it becomes
bound after the date of this Agreement, a " _Company Material Contract_ "):

 


 

 

 

 

(i) any Contract, including any manufacturing, supply or distribution
agreement, that requires by its terms or is reasonably likely to require the
payment or delivery of cash or other consideration  by or to the Company or
any of its Subsidiaries in an amount having an expected value in excess of
$100,000,000 in the fiscal year ending December 31, 2018 or any fiscal year
thereafter and which cannot be terminated by the Company or  such Subsidiary
on less than sixty (60) days' notice without material payment or penalty;

 

 


 

 

 

38  

 

 

 

(ii) each Contract providing for or (in the case of subclause (B)) related to
the acquisition or disposition of assets or securities by or from any Persons
or any business (or any Contract providing  for an option, right first
refusal or offer or similar rights with respect to any of the foregoing)
(including the Abraxis CVR Agreement) (A) entered into since December 31, 2015
that involved or would reasonably be expected to involve  the payment of
consideration in excess of $250,000,000 in the aggregate with respect to such
Contract or series of related Contracts, or (B) that contains (or would
contain, in the case of an option, right of first refusal or offer or 
similar rights) (x) ongoing representations, warranties, covenants,
indemnities or other obligations (including "earn-out", contingent value
rights or other contingent payment or value obligations) that would reasonably
be expected to  involve or may require the receipt or making of payments or
the issuance of any Equity Securities of the Company or any of its
Subsidiaries in excess of $250,000,000 in the fiscal year ending December 31,
2018 or any fiscal year  thereafter or (y) any other material ongoing
obligations of the Company or any of its Subsidiaries outside of the ordinary
course of business;

 

 


 

 

 

 

 

(iii) any Contract with any Governmental Authority involving or that would
reasonably be expected to involve payments to or from any Governmental
Authority in an amount having an expected value in  excess of $50,000,000 in
the fiscal year ending December 31, 2018 or any fiscal year thereafter;

 

 


 

 

 

 

 

(iv) any Contract that (A) limits or purports to limit, in any material
respect, the freedom of the Company or any of its Subsidiaries to engage or
compete in any line of business or with any Person  or in any area or that
would so limit or purport to limit, in any material respect, the freedom of
Parent or any of its Affiliates after the Merger Effective Time, (B) contains
material exclusivity or "most favored nation" obligations or  restrictions to
which the Company or any of its Subsidiaries is subject (or, following the
Closing, to which Parent or any of its Subsidiaries would be subject) or (C)
contains any other provisions restricting or purporting to restrict  the
ability of the Company or any of its Subsidiaries to sell, market, distribute,
promote, manufacture, develop, commercialize, or test or research any current
product material to the Company or any of its Subsidiaries, directly or 
indirectly through third parties in any material respect, or that would so
limit or purport to limit Parent or any of its Affiliates after the Merger
Effective Time in any material respect;

 

 


 

 

 

 

 

(v) any Contract relating to third-party indebtedness for borrowed money
(including under any short-term financing facility), in each case in excess of
$35,000,000 (whether incurred, assumed,  guaranteed or secured by any asset)
of the Company or any of its Subsidiaries;

 

 


 

 

 

 

 

(vi) any Contract restricting the payment of dividends or the making of
distributions to stockholders or the repurchase or redemptions of stock or
other Equity Securities;

 

 


 

 

 

39  

 

 

 

(vii) any collective bargaining agreements or other agreements with any labor
organization, labor union or other employee representative with respect to
employees of the Company or any of its  Subsidiaries;

 

 


 

 

 

 

 

(viii) any material joint venture, profit-sharing, partnership, collaboration,
co-promotion, commercialization, research, development or other similar
agreement;

 

 


 

 

 

 

 

(ix) any Contract with any Person (A) pursuant to which the Company or its
Subsidiaries may be required to pay milestones, royalties or other contingent
payments based on any research, testing,  development, regulatory filings or
approval, sale, distribution, commercial manufacture or other similar
occurrences, developments, activities or events, or (B) under which the
Company or its Subsidiaries grants to any Person any right of  first refusal,
right of first negotiation, option to purchase, option to license, or any
other similar rights with respect to any Company Product or any material
Intellectual Property (or, following the Closing, with respect to any Parent 
Product or any material Intellectual Property of Parent or any of its
Subsidiaries), in each case, which payments are in an amount having an
expected value in excess of $250,000,000 in the fiscal year ending December
31, 2018 or any  fiscal year thereafter;

 

 


 

 

 

 

 

(x) any lease or sublease for real or personal property for which annual
rental payments made by the Company or any of its Subsidiaries are expected to
be in excess of $50,000,000 in the fiscal year  ending December 31, 2018 or
any fiscal year thereafter;

 

 


 

 

 

 

 

(xi) all material Contracts pursuant to which the Company or any of its
Subsidiaries (A) receives or is granted any license (including any sublicense)
to, or covenant not to be sued under, any  Intellectual Property (other than
licenses to Software that is commercially available on non-discriminatory
pricing terms) or (B) grants any license (including any sublicense) to, or
covenant not to be sued under, any Intellectual  Property (other than non-
exclusive licenses granted in the ordinary course of business), in the case of
each of clauses (A) and (B), other than any grant of a license in the ordinary
course of business in connection with any distribution  agreement (but, for
clarity, excluding any distribution agreement that was entered into in
connection with the settlement or compromise of any claim, action or
proceeding or to avoid any actual or threatened claim, action or proceeding);

 

 


 

 

 

 

 

(xii) any Contracts or other transactions with any (A) executive officer or
director of the Company, (B) record or, to the knowledge of the Company,
beneficial owner of five percent (5%) or more of the  voting securities of
the Company, or (C) affiliate (as such term is defined in Rule 12b-2
promulgated under the 1934 Act) or "associates" (or members of any of their
"immediate family") (as such terms are respectively defined in Rule  12b-2
and Rule 16a-1 of the 1934 Act) of any such executive officer, director or
beneficial owner;

 

 


 

 

 

 

 

(xiii) any Contract involving the settlement or compromise of any claim,
action or proceeding or threatened claim, action or proceeding (or series of
related, claims actions or proceedings) which  (A) involves either (1)
payments by the Company or any of its Subsidiaries after the date hereof in
excess of $100,000,000, and/or (2) any Covered Product in the United States or
Europe, or (B) imposes any materially burdensome  monitoring or reporting
obligations to any other Person outside the ordinary course of business or any
other material restrictions or liabilities on the Company or any Subsidiary of
the Company (or, following the Closing, on Parent or any  Subsidiary of
Parent);

 


 

 

 

 

 

40  

 

 

 

(xiv) [intentionally omitted]; and

 

 


 

 

 

 

 

(xv) any other Contract required to be filed by the Company pursuant to Item
601(b)(10) of Regulation S-K.

 

 


 

 

 

(b) All of the Company Material Contracts are,  subject to the Bankruptcy and
Equity Exceptions, (i) valid and binding obligations of the Company or a
Subsidiary of the Company (as the case may be) and, to the knowledge of the
Company, each of the other parties thereto, and (ii) in full  force and
effect and enforceable in accordance with their respective terms against the
Company or its Subsidiaries (as the case may be) and, to the knowledge of the
Company, each of the other parties thereto (in each case except for such 
Company Material Contracts that are terminated after the date of this
Agreement in accordance with their respective terms, other than as a result of
a default or breach by the Company or any of its Subsidiaries of any of the
provisions  thereof), except where the failure to be valid and binding
obligations and in full force and effect and enforceable has not had and would
not reasonably be expected to have, individually or in the aggregate, a
Company Material Adverse  Effect. To the knowledge of the Company, as of the
date hereof, no Person is seeking to terminate or challenging the validity or
enforceability of any Company Material Contract, except such terminations or
challenges which have not had and  would not reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect. Neither
the Company nor any of its Subsidiaries, nor, as of the date hereof and to the
knowledge of the Company, any of the other  parties thereto, has violated any
provision of, or committed or failed to perform any act that (with or without
notice, lapse of time or both) would constitute a default under any provision
of, and, as of the date hereof, neither the Company  nor any of its
Subsidiaries has received written notice that it has violated or defaulted
under, any Company Material Contract, except for those violations and defaults
(or potential defaults) which have not had and would not reasonably be 
expected to have, individually or in the aggregate, a Company Material Adverse
Effect. The Company has made available to Parent true and complete copies of
each Company Material Contract as in effect as of the date hereof.

 


 

 

Section 4.17 _Taxes_. Except as has not had and would not reasonably be
expected to have, individually or in the aggregate, a Company Material Adverse
Effect:

 


 

 

(a) All Tax Returns required by Applicable Law to be  filed with any Taxing
Authority by, or on behalf of, the Company or any of its Subsidiaries have
been filed when due (giving effect to all extensions) in accordance with all
Applicable Law, and all such Tax Returns are true and complete in  all
respects.

 


 

 

 

41  

(b) The Company and each of its Subsidiaries has  paid (or has had paid on
its behalf) all Taxes shown as due and payable on any Tax Returns, or (i)
where payment is not yet due, has established (or has had established on its
behalf and for its sole benefit and recourse) in accordance with  GAAP an
adequate accrual or (ii) where payment is being contested in good faith
pursuant to appropriate procedures, has established (or has had established on
its behalf and for its sole benefit and recourse) in accordance with GAAP an 
adequate reserve, in each case for all Taxes through the end of the last
period for which the Company and its Subsidiaries ordinarily record items on
their respective books and records.

 


 

 

(c) The Company and each of its Subsidiaries has  duly and timely withheld
all Taxes required to be withheld, and such withheld Taxes have been either
duly and timely paid to the proper Taxing Authority or properly set aside in
accounts for such purpose.

 


 

 

(d) (i) All federal income Tax Returns of the  affiliated group of which the
Company is the common parent through the Tax year ended December 31, 2008 have
been examined and closed or are Tax Returns with respect to which the
applicable period for assessment under Applicable Law, after  giving effect
to extensions or waivers, has expired, and (ii) neither the Company nor any of
its Subsidiaries (or any member of any affiliated, consolidated, combined or
unitary group of which the Company or any of its Subsidiaries is or has  been
a member) has granted any extension or waiver of the limitation period
applicable to the assessment or collection of any federal income Tax, and no
power of attorney with respect to any such Taxes has been granted to any
Person, in each  case, that remains in effect.

 


 

 

(e) There is no claim, action, suit, proceeding or  investigation (including
an audit) pending or, to the Company's knowledge, threatened in writing
against or with respect to the Company or its Subsidiaries in respect of any
Tax or Tax asset.

 


 

 

(f) There are no requests for rulings or  determinations in respect of any
Tax or Tax asset pending between the Company or any of its Subsidiaries and
any Taxing Authority. 
  
 

 

(g) During the two (2)-year period ending on the  date of this Agreement, the
Company was not a distributing corporation or a controlled corporation in a
transaction intended to be governed by Section 355 of the Code.

 


 

 

(h) There are no Liens for Taxes (other than  Permitted Liens) upon any of
the assets of the Company or any of its Subsidiaries.

 


 

 

(i) No claim has been made in writing by any  Taxing Authority in a
jurisdiction where the Company and/or the Company's Subsidiaries do not file
Tax Returns that the Company or any of its Subsidiaries is or may be subject
to taxation by, or required to file any Tax Return in, that  jurisdiction.

 


 

 

(j) Neither the Company nor any of its  Subsidiaries (i) has been a member of
an affiliated, consolidated, combined or unitary group other than one of which
the Company or any of its Subsidiaries was the common parent, (ii) is party to
any Tax Sharing Agreement (other than any such  agreement solely between the
Company and its Subsidiaries), (iii) has entered into a closing agreement
pursuant to Section 7121 of the Code, or any predecessor provision or any
similar provision of state, local or non-U.S. law or (iv) has any  liability
for the Taxes of any Person (other than the Company or any of its
Subsidiaries) under Treasury Regulation Section 1.1502-6 (or any similar
provision of state, local or non-U.S. law) or any Tax Sharing Agreement or as
a transferee or  successor.

 


 

 

 

42  

(k) Neither the Company nor any of its Subsidiaries  has engaged in any
"listed transaction" within the meaning of Treasury Regulation Section
1.6011-4(b)(2).

 


 

 

Section 4.18 _Employees and Employee Benefit Plans_.

 


 

 

(a) _Section  4.18(a)_ of the Company Disclosure Schedule sets forth a true
and complete list as of the date of this Agreement of each material Company
Employee Plan that covers employees of the Company and its Subsidiaries
working in the  United States (each, a " _U.S. Company Employee Plan_ ") and
each U.S. Company Employee Plan that is subject to ERISA. For each material
U.S. Company Employee  Plan and each U.S. Company Employee Plan that is
subject to ERISA, the Company has made available to Parent a copy of such plan
(or a description, if such plan is not written) and all amendments thereto and
material written interpretations  thereof, together with a copy of (if
applicable) (i) each trust, insurance or other funding arrangement, (ii) each
summary plan description and summary of material modifications, (iii) the most
recently filed Internal Revenue Service Forms  5500, (iv) the most recent
favorable determination or opinion letter from the Internal Revenue Service,
(v) the most recently prepared actuarial reports and financial statements in
connection with each such U.S. Company Employee Plan, and  (vi) all documents
and correspondence relating thereto received from or provided to the
Department of Labor, the PBGC, the Internal Revenue Service or any other
Governmental Authority during the past year.

 


 

 

(b) Neither the Company nor any of its ERISA  Affiliates (nor any predecessor
of any such entity) sponsors, maintains, administers or contributes to (or has
any obligation to contribute to), or has, since January 1, 2017, sponsored,
maintained, administered or contributed to (or had any  obligation to
contribute to), any plan subject to Title IV of ERISA, including any
multiemployer plan, as defined in Section 3(37) of ERISA.

 


 

 

(c) Except as has not had and would not reasonably  be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, each
Company Employee Plan that is intended to be qualified under Section 401(a) of
the Code has received a favorable determination or opinion letter  from the
Internal Revenue Service or has applied to the Internal Revenue Service for
such a letter within the applicable remedial amendment period or such period
has not expired and, to the knowledge of the Company, no circumstances exist 
that would reasonably be expected to result in any such letter being revoked
or not being reissued or a penalty under the Internal Revenue Service Closing
Agreement Program if discovered during an Internal Revenue Service audit or 
investigation. Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Company Material Adverse Effect,
each trust created under any such Company Employee Plan is exempt from tax
under Section  501(a) of the Code and has been so exempt since its creation.

 


 

 

 

43  

(d) Except as has not had and would not reasonably  be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, since
January 1, 2017, each Company Employee Plan has been maintained in compliance
with its terms and all Applicable Law, including ERISA and the Code,  and all
contributions required to have been made by the Company or any of its
Subsidiaries with respect to any benefit or compensation plan, program or
other arrangement maintained by a Governmental Authority have been timely
made. Except as  has not had and would not reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, no claim
(other than routine claims for benefits), action, suit, investigation or
proceeding (including an audit)  is pending against or involves or, to the
Company's knowledge, is threatened against or reasonably expected to involve,
any Company Employee Plan before any Governmental Authority, including the
Internal Revenue Service, the Department of  Labor or the PBGC. To the
knowledge of the Company, since January 1, 2017, no events have occurred with
respect to any Company Employee Plan that would reasonably be expected to
result in the assessment of any excise taxes or penalties  against the
Company or any of its Subsidiaries, except for events that have not had and
would not reasonably be expected to have, individually or in the aggregate, a
Company Material Adverse Effect.

 


 

 

(e) Except as has not had and would not reasonably  be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, with
respect to each director, officer, or employee (including each former
director, officer, or employee) of the Company or any of its Subsidiaries, 
the consummation of the transactions contemplated by this Agreement will not,
either alone or together with any other event: (i) entitle any such individual
to any payment or benefit, including any bonus, retention, severance,
retirement or  job security payment or benefit, (ii) accelerate the time of
payment or vesting or trigger any payment or funding (through a grantor trust
or otherwise) of compensation or benefits under, or increase the amount
payable or trigger any other  obligation under, any Company Employee Plan or
(iii) contractually limit or restrict the right of the Company or any of its
Subsidiaries or, after the Closing, Parent to merge, amend or terminate any
material Company Employee Plan.

 


 

 

(f) Neither the Company nor any of its Subsidiaries  has any material current
or projected liability for, and no Company Employee Plan provides or promises,
any material post-employment or post-retirement medical, dental, disability,
hospitalization, life or similar benefits (whether insured or  self-insured)
to any director, officer, or employee (including any former director, officer,
or employee) of the Company or any of its Subsidiaries (other than coverage
mandated by Applicable Law).

 


 

 

(g) Neither the Company nor any of its Subsidiaries  has any obligation to
gross-up, indemnify or otherwise reimburse any Person for any Tax incurred by
such Person under Section 409A or 4999 of the Code.

 


 

 

(h) Except as has not had and would not reasonably  be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, with
respect to any Company Employee Plan covered by Subtitle B, Part 4 of Title I
of ERISA or Section 4975 of the Code, no non-exempt prohibited  transaction
has occurred that has caused or would reasonably be expected to cause the
Company or any of its Subsidiaries to incur any liability under ERISA or the
Code.

 


 

 

 

44  

Section 4.19 _Labor Matters_.

 


 

 

(a) Except as has not had and would not reasonably  be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, the
Company and its Subsidiaries are, and since January 1, 2017 have been, in
compliance with all Applicable Laws relating to labor and employment, 
including those relating to labor management relations, wages, hours,
overtime, employee classification, discrimination, sexual harassment, civil
rights, affirmative action, work authorization, immigration, safety and
health, information  privacy and security, workers compensation, continuation
coverage under group health plans, wage payment and the payment and
withholding of taxes.

 


 

 

(b) Neither the Company nor any of its Subsidiaries  is, or since January 1,
2017 has been, a party to or subject to, or is currently negotiating in
connection with entering into, any collective bargaining agreement or any
other similar agreement with respect to employees of the Company or any  of
its Subsidiaries with any labor organization, labor union or other employee
representative, and, to the Company's knowledge, since January 1, 2017 through
the date hereof, there has not been any organizational campaign, card
solicitation,  petition or other unionization or similar activity seeking
recognition of a collective bargaining or similar unit relating to any
director, officer or employee of the Company or any of its Subsidiaries.
Except as has not had and would not  reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, (i) there
are no unfair labor practice complaints pending or, to the Company's
knowledge, threatened against the Company or any of its  Subsidiaries before
the National Labor Relations Board or any other Governmental Authority or any
current union representation questions involving any director, officer, or
employee (including any former director, officer, or employee) of the 
Company or any of its Subsidiaries with respect to the Company or its
Subsidiaries, and (ii) there is no labor strike, slowdown, stoppage,
picketing, interruption of work or lockout pending or, to the Company's
knowledge, threatened against  or affecting the Company or any of its
Subsidiaries.

 


 

 

Section 4.20 _Intellectual Property_.

 


 

 

(a) The Company has made available to Parent a true  and complete list, as of
the date of this Agreement, of all issued U.S. patents and registrations for
U.S. trademarks and U.S. patent applications and applications for registration
of U.S. trademarks, in each case, constituting Owned  Intellectual Property
included in the Company Intellectual Property, or that are included in the
Company Intellectual Property and are exclusively inlicensed by the Company
or any of its Subsidiaries, in each case, that are material to any  Company
Pipeline Products or are material to the current or currently planned
commercialization of any other Covered Product (including the exercise of any
Covered Rights with respect thereto) (the " _Scheduled Covered Product IP_ ").
Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, (i) no
Scheduled Covered  Product IP has lapsed, expired, been abandoned or been
adjudged invalid or unenforceable, and (ii) to the knowledge of the Company,
all Company Registered IP is subsisting, and if registered, valid and
enforceable.

 


 

 

 

45  

(b) Except as has not had and would not reasonably  be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, (i) the
Company and its Subsidiaries (A) are the sole and exclusive owners of all
Owned Intellectual Property that is (1) Scheduled Covered Product IP,   (2) a
related U.S. or global issued or pending patent, or (3) material Company
Intellectual Property that relates to any Covered Product; (B) either own, or
have a valid and enforceable right to use all Company Intellectual Property
that  relates to any Company Product (other than a Covered Product) in any
material respect; and (C) have the exclusive right to make, use, offer for
sale, sell, import or otherwise commercialize the Covered Products, and, with
respect to the  foregoing clauses (A) through (C), hold all of their right,
title and interest in and to all of the Company Intellectual Property free and
clear of all Liens other than Permitted Liens, and (ii) to the knowledge of
the Company, the Company's  and its Subsidiaries' Owned Intellectual Property
and the Company's and its Subsidiaries' Licensed Intellectual Property,
together with any other Intellectual Property that the Company or any of its
Subsidiaries is otherwise permitted to use  (including by way of a release,
covenant not to sue or immunity from suit), constitutes all of the
Intellectual Property necessary to, or used or held for use in, the conduct of
the respective businesses of the Company and its Subsidiaries as  currently
conducted and as currently planned to be conducted prior to Closing (including
as may be necessary to exercise the Covered Rights with respect to any Covered
Product).

 


 

 

(c) Except as has not had and would not reasonably  be expected to have,
individually or in the aggregate, a Company Material Adverse Effect (and
except as disclosed by the Company to Parent during the course of Parent's due
diligence prior to the date hereof), during the past four (4) years  (i) to
the knowledge of the Company, neither the Company nor any of its Subsidiaries
nor the conduct of their respective businesses has infringed, misappropriated,
diluted or otherwise violated any Intellectual Property rights of any Third 
Party (or will, to the knowledge of the Company, infringe, misappropriate or
otherwise violate the Intellectual Property rights of any Third Party through
the exercise prior to or after Closing of any Covered Rights with respect to
any  Covered Product), (ii) there is no claim, action, proceeding or suit or,
to the knowledge of the Company, investigation pending or, to the knowledge of
the Company, threatened against or affecting the Company or any of its
Subsidiaries (A)  alleging that the Company or any of its Subsidiaries has
infringed, misappropriated, diluted or otherwise violated any Intellectual
Property rights of any Third Party (including due to the exercise of any
Covered Rights with respect to any  Covered Products), or (B) based upon, or
challenging or seeking to deny or restrict, the rights of the Company or any
of its Subsidiaries in any of the Company Intellectual Property (including any
challenges to the validity, enforceability,  registerability, inventorship,
ownership or use of any of the Company Intellectual Property that is Owned
Intellectual Property), and (iii) to the knowledge of the Company, no Third
Party has infringed, misappropriated, diluted or otherwise  violated any of
the Company Intellectual Property that is Owned Intellectual Property.
Notwithstanding anything contained herein, the representations and warranties
set forth herein shall be read without application of 35 U.S.C. 271(e)(1) 
(the statutory research exemption) and any similar Applicable Laws outside the
U.S. to the same extent as if such Applicable Laws did not exist.

 


 

 

 

46  

(d) Except as has not had and would not reasonably  be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, (i) since
January 1, 2017, the Company and its Subsidiaries have provided reasonable
notice of its privacy and personal data collection and use policies  on its
websites and other customer and public communications and the Company and its
Subsidiaries have complied since January 1, 2017 with such policies and all
Applicable Laws relating to (A) the privacy of the users of the Company's and
its  Subsidiaries' respective products, services and websites and (B) the
collection, use, storage and disclosure of any personally-identifiable
information (including personal health information), (ii) since January 1,
2017, there is no claim,  action, proceeding or suit or, to the knowledge of
the Company, investigation pending or, to the knowledge of the Company,
threatened against the Company or any of its Subsidiaries alleging any
violation of such policies or Applicable Laws,  (iii) neither this Agreement
nor the consummation of the transactions contemplated hereby will violate any
such policy or Applicable Laws, and (iv) the Company and its Subsidiaries have
taken commercially reasonable steps to protect the types  of information
referred to in this _Section 4.20(d)_ against loss and unauthorized access,
use, modification, disclosure or other misuse, and, to the  knowledge of the
Company, since January 1, 2017, there has been no unauthorized access, use,
modification, disclosure or other misuse of such data or information.

 


 

 

(e) Except as has not had, and would not reasonably  be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, (i) the
Company's IT Assets operate in a manner that permits the Company and its
Subsidiaries to conduct their respective businesses as currently  conducted,
(ii) the Company and its Subsidiaries take commercially reasonable actions to
protect the confidentiality, integrity and security of the Company's IT Assets
(and all data and other information and transactions stored or contained 
therein or transmitted thereby) against any unauthorized use, access,
interruption, modification or corruption, including the implementation of
commercially reasonable data backup, disaster avoidance and recovery
procedures and business  continuity procedures, and (iii) since January 1,
2017, to the knowledge of the Company, there has been no unauthorized use or
access or security breaches, or interruption, modification, loss or corruption
of any of the Company's IT Assets  (or any data or other information or
transactions stored or contained therein or transmitted thereby).

 


 

 

Section 4.21 _Properties_. Except as has not had and would not reasonably be
expected to have, individually or in the aggregate, a Company Material Adverse
Effect, (a) the Company and each of its  Subsidiaries has good, valid and
marketable fee simple title to, or valid leasehold interests in, as the case
may be, each parcel of real property of the Company or any of its
Subsidiaries, free and clear of all Liens, except for Permitted  Liens, (b)
each lease, sublease or license (each, a " _Lease_ ") under which the Company
or any of its Subsidiaries leases, subleases or licenses any real  property
is, subject to the Bankruptcy and Equity Exceptions, a valid and binding
obligation of the Company or a Subsidiary of the Company (as the case may be)
and, to the knowledge of the Company, each of the other parties thereto, and
in  full force and effect and enforceable in accordance with its terms
against the Company or its Subsidiaries (as the case may be) and, to the
knowledge of the Company, each of the other parties thereto (except for such
Leases that are  terminated after the date of this Agreement in accordance
with their respective terms, other than as a result of a default or breach by
the Company or any of its Subsidiaries of any of the provisions thereof), (c)
neither the Company nor any  of its Subsidiaries, nor, to the knowledge of
the Company, any of the other parties thereto has violated or committed or
failed to perform any act which (with or without notice, lapse of time or
both) would constitute a default under any  provision of any Lease, and (d)
neither the Company nor any of its Subsidiaries has received written notice
that it has violated or defaulted under any Lease.

 


 

 

Section 4.22 _Environmental Matters_. Except as has not had and would not
reasonably be expected to have, individually or in the aggregate, a Company
Material Adverse Effect:

 


 

 

 

47  

(a) no notice, notification, demand, request for  information, citation,
summons or order has been received, no complaint has been filed, no penalty
has been assessed, and no claim, action, proceeding or suit or, to the
knowledge of the Company, investigation (including a review) is pending  or,
to the knowledge of the Company, threatened by any Governmental Authority or
other Person relating to the Company or any of its Subsidiaries that relates
to, or arises under, any Environmental Law, Environmental Permit or
Hazardous  Substance;

 


 

 

(b) the Company and its Subsidiaries are, and since  January 1, 2017 have
been, in compliance with all Environmental Laws and all Environmental Permits
and hold all applicable Environmental Permits; and

 


 

 

(c) there are no liabilities or obligations of the  Company or any of its
Subsidiaries of any kind whatsoever, whether accrued, contingent, absolute,
determined, determinable or otherwise arising under or relating to any
Environmental Law, Environmental Permit or Hazardous Substance and there  is
no existing condition, situation or set of circumstances that could reasonably
be expected to result in any such liability or obligation.

 


 

 

Section 4.23 _FCPA; Anti-Corruption; Sanctions_.

 

_ 
  _

 

(a) Except as has not had and would not reasonably  be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, neither
the Company nor any of its Subsidiaries, nor, to the knowledge of the Company,
any director, manager, employee, agent or representative of the  Company or
any of its Subsidiaries, in each case acting on behalf of the Company or any
of its Subsidiaries, has, in the last five (5) years, in connection with the
business of the Company or any of its Subsidiaries, taken any action in 
violation of the FCPA or other applicable Bribery Legislation (in each case to
the extent applicable).

 


 

 

(b) Neither the Company nor any of its Subsidiaries  nor, to the knowledge of
the Company, any director, manager or employee of the Company or any of its
Subsidiaries, is, or in the last five (5) years has been, subject to any
actual or pending or, to the knowledge of the Company, threatened  civil,
criminal, or administrative actions, suits, demands, claims, hearings, notices
of violation, investigations, proceedings, demand letters, settlements, or
enforcement actions, or made any voluntary disclosures to any Governmental 
Authority, involving the Company or any of its Subsidiaries relating to
applicable Bribery Legislation, including the FCPA.

 


 

 

(c) The Company and each of its Subsidiaries has  made and kept books and
records, accounts and other records, which, in reasonable detail, accurately
and fairly reflect in all material respects the transactions and dispositions
of the assets of the Company and each of its Subsidiaries as  required by the
FCPA.

 


 

 

(d) The Company and each of its Subsidiaries has  instituted policies and
procedures reasonably designed to ensure compliance in all material respects
with the FCPA and other applicable Bribery Legislation and maintain such
policies and procedures in force.

 


 

 

(e) To the knowledge of the Company, no officer,  director, or employee of
the Company or any of its Subsidiaries is a Government Official.

 


 

 

 

48  

(f) Except as has had not and would not reasonably  be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, none of
the Company or any of its Subsidiaries, nor, to the knowledge of the Company,
any of their respective directors, managers or employees (i) is a  Sanctioned
Person, (ii) has, in the last five (5) years, engaged in, has any plan or
commitment to engage in, direct or indirect dealings with any Sanctioned
Person or in any Sanctioned Country on behalf of the Company or any of its 
Subsidiaries in violation of applicable Sanctions Law or (iii) has, in the
last five (5) years, violated, or engaged in any conduct sanctionable under,
any Sanctions Law, nor to the knowledge of the Company, been the subject of
an  investigation or allegation of such a violation or sanctionable conduct. 
  
 

 

Section 4.24 _Insurance_. Except as has not had and would not reasonably be
expected to have, individually or in the aggregate, a Company Material Adverse
Effect, the Company and its Subsidiaries  maintain insurance coverage with
reputable insurers in such amounts and covering such risks as the Company
reasonably believes, based on past experience, is adequate for the businesses
and operations of the Company and its Subsidiaries  (taking into account the
cost and availability of such insurance).

 


 

 

Section 4.25 _Transactions with Affiliates_. To the knowledge of the Company
and as of the date of this Agreement, since January 1, 2017, there have been
no transactions, or series of related  transactions, agreements, arrangements
or understandings in effect, nor are there any currently proposed
transactions, or series of related transactions, agreements, arrangements or
understandings, that would be required to be disclosed under  Item 404(a) of
Regulation S-K that have not been otherwise disclosed in the Company SEC
Documents filed prior to the date hereof.

 


 

 

Section 4.26 _Antitakeover Statutes_. Assuming the representations and
warranties set forth in _Section 5.26_   are true and correct, neither the
restrictions set forth in Section 203 of the DGCL nor any other "control share
acquisition," "fair price," "moratorium" or other antitakeover laws enacted
under U.S. state or federal laws apply to this  Agreement or any of the
transactions contemplated hereby.

 


 

 

Section 4.27 _Opinions of Financial Advisors_. The Board of Directors of the
Company has received the opinion of each of J.P. Morgan Securities LLC and
Citigroup Global Markets Inc., financial  advisors to the Company, each to
the effect that, as of the date of such respective opinion and based upon and
subject to the various assumptions, limitations, qualifications and other
matters set forth therein, the Merger Consideration to be  paid to the
holders of Company Common Stock in the Merger pursuant to this Agreement is
fair, from a financial point of view, to such holders. A written copy of each
such opinion will be delivered promptly to Parent after the date hereof for 
informational purposes only.

 


 

 

Section 4.28 _Finders ' Fees_. Except for J.P. Morgan Securities LLC and
Citigroup Global Markets Inc., there is no investment banker, broker, finder
or other intermediary that has been retained by  or is authorized to act on
behalf of the Company or any of its Subsidiaries (collectively, the " _Company
Bankers_ ") who might be entitled to any fee or  commission from the Company
or any of its Affiliates in connection with the transactions contemplated by
this Agreement. _Section 4.28_ of the Company  Disclosure Schedule sets forth
the aggregate amount of fees and commissions that are or would be payable to
each Company Banker in connection with the transactions contemplated by this
Agreement.

 


 

 

 

49  

Section 4.29 _No Ownership of Parent Common Stock_. Neither the Company nor
any of its Subsidiaries beneficially owns, directly or indirectly, any shares
of Parent Common Stock or other securities  convertible into, exchangeable
for or exercisable for shares of Parent Common Stock, and neither the Company
nor any of its Subsidiaries has any rights to acquire any shares of Parent
Common Stock (other than any such securities owned by the  Company or any of
its Subsidiaries in a fiduciary, representative or other capacity on behalf of
other Persons, whether or not held in a separate account). There are no voting
trusts or other agreements or understandings to which the Company  or any of
its Subsidiaries is a party with respect to the voting of the capital stock or
other Equity Securities of Parent or any of its Subsidiaries.

 


 

 

Section 4.30 _No Other Company Representations and Warranties_. Except for the
representations and warranties made by the Company in this _Article IV_ (as
qualified by the applicable items disclosed in the Company Disclosure Schedule
in accordance with Section _11.05_   and the introduction to this _Article
IV_ ), neither the Company nor any other Person makes or has made any
representation or warranty, expressed or implied,  at law or in equity, with
respect to or on behalf of the Company or its Subsidiaries, their businesses,
operations, assets, liabilities, financial condition, results of operations,
future operating or financial results, estimates,  projections, forecasts,
plans or prospects (including the reasonableness of the assumptions underlying
such estimates, projections, forecasts, plans or prospects) or the accuracy or
completeness of any information regarding the Company or its  Subsidiaries or
any other matter furnished or provided to Parent or made available to Parent
in any "data rooms," "virtual data rooms," management presentations or in any
other form in expectation of, or in connection with, this Agreement or  the
transactions contemplated hereby. The Company and its Subsidiaries disclaim
any other representations or warranties, whether made by the Company or any of
its Subsidiaries or any of their respective Affiliates or Representatives.
The  Company acknowledges and agrees that, except for the representations and
warranties made by Parent in _Article V_ (as qualified by the applicable
items  disclosed in the Parent Disclosure Schedule in accordance with Section
_11.05_ and the introduction to _Article V_ ), neither Parent nor any other
Person is making or has made any representations or warranty, expressed or
implied, at law or in equity, with respect to or on behalf of Parent or its 
Subsidiaries, their businesses, operations, assets, liabilities, financial
condition, results of operations, future operating or financial results,
estimates, projections, forecasts, plans or prospects (including the
reasonableness of the  assumptions underlying such estimates, projections,
forecasts, plans or prospects) or the accuracy or completeness of any
information regarding Parent or its Subsidiaries or any other matter furnished
or provided to Parent or made available  to the Company in any "data rooms,"
"virtual data rooms," management presentations or in any other form in
expectation of, or in connection with, this Agreement, or the transactions
contemplated hereby or thereby. The Company specifically  disclaims that it
is relying upon or has relied upon any such other representations or
warranties that may have been made by any Person, and acknowledges and agrees
that Parent and its Affiliates have specifically disclaimed and do hereby 
specifically disclaim any such other representations and warranties.

 


 

 

 

50  

ARTICLE V 
  
  REPRESENTATIONS AND WARRANTIES OF PARENT

 


 

 

Subject to _Section 11.05_ , except  (i) as disclosed in any publicly
available Parent SEC Document or (ii) as set forth in the Parent's Disclosure
Schedule, Parent and Merger Sub jointly and severally represent and warrant to
the Company that:

 


 

 

Section 5.01 _Corporate Existence and Power_. Parent is a corporation duly
incorporated, validly existing and in good standing under the laws of the
State of Delaware, and Merger Sub is a  corporation duly incorporated,
validly existing and in good standing under the laws of the State of Delaware.
Each of Parent and Merger Sub has all requisite corporate power and authority
required to own or lease all of its properties or  assets and to carry on its
business as now conducted. Each of Parent and Merger Sub is duly qualified to
do business and is in good standing in each jurisdiction where such
qualification is necessary, except for those jurisdictions where  failure to
be so qualified or in good standing has not had and would not reasonably be
expected to have, individually or in the aggregate, a Parent Material Adverse
Effect. Parent directly owns all of the outstanding shares of capital stock 
of Merger Sub. Prior to the date of this Agreement, Parent has made available
to the Company true and complete copies of the certificate of incorporation
and bylaws of each of Parent and Merger Sub, in each case, as in effect on the
date of  this Agreement (the " _Parent Organizational Documents_ "). Since
the date of its incorporation, Merger Sub has not engaged in any activities
other than (a) in connection with the preparation,  negotiation and execution
of this Agreement or the consummation of the transactions contemplated hereby
or as expressly contemplated by this Agreement or (b) those incident or
related to its incorporation.

 


 

 

Section 5.02 _Corporate Authorization_.

 


 

 

(a) The execution, delivery and performance by each  of Parent and Merger Sub
of this Agreement and the consummation by Parent and Merger Sub of the
transactions contemplated by this Agreement (including, in the case of Parent,
the entry into the New CVR Agreement at or immediately prior to the  Merger
Effective Time) are within the corporate powers and authority of each of
Parent and Merger Sub and, except for the Parent Stockholder Approval and the
required approval of the stockholder of Merger Sub in connection with the 
transactions contemplated by this Agreement (including the Merger), have been
duly authorized by all necessary corporate action on the part of Parent and
Merger Sub. The affirmative vote of at least a majority of the votes cast by
holders of  outstanding shares of Parent Common Stock at a duly called and
held meeting of Parent's stockholders at which a quorum is present approving
the issuance of shares of Parent Common Stock in connection with the Merger
(the " _Parent Share Issuance_ ") is the only vote of the holders of any of
Parent's capital stock necessary in connection with the consummation of the
Merger (the " _Parent Stockholder Approval_ "). This Agreement has been duly
executed and delivered by each of Parent and Merger Sub and (assuming due
authorization, execution and delivery by the Company)  constitutes a valid,
legal and binding agreement of each of Parent and Merger Sub enforceable
against Parent and Merger Sub in accordance with its terms (subject to the
Bankruptcy and Equity Exceptions), and the New CVR Agreement will, at the 
time of its execution by Parent, be duly executed and delivered by Parent and
constitute a valid, legal and binding agreement of Parent enforceable against
Parent in accordance with its terms (subject to the Bankruptcy and Equity
Exceptions).

 


 

 

 

51  

(b) At a meeting duly called and held, the Board of  Directors of Parent
adopted resolutions (i) determining that this Agreement and the transactions
contemplated hereby (including the Parent Share Issuance) are fair to and in
the best interests of Parent and its stockholders, (ii) approving,  adopting
and declaring advisable this Agreement and the transactions contemplated
hereby (including the Parent Share Issuance), (iii) directing that the
approval of the Parent Share Issuance be submitted to a vote at a meeting of
Parent's  stockholders and (iv) recommending approval of the Parent Share
Issuance by Parent's stockholders (such recommendation, the " _Parent Board
Recommendation_ ").        Except as permitted by _Section 7.02_ , the
Board of Directors of Parent has not subsequently rescinded, modified or
withdrawn any of the foregoing  resolutions.

 


 

 

(c) The Board of Directors of Merger Sub has  unanimously adopted resolutions
(i) determining that this Agreement and the transactions contemplated hereby
(including the Merger) are fair to and in the best interests of Merger Sub and
its stockholder, (ii) approving, adopting and  declaring advisable this
Agreement and the transactions contemplated hereby (including the Merger),
(iii) directing that the approval and adoption of this Agreement be submitted
to a vote of Merger Sub's stockholder and (iv) recommending  approval and
adoption of this Agreement by Merger Sub's stockholder.

 


 

 

Section 5.03 _Governmental Authorization_. The execution, delivery and
performance by each of Parent and Merger Sub of this Agreement and the
consummation by each of Parent and Merger Sub of the  transactions
contemplated hereby require no action by or in respect of, Consents of, or
Filings with, any Governmental Authority other than (a) the filing of the
Certificate of Merger with the Delaware Secretary of State and appropriate 
documents with the relevant authorities of other states in which Parent or
Merger Sub is qualified to do business, (b) compliance with any applicable
requirements of the HSR Act, (c) compliance with and Filings under any
applicable Foreign  Antitrust Laws, (d) compliance with any applicable
requirements of the 1933 Act, the 1934 Act and any other applicable U.S. state
or federal securities laws or pursuant to the rules of the NYSE, (d) in the
case of the New CVR Agreement and  the transactions contemplated thereby,
compliance with any requirements of the Trust Indenture Act of 1939 (the "
_Trust Indenture Act_ ") and (e) any other  actions, Consents or Filings the
absence of which has not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect.

 


 

 

Section 5.04 _Non-contravention_. The execution, delivery and performance by
each of Parent and Merger Sub of this Agreement and the consummation of the
transactions contemplated hereby do not and  will not (a) contravene,
conflict with, or result in any violation or breach of any provision of the
Parent Organizational Documents, (b) assuming compliance with the matters
referred to in _Section 5.03_ and receipt of the Parent Stockholder Approval,
contravene, conflict with or result in any violation or breach of any
provision of any Applicable Law, (c) assuming compliance with the  matters
referred to in _Section 5.03_ and receipt of the Parent Stockholder Approval,
require any Consent or other action by any Person under, constitute a 
default, or an event that, with or without notice or lapse of time or both,
would constitute a default under, or cause or permit the termination,
cancellation, acceleration or other change of any right or obligation or the
loss of any benefit  to which Parent or any of its Subsidiaries is entitled
under, any provision of any Parent Permit or any Contract binding upon Parent
or any of its Subsidiaries, or (d) result in the creation or imposition of any
Lien on any asset of Parent or  any of its Subsidiaries, except, in the case
of each of clauses (b) through (d), as has not had and would not reasonably be
expected to have, individually or in the aggregate, a Parent Material Adverse
Effect.

 


 

 

 

52  

Section 5.05 _Capitalization_.

 


 

 

(a) The authorized capital stock of Parent consists  of (i) 4,500,000,000
shares of Parent Common Stock, (ii) 10,000,000 shares of preferred stock, par
value $1.00 per share (" _Parent Preferred Stock_ ") and  (iii) 1,300,188
shares of $2 Convertible Preferred Stock, par value $1.00 per share (" _Parent
Convertible Preferred Stock_ "). As of December 31, 2018, there  were
outstanding (A) 1,632,464,617.509 shares of Parent Common Stock, (B) no shares
of Parent Preferred Stock, (C) 3,605 shares of Parent Convertible Preferred
Stock, (D) options to purchase shares of Parent Common Stock (" _Parent Stock
Options_ ") with respect to an aggregate of 1,666,999 shares of Parent Common
Stock, (E) 4,993,334 restricted stock units under Parent's equity 
compensation plans (" _Parent Restricted Stock Units_ "), (F) 1,475,713 market
share units under Parent's employee stock benefit plan (" _Market Based Units_
"), determined assuming target performance levels were assumed, and (G)
2,819,421 performance share units under Parent's employee stock benefit plan
(" _Performance Share Units_ "), determined assuming target performance levels
were achieved (together with Parent Stock Options, Parent Restricted Stock
Units,  Market Based Units, Performance Share Units and any other equity or
equity-linked awards granted after December 31, 2018, " _Parent Equity Awards_
"). The  shares of Parent Common Stock to be issued as part of the Merger
Consideration have been duly authorized and, when issued and delivered in
accordance with the terms of this Agreement, will have been validly issued and
will be fully paid and  nonassessable and the issuance thereof will be free
of preemptive rights. Parent owns all of the issued and outstanding capital
stock of Merger Sub. Except as set forth in this _Section 5.05(a)_ and for
changes since December 31, 2018 resulting from (x) the exercise or vesting and
settlement of Parent Equity Awards outstanding on such date or issued on or
after such date to the extent  permitted by _Section 6.01_ , or (y) the
issuance of Equity Securities of Parent on or after the date hereof to the
extent permitted by _Section 6.01_ , there are no issued, reserved for
issuance or outstanding Equity Securities of Parent.

 


 

 

(b) All outstanding shares of capital stock of  Parent have been, and all
shares that may be issued pursuant to any employee stock option or other
compensation plan or arrangement will be, when issued in accordance with the
respective terms thereof, duly authorized and validly issued,  fully paid and
nonassessable and free of preemptive rights. No Subsidiary of Parent owns any
shares of capital stock of Parent (other than any such shares owned by
Subsidiaries of Parent in a fiduciary, representative or other capacity on 
behalf of other Persons, whether or not held in a separate account). There are
no outstanding bonds, debentures, notes or other indebtedness of Parent having
the right to vote (or convertible into, or exchangeable for, securities having
the  right to vote) on any matters on which stockholders of Parent have the
right to vote. There are no outstanding obligations of Parent or any of its
Subsidiaries to repurchase, redeem or otherwise acquire any Equity Securities
of Parent.   Neither Parent nor any of its Subsidiaries is a party to any
agreement with respect to the voting of any Equity Securities of Parent.

 


 

 

 

53  

Section 5.06 _Subsidiaries_.

 


 

 

(a) Each Major Subsidiary of Parent is a corporation  or other entity duly
incorporated or organized, validly existing and in good standing (except to
the extent such concept is not applicable under Applicable Law of such
Subsidiary's jurisdiction of incorporation, formation or organization, as 
applicable) under the laws of its jurisdiction of incorporation, formation or
organization, as applicable, and has all corporate or other organizational
powers and authority, as applicable, required to own, lease and operate its
properties  and assets and to carry on its business as now conducted, except
for those jurisdictions where failure to be so organized, validly existing and
in good standing or to have such power or authority has not had and would not
reasonably be  expected to have, individually or in the aggregate, a Parent
Material Adverse Effect. Each such Major Subsidiary is duly qualified to do
business and is in good standing in each jurisdiction where such qualification
is necessary, except for  those jurisdictions where failure to be so
qualified or in good standing has not had and would not reasonably be expected
to have, individually or in the aggregate, a Parent Material Adverse Effect.

 


 

 

(b) All of the issued and outstanding capital stock  or other Equity
Securities of each Subsidiary of Parent have been validly issued and are fully
paid and nonassessable (except to the extent such concepts are not applicable
under Applicable Law of such Subsidiary's jurisdiction of  incorporation,
formation or organization, as applicable) and are owned by Parent, directly or
indirectly, free and clear of any Lien (other than any restrictions imposed by
Applicable Law) and free of preemptive rights, rights of first  refusal,
subscription rights or similar rights of any Person and transfer restrictions
(other than transfer restrictions under Applicable Law or under the
organizational documents of such Subsidiary). There are no outstanding
obligations of  Parent or any of its Subsidiaries to repurchase, redeem or
otherwise acquire any Equity Securities of any Subsidiary of Parent. Except
for the capital stock or other Equity Securities of its Subsidiaries and
publicly traded securities held  for investment which do not exceed five
percent (5%) of the outstanding securities of any entity, Parent does not own,
directly or indirectly, any capital stock or other Equity Securities of any
Person.

 


 

 

Section 5.07 _SEC Filings and the Sarbanes-Oxley Act_.

 


 

 

(a) Parent has timely filed with or furnished to the  SEC all reports,
schedules, forms, statements, prospectuses, registration statements and other
documents required to be filed with or furnished to the SEC by Parent since
January 1, 2017 (collectively, together with any exhibits and schedules 
thereto and other information incorporated therein, the " _Parent SEC
Documents_ "). No Subsidiary of Parent is required to file any report,
schedule, form,  statement, prospectus, registration statement or other
document with the SEC.

 


 

 

(b) As of its filing date (or, if amended or  superseded by a filing prior to
the date of this Agreement, on the date of such amended or superseding
filing), the Parent SEC Documents filed or furnished prior to the date of this
Agreement complied, and each Parent SEC Document filed or  furnished
subsequent to the date of this Agreement (assuming, in the case of each of the
Registration Statement and the Joint Proxy Statement/Prospectus, that the
representation and warranty set forth in _Section 4.09_ is true and correct)
will comply, in all material respects with the applicable requirements of the
NYSE, the 1933 Act, the 1934 Act and the Sarbanes-Oxley Act, as the case  may
be.

 


 

 

 

54  

(c) As of its filing date (or, if amended or  superseded by a filing prior to
the date of this Agreement, on the date of such amended or superseding
filing), each Parent SEC Document filed or furnished prior to the date of this
Agreement did not, and each Parent SEC Document filed or  furnished
subsequent to the date of this Agreement (assuming, in the case of each of the
Registration Statement and the Joint Proxy Statement/Prospectus, that the
representation and warranty set forth in _Section 4.09_ is true and correct)
will not, contain any untrue statement of a material fact or omit to state any
material fact necessary in order to make the statements made therein,  in
light of the circumstances under which they were made, not misleading.

 


 

 

(d) Parent is, and since January 1, 2017 has been,  in compliance in all
material respects with (i) the applicable provisions of the Sarbanes-Oxley Act
and (ii) the applicable listing and corporate governance rules and regulations
of the NYSE.

 


 

 

(e) Except as has not had and would not reasonably  be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, Parent and
its Subsidiaries have established and maintain disclosure controls and
procedures (as defined in Rule 13a-15 under the 1934 Act) designed to  ensure
that material information relating to Parent, including its consolidated
Subsidiaries, is made known to Parent's principal executive officer and its
principal financial officer by others within those entities, including during
the  periods in which the periodic reports required under the 1934 Act are
being prepared.

 


 

 

(f) Except as has not had and would not reasonably  be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, Parent and
its Subsidiaries have established and maintain a system of internal controls
designed to provide reasonable assurance regarding the  reliability of
Parent's financial reporting and the preparation of Parent's financial
statements for external purposes in accordance with GAAP, and Parent's
principal executive officer and principal financial officer have disclosed,
based on  their most recent evaluation of such internal controls prior to the
date of this Agreement, to Parent's auditors and the audit committee of the
Board of Directors of Parent (i) all significant deficiencies and material
weaknesses in the  design or operation of internal controls which are
reasonably likely to adversely affect Parent's ability to record, process,
summarize and report financial information and (ii) any fraud, whether or not
material, that involves management or  other employees who have a significant
role in internal controls. Parent has made available to the Company prior to
the date of this Agreement a true and complete (in all material respects)
summary of any disclosure of the type described in  the preceding sentence
made by management to Parent's auditors and audit committee during the period
beginning January 1, 2017 and ending as of the date hereof.

 


 

 

(g) Since January 1, 2017, each of the principal  executive officer and
principal financial officer of Parent (or each former principal executive
officer and principal financial officer of Parent, as applicable) has made all
certifications required by Rules 13a-14 and 15d-14 under the 1934  Act and
Sections 302 and 906 of the Sarbanes-Oxley Act and any related rules and
regulations promulgated by the SEC and the NYSE, and the statements contained
in any such certifications are true and complete in all material respects as
of the  date on which they were made.

 


 

 

 

55  

Section 5.08 _Financial Statements and Financial Matters_.

 


 

 

(a) The audited consolidated financial statements  and unaudited consolidated
interim financial statements of Parent included or incorporated by reference
in the Parent SEC Documents present fairly in all material respects, in
conformity with GAAP applied on a consistent basis during the  periods
presented (except as may be indicated in the notes thereto), the consolidated
financial position of Parent and its Subsidiaries as of the dates thereof and
their consolidated results of operations and cash flows for the periods then 
ended (subject to normal and recurring year-end audit adjustments in the case
of any unaudited interim financial statements). Such consolidated financial
statements have been prepared in all material respects from the books and
records of  Parent and its Subsidiaries.

 


 

 

(b) From January 1, 2017 to the date of this  Agreement, Parent has not
received written notice from the SEC or any other Governmental Authority
indicating that any of its accounting policies or practices are or may be the
subject of any review, inquiry, investigation or challenge by the  SEC or any
other Governmental Authority.

 


 

 

Section 5.09 _Disclosure Documents_. The information relating to Parent and
its Subsidiaries that is provided by Parent, any of its Subsidiaries or any of
their respective Representatives for  inclusion or incorporation by reference
in the Registration Statement or the Joint Proxy Statement/Prospectus will not
(a) in the case of the Registration Statement, at the time the Registration
Statement or any amendment or supplement  thereto becomes effective and at
the time of the Company Stockholder Meeting and the Parent Stockholder
Meeting, and (b) in the case of the Joint Proxy Statement/Prospectus, at the
time the Joint Proxy Statement/Prospectus or any amendment or  supplement
thereto is first mailed to the stockholders of the Company and the
stockholders of Parent and at the time of the Company Stockholder Meeting and
the Parent Stockholder Meeting, contain any untrue statement of a material
fact or  omit to state any material fact necessary in order to make the
statements made therein, in light of the circumstances under which they were
made, not misleading. Notwithstanding the foregoing provisions of this Section
5.09, no representation or warranty is made by Parent with respect to
information or statements made or incorporated by reference in the
Registration Statement or the Joint Proxy  Statement/Prospectus which were
not supplied by or on behalf of the Parent or Merger Sub.

 


 

 

Section 5.10 _Absence of Certain Changes_.

 


 

 

(a) (i) Since the Parent Balance Sheet Date through  the date of this
Agreement, except in connection with or related to the process in connection
with which Parent and its Representatives discussed and negotiated this
Agreement and the transactions contemplated hereby, the business of Parent 
and its Subsidiaries has been conducted in all material respects in the
ordinary course of business consistent with past practice and (ii) since the
Parent Balance Sheet Date, there has not been any event, change, effect,
development or  occurrence that has had or would reasonably be expected to
have, individually or in the aggregate, a Parent Material Adverse Effect.

 


 

 

 

56    

(b) Since the Parent Balance Sheet Date through the  date of this Agreement,
there has not been any action taken by Parent or any of its Subsidiaries that,
if taken during the period from the date of this Agreement through the Merger
Effective Time without the Company's consent, would  constitute a breach of
clause (b) or (e) of _Section 7.01_ (or, solely with respect to the foregoing
clauses, clause (f) of _Section 7.01_ ).

 


 

 

Section 5.11 _No Undisclosed Material Liabilities_. There are no liabilities
or obligations of Parent or any of its Subsidiaries of any kind whatsoever,
whether accrued, contingent, absolute,  determined, determinable or
otherwise, that would be required by GAAP to be reflected on the consolidated
balance sheet of Parent and its Subsidiaries, other than (a) liabilities or
obligations disclosed and provided for in the Parent Balance  Sheet or in the
notes thereto, (b) liabilities or obligations incurred in the ordinary course
of business consistent with past practice since the Parent Balance Sheet Date,
(c) liabilities arising in connection with the transactions  contemplated
hereby, or (d) other liabilities or obligations that have not had and would
not reasonably be expected to have, individually or in the aggregate, a Parent
Material Adverse Effect. There are no off-balance sheet arrangements of  any
type pursuant to any off-balance sheet arrangement required to be disclosed
pursuant to Item 303(a)(4) of Regulation S-K that have not been so described
in the Parent SEC Documents.

 


 

 

Section 5.12 _Litigation_. There is no claim, action, proceeding or suit or,
to the knowledge of the Parent, investigation pending or, to the knowledge of
Parent, threatened (in the case of clause  (b) below, as of the date hereof)
against Parent, any of its Subsidiaries, any present or former officers,
directors or employees of Parent or any of its Subsidiaries in their
respective capacities as such, or any of the respective properties  or assets
of Parent or any of its Subsidiaries, before (or, in the case of threatened
claims, actions, suits, investigations or proceedings, that would be before)
any Governmental Authority (a) that has had or would reasonably be expected
to  have, individually or in the aggregate, a Parent Material Adverse Effect
or (b) that, as of the date of this Agreement, in any manner challenges or
seeks to prevent, enjoin, alter or materially delay the Merger or any of the
other  transactions contemplated hereby. There is no Order outstanding
against Parent, any of its Subsidiaries, any present or former officers,
directors or employees of Parent or any of its Subsidiaries in their
respective capacities as such or  any of the respective properties or assets
of any of Parent or any of its Subsidiaries, that has had or would reasonably
be expected to have, individually or in the aggregate, a Parent Material
Adverse Effect or that, as of the date of this  Agreement, would reasonably
be expected to prevent, enjoin, alter or materially delay the Merger or any of
the other transactions contemplated hereby.

 


 

 

Section 5.13 _Permits_. Except as has not had and would not reasonably be
expected to have, individually or in the aggregate, a Parent Material Adverse
Effect, Parent and each of its Subsidiaries  hold all governmental licenses
and Consents necessary for the operation of its respective businesses (the "
_Parent Permits_ "). Parent and each of its  Subsidiaries are, and since
January 1, 2017 have been, in compliance with the terms of the Parent Permits,
except for failures to comply that have not had and would not reasonably be
expected to have, individually or in the aggregate, a  Parent Material
Adverse Effect. There is no claim, action, proceeding or suit or, to the
knowledge of Parent, investigation pending, or, to the knowledge of Parent,
threatened that seeks, or, to the knowledge of Parent, any existing 
condition, situation or set of circumstances that would reasonably be expected
to result in, the revocation, cancellation, termination, non-renewal or
adverse modification of any Parent Permit, except where such revocation,
cancellation,  termination, non-renewal or adverse modification has not had
and would not reasonably be expected to have, individually or in the
aggregate, a Parent Material Adverse Effect.

 


 

 

 

57  

   

Section 5.14 _Compliance with Laws_. Parent and each of its  Subsidiaries
are, and since January 1, 2017 have been, in compliance with all Applicable
Laws, except for failures to comply that have not had and would not reasonably
be expected to have, individually or in the aggregate, a Parent Material 
Adverse Effect.

 

 


 

Section 5.15 _Regulatory Matters_.

 


 

 

 

(a) Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, (i) each
of Parent and its Subsidiaries holds  (A) all authorizations under the FDCA,
the PHSA, and the regulations of the FDA promulgated thereunder, and (B)
authorizations of any applicable Governmental Authority that are concerned
with the quality, identity, strength, purity,  safety, efficacy,
manufacturing, marketing, distribution, sale, pricing, import or export of any
of the Parent Products (any such Governmental Authority, a "
_Parent        Regulatory Agency_ ") necessary for the lawful operating
of the businesses of Parent or any of its Subsidiaries as currently conducted
(the " _Parent Regulatory Permits_ "); (ii) all such Parent Regulatory Permits
are valid and  in full force and effect; and (iii) Parent and its
Subsidiaries are in compliance with the terms of all Parent Regulatory
Permits. All Parent Regulatory Permits are in full force and effect, except
where the failure to be in full force  and effect has not had and would not
reasonably be expected to have, individually or in the aggregate, a Parent
Material Adverse Effect.

 


 

 

(b) Neither Parent nor any of its Subsidiaries are party to any material
corporate integrity agreements, monitoring agreements, consent decrees,
settlement orders, or similar agreements with  or imposed by any Parent
Regulatory Agency.

 


 

 

(c) All pre-clinical and clinical investigations in respect of a Parent
Product or Parent Product candidate conducted or sponsored by Parent or any of
its Subsidiaries are being and, since  January 1, 2017 have been, conducted
in compliance with all Applicable Laws administered or issued by the
applicable Parent Regulatory Agencies, including (i) FDA standards for the
design, conduct, performance, monitoring, auditing,  recording, analysis and
reporting of clinical trials contained in Title 21 parts 50, 54, 56, 312, 314
and 320 of the Code of Federal Regulations and (ii) any applicable federal,
state and provincial Applicable Laws restricting the  collection, use and
disclosure of individually identifiable health information and personal
information, except, in each case, for such noncompliance that has not had and
would not reasonably be expected to have, individually or in the  aggregate,
a Parent Material Adverse Effect.

 


 

 

(d) Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, during the
period beginning on January 1, 2017 and  ending on the date hereof, neither
Parent nor any of its Subsidiaries has received any written notice from the
FDA or the EMA or any foreign agency with jurisdiction over the development,
marketing, labeling, sale, use handling and  control, safety, efficacy,
reliability, or manufacturing of the Parent Products which would reasonably be
expected to lead to the denial, limitation, revocation, or rescission of any
of the Parent Regulatory Permits or of any  application for marketing
approval currently pending before the FDA or such other Parent Regulatory
Agency.

 


 

 

 

58  

(e) During the period beginning on January 1, 2017 and ending on the date
hereof, all reports, documents, claims, permits and notices required to be
filed, maintained or furnished to the FDA  or any other Parent Regulatory
Agency by Parent and its Subsidiaries have been so filed, maintained or
furnished, except where failure to file, maintain or furnish such reports,
documents, claims, permits or notices have not had and  would not reasonably
be expected to have, individually or in the aggregate, a Parent Material
Adverse Effect. All such reports, documents, claims, permits and notices were
true and complete in all material respects on the date filed  (or were
corrected in or supplemented by a subsequent filing). Since January 1, 2017,
neither Parent nor any of its Subsidiaries, nor, to the knowledge of Parent,
any officer, employee, agent or distributor of Parent or any of its 
Subsidiaries, has made an untrue statement of a material fact or a fraudulent
statement to the FDA or any other Parent Regulatory Agency, failed to disclose
a material fact required to be disclosed to the FDA or any other Parent 
Regulatory Agency, or committed an act, made a statement, or failed to make a
statement, in each such case, related to the business of Parent or any of its
Subsidiaries, that, at the time such disclosure was made, would reasonably
be  expected to provide a basis for the FDA to invoke its policy respecting
"Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities",
set forth in 56 Fed. Reg. 46191 (September 10, 1991) or for the FDA or any
other  Parent Regulatory Agency to invoke any similar policy, except for any
act or statement or failure to make a statement that has not had and would not
reasonably be expected to have, individually or in the aggregate, a Parent
Material  Adverse Effect. Except as has not had and would not reasonably be
expected to have, individually or in the aggregate, a Parent Material Adverse
Effect, since January 1, 2017, (i) neither Parent nor any of its Subsidiaries,
nor, to the  knowledge of Parent, any officer, employee, agent or distributor
of Parent or any of its Subsidiaries, has been debarred or convicted of any
crime or engaged in any conduct for which debarment is mandated by 21 U.S.C. 
335a(a) or any  similar Applicable Law or authorized by 21 U.S.C.  335a(b)
or any similar Applicable Law applicable in other jurisdictions in which
material quantities of any of the Parent Products or Parent Product candidates
are sold or intended by  Parent to be sold; and (ii) neither Parent nor any
of its Subsidiaries, nor, to the knowledge of the Parent, any officer,
employee, agent or distributor of Parent or any of its Subsidiaries, has been
excluded from participation in any  federal health care program or convicted
of any crime or engaged in any conduct for which such Person could be excluded
from participating in any federal health care program under Section 1128 of
the Social Security Act of 1935, as  amended, or any similar Applicable Law
or program.

 


 

 

(f) Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, as to each
Parent Product or Parent Product  candidate subject to the FDCA and the
regulations of the FDA promulgated thereunder or any similar Applicable Law in
any foreign jurisdiction in which material quantities of any of the Parent
Products or Parent Product candidates are  sold or intended by Parent or any
of its Subsidiaries to be sold that is or has been developed, manufactured,
tested, distributed or marketed by or on behalf of Parent or any of its
Subsidiaries, each such Parent Product or Parent  Product candidate is being
or has been developed, manufactured, stored, distributed and marketed in
compliance with all Applicable Laws, including those relating to
investigational use, marketing approval, current good manufacturing 
practices, packaging, labeling, advertising, record keeping, reporting, and
security. There is no action or proceeding pending or, to the knowledge of
Parent, threatened, including any prosecution, injunction, seizure, civil
fine,  debarment, suspension or recall, in each case alleging any violation
applicable to any Parent Product or Parent Product candidate by Parent or any
of its Subsidiaries of any Applicable Law, except as has not had and would not
reasonably  be expected to have, individually or in the aggregate, a Parent
Material Adverse Effect.

 


 

 

 

59  

(g) Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, during the
period beginning on January 1, 2017 and  ending on the date hereof, neither
Parent nor any of its Subsidiaries have voluntarily or involuntarily
initiated, conducted or issued, or caused to be initiated, conducted or
issued, any material recall, field corrections, market  withdrawal or
replacement, safety alert, warning, "dear doctor" letter, investigator notice,
or other notice or action to wholesalers, distributors, retailers, healthcare
professionals or patients relating to an alleged lack of safety,  efficacy or
regulatory compliance of any Parent Product. To the knowledge of Parent, there
are no facts as of the date hereof which are reasonably likely to cause, and
neither Parent nor any of its Subsidiaries has received any written  notice
from the FDA or any other Parent Regulatory Agency during the period beginning
on January 1, 2017 and ending on the date hereof regarding (i) the recall,
market withdrawal or replacement of any Parent Product sold or intended to 
be sold by Parent or its Subsidiaries (other than recalls, withdrawals or
replacements that are not material to Parent and its Subsidiaries, taken as a
whole), (ii) a material change in the marketing classification or a material
change  in the labeling of any such Parent Products, (iii) a termination or
suspension of the manufacturing, marketing, or distribution of such Parent
Products, or (iv) a material negative change in reimbursement status of a
Parent Product.

 


 

 

Section 5.16 _Taxes_. Except as has not had and would not reasonably be
expected to have, individually or in the aggregate, a Parent Material Adverse
Effect:

 


 

 

(a) All Tax Returns required by Applicable Law to be filed with any Taxing
Authority by, or on behalf of, Parent or any of its Subsidiaries have been
filed when due (giving effect to all  extensions) in accordance with all
Applicable Law, and all such Tax Returns are true and complete in all
respects.

 


 

 

(b) Parent and each of its Subsidiaries has paid (or has had paid on its
behalf) all Taxes shown as due and payable on any Tax Returns, or (i) where
payment is not yet due, has established  (or has had established on its
behalf and for its sole benefit and recourse) in accordance with GAAP an
adequate accrual or (ii) where payment is being contested in good faith
pursuant to appropriate procedures, has established (or has  had established
on its behalf and for its sole benefit and recourse) in accordance with GAAP
an adequate reserve, in each case for all Taxes through the end of the last
period for which Parent and its Subsidiaries ordinarily record  items on
their respective books and records.

 


 

 

(c) Parent and each of its Subsidiaries has duly and timely withheld all Taxes
required to be withheld, and such withheld Taxes have been either duly and
timely paid to the proper Taxing  Authority or properly set aside in accounts
for such purpose.

 


 

 

 

60  

(d) (i) All federal income Tax Returns of the affiliated group of which Parent
is the common parent through the Tax year ended December 31, 2007 have been
examined and closed or are Tax  Returns with respect to which the applicable
period for assessment under Applicable Law, after giving effect to extensions
or waivers, has expired, and (ii) neither Parent nor any of its Subsidiaries
(or any member of any affiliated,  consolidated, combined or unitary group of
which Parent or any of its Subsidiaries is or has been a member) has granted
any extension or waiver of the limitation period applicable to the assessment
or collection of any federal income  Tax, and no power of attorney with
respect to any such Taxes has been granted to any Person, in each case, that
remains in effect.

 


 

 

(e) There is no claim, action, suit, proceeding or investigation (including an
audit) pending or, to Parent's knowledge, threatened in writing against or
with respect to Parent or its  Subsidiaries in respect of any Tax or Tax
asset.

 


 

 

(f) There are no requests for rulings or determinations in respect of any Tax
or Tax asset pending between Parent or any of its Subsidiaries and any Taxing
Authority.

 


 

 

(g) During the two (2) year period ending on the date of this Agreement,
Parent was not a distributing corporation or a controlled corporation in a
transaction intended to be governed by  Section 355 of the Code.

 


 

 

(h) There are no Liens for Taxes (other than Permitted Liens) upon any of the
assets of Parent or any of its Subsidiaries.

 


 

 

(i) No claim has been made in writing by any Taxing Authority in a
jurisdiction where Parent and/or Parent's Subsidiaries do not file Tax Returns
that Parent or any of its Subsidiaries is or  may be subject to taxation by,
or required to file any Tax Return in, that jurisdiction.

 


 

 

(j) Neither Parent nor any of its Subsidiaries (i) has been a member of an
affiliated, consolidated, combined or unitary group other than one of which
Parent or any of its Subsidiaries was  the common parent, (ii) is party to
any Tax Sharing Agreement (other than any such agreement solely between Parent
and its Subsidiaries), (iii) has entered into a closing agreement pursuant to
Section 7121 of the Code, or any  predecessor provision or any similar
provision of state, local or non-U.S. law or (iv) has any liability for the
Taxes of any Person (other than Parent or any of its Subsidiaries) under
Treasury Regulation Section 1.1502-6 (or any  similar provision of state,
local or non-U.S. law) or any Tax Sharing Agreement or as a transferee or
successor.

 


 

 

(k) Neither Parent nor any of its Subsidiaries has engaged in any "listed
transaction" within the meaning of Treasury Regulation Section 1.6011-4(b)(2).

 


 

 

Section 5.17 _Employees and Employee Benefit Plans_.

 


 

 

(a) Neither Parent nor any of its ERISA Affiliates (nor any predecessor of any
such entity) sponsors, maintains, administers or contributes to (or has any
obligation to contribute to), or  has, since January 1, 2017, sponsored,
maintained, administered or contributed to (or had any obligation to
contribute to), any plan subject to Title IV of ERISA, including any
multiemployer plan, as defined in Section 3(37) of ERISA.

 


 

 

 

61  

(b) Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, each
Parent Employee Plan that is intended to be  qualified under Section 401(a)
of the Code has received a favorable determination or opinion letter from the
Internal Revenue Service or has applied to the Internal Revenue Service for
such a letter within the applicable remedial  amendment period or such period
has not expired and, to the knowledge of Parent, no circumstances exist that
would reasonably be expected to result in any such letter being revoked or not
being reissued or a penalty under the Internal  Revenue Service Closing
Agreement Program if discovered during an Internal Revenue Service audit or
investigation. Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Parent Material  Adverse Effect,
each trust created under any such Parent Employee Plan is exempt from tax
under Section 501(a) of the Code and has been so exempt since its creation.

 


 

 

(c) Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, since
January 1, 2017, each Parent Employee Plan  has been maintained in compliance
with its terms and all Applicable Law, including ERISA and the Code and all
contributions required to have been made by Parent or any of its Subsidiaries
with respect to any benefit or compensation  plan, program or other
arrangement maintained by a Governmental Authority have been timely made.
Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, no  claim
(other than routine claims for benefits), action, suit, investigation or
proceeding (including an audit) is pending against or involves or, to Parent's
knowledge, is threatened against or reasonably expected to involve, any
Parent  Employee Plan before any Governmental Authority, including the
Internal Revenue Service, the Department of Labor or the PBGC. To the
knowledge of Parent, since January 1, 2017, no events have occurred with
respect to any Parent  Employee Plan that would reasonably be expected to
result in the assessment of any excise taxes or penalties against Parent or
any of its Subsidiaries, except for events that have not had and would not
reasonably be expected to have,  individually or in the aggregate, a Parent
Material Adverse Effect.

 


 

 

(d) Neither Parent nor any of its Subsidiaries has any material current or
projected liability for, and no Parent Employee Plan provides or promises, any
material post-employment or  post-retirement medical, dental, disability,
hospitalization, life or similar benefits (whether insured or self-insured) to
any director, officer, or employee (including any former director, officer, or
employee) of Parent or any of its  Subsidiaries (other than coverage mandated
by Applicable Law).

 


 

 

(e) Neither Parent nor any of its Subsidiaries has any obligation to gross-up,
indemnify or otherwise reimburse any Person for any Tax incurred by such
Person under Section 409A or 4999 of  the Code.

 


 

 

(f) Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, with
respect to any Parent Employee Plan covered by  Subtitle B, Part 4 of Title I
of ERISA or Section 4975 of the Code, no non-exempt prohibited transaction has
occurred that has caused or would reasonably be expected to cause Parent or
any of its Subsidiaries to incur any liability  under ERISA or the Code.

 


 

 

 

62  

Section 5.18 _Labor Matters_.

 


 

 

(a) Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, Parent and
its Subsidiaries are, and since January  1, 2017 have been, in compliance
with all Applicable Laws relating to labor and employment, including those
relating to labor management relations, wages, hours, overtime, employee
classification, discrimination, sexual harassment,  civil rights, affirmative
action, work authorization, immigration, safety and health, information
privacy and security, workers compensation, continuation coverage under group
health plans, wage payment and the payment and withholding  of taxes.

 


 

 

(b) Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, as of the
date hereof (i) there are no unfair labor  practice complaints pending or, to
Parent's knowledge, threatened against Parent or any of its Subsidiaries
before the National Labor Relations Board or any other Governmental Authority
or any current union representation questions  involving any director,
officer, or employee (including any former director, officer, or employee) of
Parent or any of its Subsidiaries with respect to Parent or its Subsidiaries,
and (ii) there is no labor strike, slowdown, stoppage,  picketing,
interruption of work or lockout pending or, to Parent's knowledge, threatened
against or affecting Parent or any of its Subsidiaries.

 


 

 

Section 5.19 _Intellectual Property_.

 


 

 

(a) Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, none of
the registrations (including patents,  trademarks and copyrights, and
material domain name registrations) and applications for registration for
Owned Intellectual Property included in the Parent Intellectual Property (the
" _Parent Registered IP_ ") that is an issued U.S. patent or a registration
for a U.S. trademark or a U.S. patent  application or an application for
registration of a U.S. trademark has lapsed, expired, been abandoned or been
adjudged invalid or unenforceable, and, to the knowledge of Parent, all Parent
Registered IP is subsisting, and if  registered, valid and enforceable.

 


 

 

(b) Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, (i) Parent
and its Subsidiaries are the sole and  exclusive owners of all Owned
Intellectual Property included in the Parent Intellectual Property that is (A)
an issued U.S. patent or a registration for a U.S. trademark or a U.S. patent
application or an application for registration of  a U.S. trademark and any
U.S. or global issued or pending patents relating thereto, or (B) material
Parent Intellectual Property that relates to any material Parent Product, and,
with respect to the foregoing clauses (A) and (B), hold  all of their right,
title and interest in and to all of the Parent Intellectual Property free and
clear of all Liens other than Permitted Liens, and (ii) to the knowledge of
Parent, Parent's and its Subsidiaries' Owned Intellectual  Property and
Parent's and its Subsidiaries' Licensed Intellectual Property, together with
any other Intellectual Property that Parent or any of its Subsidiaries is
otherwise permitted to use (including by way of a release, covenant not  to
sue or immunity from suit), constitutes all of the Intellectual Property
necessary to, or used or held for use in, the conduct of the respective
businesses of Parent and its Subsidiaries as currently conducted, and as
currently  planned to be conducted prior to Closing.

 


 

 

 

63  

(c) Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect (and except
as disclosed by Parent to the Company  during the course of Company's due
diligence prior to the date hereof), during the past four (4) years (i) to the
knowledge of Parent, neither Parent nor any of its Subsidiaries nor the
conduct of their respective businesses has  infringed, misappropriated,
diluted or otherwise violated any Intellectual Property rights of any Third
Party, (ii) there is no claim, action, proceeding or suit or, to the knowledge
of Parent, investigation pending or, to the knowledge  of Parent, threatened
against or affecting Parent or any of its Subsidiaries (A) alleging that
Parent or any of its Subsidiaries has infringed, misappropriated, diluted or
otherwise violated any Intellectual Property rights of any Third  Party or
(B) based upon, or challenging or seeking to deny or restrict, the rights of
Parent or any of its Subsidiaries in any of Parent Intellectual Property
(including any challenges to the validity, enforceability, registerability, 
inventorship, ownership or use of any of the Parent Intellectual Property that
is Owned Intellectual Property), and (iii) to the knowledge of Parent, no
Third Party has infringed, misappropriated, diluted or otherwise violated any
of  the Parent Company Intellectual Property that is Owned Intellectual
Property. Notwithstanding anything contained herein, the representations and
warranties set forth herein shall be read without application of 35 U.S.C.
271(e)(1) (the  statutory research exemption) and any similar Applicable
Laws outside the U.S. to the same extent as if such Applicable Laws did not
exist.

 


 

 

(d) Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, (i) since
January 1, 2017, Parent and its  Subsidiaries have provided reasonable notice
of its privacy and personal data collection and use policies on its websites
and other customer and public communications and Parent and its Subsidiaries
have complied since January 1, 2017  with such policies and all Applicable
Laws relating to (A) the privacy of the users of Parent's and its
Subsidiaries' respective products, services and websites and (B) the
collection, use, storage and disclosure of any  personally-identifiable
information (including personal health information), (ii) since January 1,
2017, there is no claim, action, proceeding or suit or, to the knowledge of
Parent, investigation pending or, to the knowledge of Parent,  threatened
against Parent or any of its Subsidiaries alleging any violation of such
policies or Applicable Laws, (iii) neither this Agreement nor the consummation
of the transactions contemplated hereby will violate any such policy or 
Applicable Laws, and (iv) Parent and its Subsidiaries have taken commercially
reasonable steps to protect the types of information referred to in this
_Section 5.19(d)_ against loss and unauthorized access, use, modification, 
disclosure or other misuse, and, to the knowledge of Parent, since January 1,
2017, there has been no unauthorized access, use, modification, disclosure or
other misuse of such data or information.

 


 

 

(e) Except as has not had, and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, (i)
Parent's IT Assets operate in a manner that  permits Parent and its
Subsidiaries to conduct their respective businesses as currently conducted,
(ii) Parent and its Subsidiaries take commercially reasonable actions to
protect the confidentiality, integrity and security of Parent's  IT Assets
(and all data and other information and transactions stored or contained
therein or transmitted thereby) against any unauthorized use, access,
interruption, modification or corruption, including the implementation of 
commercially reasonable data backup, disaster avoidance and recovery
procedures and business continuity procedures, and (iii) since January 1,
2017, to the knowledge of Parent, there has been no unauthorized use or access
or security  breaches, or interruption, modification, loss or corruption of
any of Parent's IT Assets (or any data or other information or transactions
stored or contained therein or transmitted thereby).

 


 

 

 

64  

Section 5.20 _Environmental Matters_. Except as has not had and would not
reasonably be expected  to have, individually or in the aggregate, a Parent
Material Adverse Effect:

 


 

 

(a) no notice, notification, demand, request for information, citation,
summons or order has been received, no complaint has been filed, no penalty
has been assessed, and no claim, action  proceeding or suit or, to the
knowledge of Parent, investigation (including a review) is pending or, to the
knowledge of Parent, threatened by any Governmental Authority or other Person
relating to Parent or any of its Subsidiaries that  relates to, or arises
under, any Environmental Law, Environmental Permit or Hazardous Substance;

 


 

 

(b) Parent and its Subsidiaries are, and since January 1, 2017 have been, in
compliance with all Environmental Laws and all Environmental Permits and hold
all applicable Environmental  Permits; and

 


 

 

(c) there are no liabilities or obligations of Parent or any of its
Subsidiaries of any kind whatsoever, whether accrued, contingent, absolute,
determined, determinable or otherwise arising  under or relating to any
Environmental Law, Environmental Permit or Hazardous Substance and there is no
existing condition, situation or set of circumstances that could reasonably be
expected to result in any such liability or  obligation.

 


 

 

Section 5.21 _FCPA; Anti-Corruption; Sanctions_.

 


 

 

(a) Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, neither
Parent nor any of its Subsidiaries, nor, to  the knowledge of Parent, any
director, manager, employee, agent or representative of Parent or any of its
Subsidiaries, in each case acting on behalf of Parent or any of its
Subsidiaries, has, in the last five (5) years, in connection  with the
business of Parent or any of its Subsidiaries, taken any action in violation
of the FCPA or other applicable Bribery Legislation (in each case to the
extent applicable).

 


 

 

(b) Neither Parent nor any of its Subsidiaries nor, to the knowledge of
Parent, any director, manager or employee of Parent or any of its
Subsidiaries, is, or in the last five (5) years has  been, subject to any
actual or pending or, to the knowledge of Parent, threatened civil, criminal,
or administrative actions, suits, demands, claims, hearings, notices of
violation, investigations, proceedings, demand letters,  settlements, or
enforcement actions, or made any voluntary disclosures to any Governmental
Authority, involving Parent or any of its Subsidiaries relating to applicable
Bribery Legislation, including the FCPA.

 


 

 

 

65  

(c) Parent and each of its Subsidiaries has made and kept books and records,
accounts and other records, which, in reasonable detail, accurately and fairly
reflect in all material respects  the transactions and dispositions of the
assets of Parent and each of its Subsidiaries as required by the FCPA.

 


 

 

(d) Parent and each of its Subsidiaries has instituted policies and procedures
reasonably designed to ensure compliance in all material respects with the
FCPA and other applicable Bribery  Legislation and maintain such policies and
procedures in force.

 


 

 

(e) To the knowledge of Parent, no officer, director, or employee of Parent or
any of its Subsidiaries is a Government Official.

 


 

 

(f) Except as has had not and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, none of
Parent or any of its Subsidiaries, nor, to  the knowledge of Parent, any of
their respective directors, managers or employees (i) is a Sanctioned Person,
(ii) has, in the last five (5) years, engaged in, has any plan or commitment
to engage in, direct or indirect dealings with  any Sanctioned Person or in
any Sanctioned Country on behalf of the Parent or any of its Subsidiaries in
violation of applicable Sanctions Law or (iii) has, in the last five (5)
years, violated, or engaged in any conduct sanctionable  under, any Sanctions
Law, nor to the knowledge of Parent, been the subject of an investigation or
allegation of such a violation or sanctionable conduct.

 


 

 

Section 5.22 _Transactions        with Affiliates_. To the knowledge of
Parent and as of the date of this Agreement, since January 1, 2017, there have
been no transactions, or series  of related transactions, agreements,
arrangements or understandings in effect, nor are there any currently proposed
transactions, or series of related transactions, agreements, arrangements or
understandings, that would be required to  be disclosed under Item 404(a) of
Regulation S-K that have not been otherwise disclosed in the Parent SEC
Documents filed prior to the date hereof.

 


 

 

Section 5.23 _Antitakeover Statutes_. Assuming the representations and
warranties set forth in  Section 4.29 are true and correct, neither the
restrictions set forth in Section 203 of the DGCL nor any other "control share
acquisition," "fair price," "moratorium" or other antitakeover laws enacted
under U.S. state or federal laws  apply to this Agreement or any of the
transactions contemplated hereby.

 


 

 

Section 5.24 _Opinions of Financial Advisors_. The Board of Directors of
Parent has received  separate opinions of each of Morgan Stanley and Co. LLC,
Dyal Co. LLC and Evercore Group L.L.C., financial advisors to Parent, to the
effect that, as of the date of such opinions and subject to the various
assumptions, procedures,  matters, qualifications and limitations on the
scope of the review undertaken as set forth therein, the Merger Consideration
to be paid by Parent pursuant to this Agreement is fair, from a financial
point of view, to Parent. A written  copy of such opinions will be delivered
promptly to the Company after the date hereof for informational purposes only.

 


 

 

Section 5.25 _Finders ' Fees_. Except for Morgan Stanley and Co. LLC, Dyal Co.
LLC and Evercore  Group L.L.C., there is no investment banker, broker, finder
or other intermediary that has been retained by or is authorized to act on
behalf of Parent or any of its Subsidiaries who might be entitled to any fee
or commission from  Parent or any of its Affiliates in connection with the
transactions contemplated by this Agreement.

 


 

 

 

66  

Section 5.26 _No Ownership of Company Common Stock_. Neither Parent nor any of
its Subsidiaries  beneficially owns, directly or indirectly, any shares of
Company Common Stock or other securities convertible into, exchangeable for or
exercisable for shares of Company Common Stock, and neither Parent nor any of
its Subsidiaries has  any rights to acquire any shares of Company Common
Stock (other than any such securities owned by Parent or any of its
Subsidiaries in a fiduciary, representative or other capacity on behalf of
other Persons, whether or not held in a  separate account). There are no
voting trusts or other agreements or understandings to which Parent or any of
its Subsidiaries is a party with respect to the voting of the capital stock or
other Equity Securities of the Company or any  of its Subsidiaries.

 


 

 

Section 5.27 _Financing_.

 


 

 

(a) Parent has delivered to the Company (i) a true and complete copy of a
fully executed commitment letter, dated as of the date hereof, among Parent
and the Financing Sources party thereto  (including all exhibits, schedules,
and annexes to such letters in effect as of the date hereof), pursuant to
which the Financing Sources have committed, upon the terms and subject to the
conditions set forth therein, to provide the  debt financing described
therein in connection with the transactions contemplated hereby and (ii) a
true and complete copy of the fully executed fee letter referenced therein
(together, the " _Debt Commitment Letter_ ") relating to fees with respect to
the Debt Financing (redacted to remove only fee  amounts, the rates and
amounts included in the "market flex" provisions and certain other economic
terms (none of which could adversely affect the amounts, availability, timing
or conditionality of the Debt Financing)). The Debt  Commitment Letter and
any other debt commitment letter (including any replacement of the Debt
Commitment Letter and related fee letter in connection with any Alternative
Financing) executed in accordance with _Section 7.06_ , as  replaced,
amended, supplemented, modified or waived in accordance with _Section 7.06_ ,
including all exhibits, schedules, and annexes to such letters, are
hereinafter referred to together as the " _Debt Commitment Letters_ ". The
financing contemplated pursuant to the Debt Commitment Letters is 
hereinafter referred to as the " _Debt Financing_ ".

 


 

 

(b) As of the date of this Agreement, the Debt Commitment Letter is in full
force and effect and is a legal, valid and binding obligation of Parent, and
to the knowledge of Parent, the other  parties thereto, and enforceable in
accordance with its terms against Parent, and to the knowledge of Parent, each
of the other parties thereto, in each case, subject to the Bankruptcy and
Equity Exceptions. All commitment fees  required to be paid under the Debt
Commitment Letters have been paid in full by Parent or will be duly paid in
full by Parent as and when due, and Parent has otherwise satisfied all of the
other items and conditions required to be  satisfied by Parent, and within
its control, pursuant to the terms of the Debt Commitment Letter on or prior
to the date of this Agreement. The Debt Commitment Letter has not been
amended, restated, modified or terminated, nor has  compliance with any term
thereof been waived, on or prior to the date of this Agreement and the
respective commitments contained in the Debt Commitment Letter have not been
withdrawn, rescinded or otherwise modified in any respect on or  prior to the
date of this Agreement. As of the date of this Agreement, (i) no event has
occurred which, with or without notice, lapse of time or both, would
reasonably be expected to constitute a breach or default, in each case, on
the  part of Parent or, to the knowledge of Parent, any other party, under
the Debt Commitment Letter and (ii) assuming the accuracy of the Company's
representations and warranties contained in Article IV and compliance by the
Company with  its covenants contained in _Article VI_ and _Article VIII_ , in
each case, in all material respects, Parent has no knowledge that any of the
conditions to the Debt Financing will not be satisfied on the Closing Date or
that  the Debt Financing or any other funds necessary for the satisfaction of
all of Parent's and its Subsidiaries' obligations under this Agreement will
not be available to Parent on the Closing Date. The consummation of the Debt
Financing  is subject to no conditions precedent other than those expressly
set forth in the copy of the Debt Commitment Letter delivered to the Company,
and there are no contingencies that would permit the Financing Sources to
reduce the total  amount of the Debt Financing other than those expressly set
forth in the copy of the Debt Commitment Letter delivered to the Company on or
prior to the date hereof. Except for any engagement letters or related fee
letters related to  the permanent financing referred to in the Debt
Commitment Letters, as of the date of this Agreement, there are no side
letters or other agreements, Contracts or arrangements to which Parent or
Merger Sub or any of their respective  Affiliates are a party related to the
funding of the Debt Financing. Assuming (A) the funding of the full amount of
the Debt Financing in accordance with and subject to the satisfaction of the
conditions of the Debt Commitment Letter  and (B) the accuracy in all
material respects of the Company's representations and warranties set forth in
_Article IV_ of this Agreement and compliance in all material respects by the
Company with its covenants, agreements and  obligations under _Article VI_
and _Article VIII_ of this Agreement, the aggregate proceeds of the Debt
Financing, together with cash or cash equivalents held by Parent and the other
sources of funds referenced in the Debt  Commitment Letters, as of the Merger
Effective Time, will be sufficient to enable Parent to pay in cash all amounts
required to be paid by Parent and Merger Sub in cash on the Closing Date,
including the Cash Consideration, and all  payments, fees and expenses
payable by them related to or arising out of the consummation of the
transactions contemplated by this Agreement that are required to be paid as of
such date. The obligations of Parent and Merger Sub  hereunder are not
conditioned in any manner upon Parent or Merger Sub obtaining any financing.

 


 

 

 

67  

Section 5.28 _No Other Parent Representations and Warranties_. Except for the
representations  and warranties made by Parent in this _Article V_ (as
qualified by the applicable items disclosed in the Parent Disclosure Schedule
in accordance with _Section 11.05_ and the introduction to this _Article V_ ),
neither  Parent nor any other Person (including Merger Sub) makes or has made
any representation or warranty, expressed or implied, at law or in equity,
with respect to or on behalf of Parent or its Subsidiaries, their businesses,
operations,  assets, liabilities, financial condition, results of operations,
future operating or financial results, estimates, projections, forecasts,
plans or prospects (including the reasonableness of the assumptions underlying
such estimates,  projections, forecasts, plans or prospects) or the accuracy
or completeness of any information regarding Parent or its Subsidiaries or any
other matter furnished or provided to the Company or made available to the
Company in any "data  rooms," "virtual data rooms," management presentations
or in any other form in expectation of, or in connection with, this Agreement
or the transactions contemplated hereby. Parent and its Subsidiaries disclaim
any other  representations or warranties, whether made by Parent or any of
its Subsidiaries or any of their respective Affiliates or Representatives.
Each of Parent and Merger Sub acknowledges and agrees that, except for the
representations and  warranties made by the Company in _Article IV_ (as
qualified by the applicable items disclosed in the Company Disclosure Schedule
in accordance with _Section 11.05_ and the introduction to _Article IV_ ),
neither the  Company nor any other Person is making or has made any
representations or warranty, expressed or implied, at law or in equity, with
respect to or on behalf of the Company or its Subsidiaries, their businesses,
operations, assets,  liabilities, financial condition, results of operations,
future operating or financial results, estimates, projections, forecasts,
plans or prospects (including the reasonableness of the assumptions underlying
such estimates,  projections, forecasts, plans or prospects) or the accuracy
or completeness of any information regarding the Company or its Subsidiaries
or any other matter furnished or provided to Parent or made available to
Parent in any "data  rooms," "virtual data rooms," management presentations
or in any other form in expectation of, or in connection with, this Agreement,
or the transactions contemplated hereby or thereby. Each of Parent and Merger
Sub specifically  disclaims that it is relying upon or has relied upon any
such other representations or warranties that may have been made by any
Person, and acknowledges and agrees that the Company and its Affiliates have
specifically disclaimed and do  hereby specifically disclaim any such other
representations and warranties.

 


 

 

 

68  

ARTICLE VI 
  
  COVENANTS OF THE COMPANY

 


 

 

The Company agrees that:

 


 

 

Section 6.01 _Conduct of the Company_. From the date of this Agreement until
the earlier of the  Merger Effective Time and the termination of this
Agreement, except (x) as prohibited or required by Applicable Law, (y) as set
forth in _Section 6.01_ of the Company Disclosure Schedule, or (z) as
otherwise required or expressly  contemplated by this Agreement, unless
Parent shall otherwise consent in writing (which consent shall not be
unreasonably withheld, conditioned or delayed), the Company shall, and shall
cause each of its Subsidiaries to, use  commercially reasonable efforts to
conduct its business in all material respects in the ordinary course of
business consistent with past practice and to preserve intact its business
organization and relationships with customers,  members, suppliers,
licensors, licensees and other Third Parties and keep available the services
of its present officers and employees; _provided_ that (i) no action by the
Company or any of its Subsidiaries to the extent expressly permitted by an
exception to any of _Section 6.01(a)_ through _Section  6.01(o)_ will be a
breach of this sentence and (ii) if the Company or any of its Subsidiaries
seeks the consent of Parent to take any action prohibited by any of _Section
6.01(a)_ through _Section 6.01(o)_ , and such  consent is withheld by Parent,
the failure to take such action will not be deemed to be a breach of this
sentence. Without limiting the generality of the foregoing, except (A) as
prohibited or required by Applicable Law, (B) as set  forth in _Section 6.01_
of the Company Disclosure Schedule, or (C) as otherwise required or expressly
contemplated by this Agreement, without Parent's prior written consent (which
consent shall not be unreasonably withheld,  conditioned or delayed), the
Company shall not, and shall cause each of its Subsidiaries not to:

 


 

 

(a) adopt or propose any change to its certificate of incorporation, bylaws or
other organizational documents (whether by merger, consolidation or otherwise)
(including the Company  Organizational Documents);

 


 

 

 

69  

(b) (i) merge or consolidate with any other Person, (ii) acquire (including by
merger, consolidation, or acquisition of stock or assets) any interest in any
corporation, partnership, other  business organization or any division
thereof or any assets, securities or property, other than (A) acquisitions of
assets, securities or property in an amount not to exceed $500,000,000
individually or $1,000,000,000 in the aggregate  for all such acquisitions
(measured for each acquisition on a risk adjusted net present value basis as
of the closing of such acquisition), (B) acquisitions of securities under the
Company's investment portfolio consistent with the  Company's investment
policy in effect as of the date hereof, (C) transactions (1) solely among the
Company and one or more of its wholly owned Subsidiaries or (2) solely among
the Company's wholly owned Subsidiaries and (D) acquisitions  of inventory or
equipment in the ordinary course of business consistent with past practice
(provided that any of the acquisitions or transactions described in clauses
(A) through (D) shall require the prior written consent of Parent if  such
acquisition or transaction would, individually or in the aggregate, reasonably
be expected to prevent or materially delay the consummation of the
transactions contemplated by this Agreement), or (iii) adopt a plan of
complete or  partial liquidation, dissolution, recapitalization or
restructuring;

 


 

 

(c) (i) split, combine or reclassify any shares of its capital stock (other
than transactions (1) solely among the Company and one or more of its wholly
owned Subsidiaries or (2) solely among  the Company's wholly owned
Subsidiaries), (ii) amend any term or alter any rights of any of its
outstanding Equity Securities, (iii) declare, set aside or pay any dividend or
make any other distribution (whether in cash, stock, property  or any
combination thereof) in respect of any shares of its capital stock or other
Equity Securities, other than dividends or distributions by a Subsidiary of
the Company to the Company or a wholly owned Subsidiary of the Company, or 
(iv) redeem, repurchase, cancel or otherwise acquire or offer to redeem,
repurchase, or otherwise acquire any of its Equity Securities or any Equity
Securities of any Subsidiary of the Company, other than repurchases of shares
of  Company Common Stock in connection with the exercise of Company Stock
Options or the vesting or settlement of Company RSU Awards, Company PSU
Awards, or Company RSAs (including in satisfaction of any amounts required to
be deducted or  withheld under Applicable Law), in each case outstanding as
of the date of this Agreement in accordance with the present terms of such
Company Equity Awards or granted after the date of this Agreement to the
extent permitted by this  Agreement;

 


 

 

(d) issue, deliver or sell, or authorize the issuance, delivery or sale of,
any shares of its capital stock or any other Equity Securities, other than (i)
the issuance of any shares of  Company Common Stock upon the exercise of
Company Stock Options or the vesting or settlement of shares of Company RSU
Awards or Company PSU Awards that are, in each case outstanding as of the date
of this Agreement in accordance with  the present terms of such Company
Equity Awards or granted after the date of this Agreement to the extent
permitted by this Agreement, or (ii) with respect to capital stock or Equity
Securities of any Subsidiary of the Company, in  connection with transactions
(A) solely among the Company and one or more of its wholly owned Subsidiaries
or (B) solely among the Company's wholly owned Subsidiaries;

 


 

 

(e) authorize, make or incur any capital expenditures or obligations or
liabilities in connection therewith, other than (A) any capital expenditures
contemplated by the capital expenditure  budget of the Company and its
Subsidiaries made available to Parent prior to the date hereof and (B)
additional capital expenditures of less than $5,000,000 individually or
$40,000,000 in the aggregate;

 


 

 

 

70  

(f) sell, lease, license, transfer or otherwise dispose of any Subsidiary or
any division thereof or of the Company or any assets, securities or property
(in each case, other than  Intellectual Property, which is the subject of
_Section 6.01(g)_ ), other than (i) dispositions of securities under the
Company's investment portfolio consistent with the Company's investment policy
in effect as of the date hereof,  (ii) sales or dispositions of inventory or
tangible personal property (including equipment), in each case in the ordinary
course of business consistent with past practice or (iii) transactions (A)
solely among the Company and one or  more of its wholly owned Subsidiaries or
(B) solely among the Company's wholly owned Subsidiaries;

 


 

 

(g) sell, assign, license (including sublicense), abandon, allow to lapse,
transfer or otherwise dispose of, or create or incur any Lien (other than a
Permitted Lien) on, any Owned  Intellectual Property or, to the extent it is
material to any Covered Product or the exercise of the Covered Rights with
respect thereto, Licensed Intellectual Property, in each case other than (i)
in the ordinary course of business,  consistent with past practice (A)
pursuant to a nonexclusive license (but excluding any nonexclusive license
with respect to any Covered Product), or (B) for the purpose of abandoning or
allowing to lapse any Company Registered IP (x)  that is immaterial, (y)
during the ordinary course of prosecution, or (z) in any country with annual
Company Product revenue that is less than $20 million, or (ii) pursuant to any
Company Permitted Settlement;

 


 

 

(h) (i) make any material loans, advances or capital contributions to, or
investments in, any other Person, other than (A) loans, advances, capital
contributions or investments (1) by the  Company to or in, as applicable, one
or more of its wholly owned Subsidiaries or (2) by any Subsidiary of the
Company to or in, as applicable, the Company or any wholly owned Subsidiary of
the Company, or (B) capital contributions  required under the terms of
Contracts in effect as of the date hereof, or (ii) incur, assume, guarantee or
repurchase or otherwise become liable for any indebtedness for borrowed money,
issue or sell any debt securities or any options,  warrants or other rights
to acquire debt securities or enter into, guarantee or otherwise become liable
for any interest rate, swap, currency, commodity or other similar hedging
arrangement (in each case, whether, directly or  indirectly, on a contingent
basis or otherwise), other than (A) additional borrowings under the Credit
Agreement (as in effect as of the date hereof) in accordance with the terms
thereof and indebtedness under commercial paper  arrangements backstopped
thereby, _provided_ that (I) the aggregate  amount of commercial paper
outstanding shall not at any time exceed $750,000,000 and (II) as of the last
day of each fiscal quarter of the Company and as of the Closing Date, the
amount of such commercial paper outstanding shall be $0,  (B) intercompany
indebtedness among the Company and its wholly-owned Subsidiaries or among the
Company's wholly-owned Subsidiaries, (C) indebtedness for borrowed money
incurred to replace, renew, extend, refinance or refund any existing 
indebtedness of the Company or any of its Subsidiaries, which indebtedness is
(I) on terms that are substantially consistent with those contained in the
indebtedness being replaced, renewed, extended, refinanced or refunded (other
than  the extension of the maturity date thereof) and (II) not in a principal
amount greater than such indebtedness being replaced, renewed, extended,
refinanced or refunded or, in the case of any "revolving" credit facility, the
aggregate  amount that may be incurred under the credit agreement governing
such indebtedness being replaced, renewed, extended, refinanced or refunded
(as in effect as of the date hereof), (D) guarantees of indebtedness of the
Company or its wholly-owned Subsidiaries outstanding on the date hereof or
otherwise incurred  in compliance with this _Section 6.01(h)_ _(ii)_ _,_ (E)
in  respect of interest rate, swap, currency, commodity or other similar
hedging arrangements which (I) are entered into in connection with the
restructuring or replacement of up to $500,000,000 in aggregate notional
amount of existing  hedging arrangements expiring in 2019 into forward
contracts, (II) are entered into in connection with the restructuring or
replacement of up to $750,000,000 in aggregate notional amount of existing
hedging arrangements expiring in 2020  into forward contracts, or (III) are
entered into in the ordinary course of business consistent with past practice
in an aggregate notional amount not to exceed $250,000,000 at any time
outstanding, and (F) other indebtedness not to  exceed $50,000,000 in the
aggregate at any time outstanding pursuant to this subclause (F);

 


 

 

 

71  

(i) (i) enter into any Company Material Contract (including by amendment of
any Contract that is not a Company Material Contract such that such Contract
becomes a Company Material Contract),  other than in the ordinary course of
business consistent with past practice (except that no Company Material
Contract of the type described in clause (iv), (vii), (viii), (ix), (xi),
(xii) or (xiii) of _Section 4.16(a)_ shall be  entered into (unless it is
entered into as part of a Company Permitted Settlement in accordance with
_Section 6.01(n)_ )), or (ii) terminate, renew, extend or in any material
respect modify or amend any Company Material Contract,  other than in the
ordinary course of business (except that no Company Material Contract of the
type described in clause (iv), (vii), (viii), (ix), (xi), (xii) or (xiii) of
_Section 4.16(a)_ shall be terminated, renewed or extended  or in any
material respect modified or waived (unless it is entered into as part of a
Company Permitted Settlement in accordance with _Section 6.01(n_ _)_ )), or
waive, release or assign any material right or claim thereunder;

 


 

 

(j) voluntarily terminate, suspend, abrogate, amend or modify any material
Company Permit in a manner materially adverse to the Company and its
Subsidiaries, taken as a whole;

 


 

 

(k) except as required by Applicable Law or Company Employee Plans as in
effect as of the date hereof, (i) grant any change in control, severance or
termination pay to (or amend any existing  arrangement with) any of their
respective directors, officers or employees (including former directors,
officers or employees), (ii) enter into any employment, deferred compensation
or other similar agreement (or any amendment to any  such existing agreement)
with any of their respective current or former director, officers or
employees, other than offer letters (and related compensation arrangements set
forth in such offer letters) with any newly hired directors or  employees of
the Company who are not considered to be executive officers (as defined in the
1934 Act) and who are not members of the executive leadership team that are
entered into in the ordinary course of business consistent with past 
practice, (iii) establish, adopt or amend any Company Employee Plan or labor
agreement, other than in the ordinary course of business consistent with past
practice or any immaterial amendment that would not increase the cost to the 
Company or any of its Subsidiaries of maintaining such Company Employee Plan,
or (iv) increase the compensation, bonus opportunity or other benefits payable
to any of their respective directors, officers or employees (including
former  directors, officers or employees);

 


 

 

 

72  

(l) make any material change in any method of financial accounting or
financial accounting principles or practices, except for any such change
required by reason of (or, in the reasonable  good-faith judgment of the
Company, advisable under) a change in GAAP or Regulation S-X under the 1934
Act (" _Regulation S-X_ "), as approved by its independent public accountants;

 


 

 

(m) (i) make, change or revoke any material Tax election; (ii) change any
annual Tax accounting period; (iii) adopt or change any material method of Tax
accounting; (iv) enter into any  material closing agreement with respect to
Taxes; (v) settle or surrender or otherwise concede, terminate or resolve any
material Tax claim, audit, investigation or assessment; or (vi) file or amend
any U.S. federal or other material  income Tax Return;

 


 

 

(n) settle or compromise any claim, action, suit, investigation or proceeding
involving or against the Company or any of its Subsidiaries (including any
action, suit, investigation, or  proceeding involving or against any
employee, officer or director of the Company or any of its Subsidiaries in
their capacities as such), other than any Company Permitted Settlement; or

 


 

 

(o) agree, commit or propose to do any of the foregoing.

 


 

 

Section 6.02 _No Solicitation by the Company_.

 


 

 

(a) From the date of this Agreement until the earlier of the Merger Effective
Time and the termination of this Agreement, except as otherwise set forth in
this _Section 6.02_ , the  Company shall not, and shall cause its
Subsidiaries and its and its Subsidiaries' directors and officers to not, and
shall use its reasonable best efforts to cause its and its Subsidiaries' other
Representatives to not, directly or  indirectly, (i) solicit, initiate or
take any action to knowingly facilitate or knowingly encourage (including by
way of furnishing information) the submission of any Company Acquisition
Proposal, (ii) enter into or participate in any  discussions or negotiations
with, furnish any information relating to the Company or any of its
Subsidiaries or afford access to the business, properties, assets, books or
records of the Company or any of its Subsidiaries to, otherwise  cooperate in
any way with, or knowingly assist, participate in, knowingly facilitate or
knowingly encourage any effort by, any Third Party that the Company knows is
seeking to make, or has made, a Company Acquisition Proposal, (iii) (A) 
withdraw or qualify, amend or modify in any manner adverse to Parent, the
Company Board Recommendation, (B) fail to include the Company Board
Recommendation in the Joint Proxy Statement/Prospectus or (C) recommend, adopt
or approve or  publicly propose to recommend, adopt or approve any Company
Acquisition Proposal (any of the foregoing in this clause (iii), a " _Company
Adverse  Recommendation Change_ "), or (iv) take any action to make any
"moratorium", "control share acquisition", "fair price", "supermajority",
"affiliate  transactions" or "business combination statute or regulation" or
other similar anti-takeover laws and regulations of the State of Delaware,
including Section 203 of the DGCL, inapplicable to any Third Party or any
Company Acquisition  Proposal.

 


 

 

 

73  

(b) Notwithstanding the foregoing, if at any time prior to the receipt of the
Company Stockholder Approval (the " _Company Approval Time_ ") (and in no
event after the Company Approval Time), the Board of Directors of the Company
receives a bona fide written Company Acquisition Proposal made after the
date  hereof which has not resulted from a violation of this _Section 6.02_ ,
the Board of Directors of the Company, directly or indirectly through its
Representatives, may (x) contact the Third Party that has made such Company 
Acquisition Proposal in order to ascertain facts or clarify terms for the sole
purpose of the Board of Directors of the Company informing itself about such
Company Acquisition Proposal and such Third Party and (y) subject to
compliance  with this _Section 6.02(b)_ , _Section 6.02(c)_ and _Section
6.02(e)_ , (i) engage in negotiations or discussions with any Third Party
that, subject to the Company's compliance with _Section 6.02(a)_ , has made 
after the date of this Agreement a Company Superior Proposal or an unsolicited
bona fide written Company Acquisition Proposal that the Board of Directors of
the Company determines in good faith, after consultation with its financial
advisor and outside legal counsel, is or could  reasonably be expected to
lead to a Company Superior Proposal, (ii) furnish to such Third Party and its
Representatives and financing sources nonpublic information relating to the
Company or any of its Subsidiaries pursuant to a  confidentiality agreement
with confidentiality and use provisions no less favorable and other provisions
no less favorable in the aggregate, in each case, to the Company than those
contained in the Confidentiality Agreement, a copy of  which shall be
provided, promptly after its execution, to Parent for informational purposes;
_provided_ that all such non-public information (to the extent that such
information has not been  previously provided or made available to Parent) is
provided or made available to Parent, as the case may be, substantially
concurrently with the time it is provided or made available to such Third
Party, and (iii) following receipt of  a Company Superior Proposal after the
date of this Agreement, (A) make a Company Adverse Recommendation Change
and/or (B) terminate this Agreement in accordance with _Section 10.01(d)(iii)_
to enter into a definitive agreement  providing for such Company Superior
Proposal, but in the case of this clause (iii) only if the Board of Directors
of the Company determines in good faith, after consultation with the Company's
outside legal counsel and financial  advisor, that the failure to take such
action would be reasonably likely to be inconsistent with its fiduciary duties
under Applicable Law. Nothing contained herein shall prevent the Board of
Directors of the Company from (x) complying  with Rule 14e-2(a) under the
1934 Act with regard to a Company Acquisition Proposal, so long as any action
taken or statement made to so comply is consistent with this _Section 6.02_ ,
or (y) making any required disclosure to the stockholders of the Company if
the Board of Directors of the  Company determines in good faith, after
consultation with its outside legal counsel, that the failure to take such
action would be reasonably likely to be inconsistent with Applicable Law;
_provided_ that any Company Adverse Recommendation Change involving or
relating to a Company Acquisition Proposal may only be made in accordance with
the provisions of this _Section 6.02(b)_ , _Section 6.02(c)_ and
_Section      6.02(e)_. A "stop, look and listen" disclosure or similar
communication of the type contemplated by Rule 14d-9(f) under the 1934 Act
shall not be a Company Adverse Recommendation Change.

 


 

 

(c) In addition to the requirements set forth in _Section 6.02(b)_ , the Board
of Directors of the Company shall not take any of the actions referred to in
clauses (i) through (iii) of _Section         6.02(b)_ unless the
Company shall have first delivered to Parent written notice advising Parent
that the Company intends to take such action. The Company shall notify Parent
as promptly as practicable (but in no event later than  forty eight (48)
hours) after receipt by the Company (or any of its Representatives) of any
Company Acquisition Proposal or any request for information relating to the
Company or any of its Subsidiaries or for access to the business, 
properties, assets, books or records of the Company or any of its Subsidiaries
by any Third Party that, to the knowledge of the Company, is reasonably likely
to make or has made any Company Acquisition Proposal, which notice shall be 
provided in writing and shall identify the Third Party making, and the
material terms and conditions of, any such Company Acquisition Proposal or
request. The Company shall thereafter (x) keep Parent reasonably informed, on
a  reasonably current basis, of any material changes in the status and
details of any such Company Acquisition Proposal or request and (y) as
promptly as practicable (but in no event later than twenty four (24) hours
after receipt) provide  to Parent copies of all material correspondence and
written materials sent or provided to the Company or any of its Subsidiaries
that describes any terms or conditions of any Company Acquisition Proposal (as
well as written summaries of  any material oral communications relating to
the terms and conditions of any Company Acquisition Proposal).

 


 

 

 

74  

(d) Notwithstanding anything in this Agreement to the contrary, at any time
prior to the Company Approval Time (and in no event after the Company Approval
Time), the Board of Directors of the  Company may effect a Company Adverse
Recommendation Change involving or relating to a Company Intervening Event if
the Board of Directors of the Company determines in good faith, after
consultation with its outside legal counsel, that  the failure to take such
action would be reasonably likely to be inconsistent with its fiduciary duties
under Applicable Law; _provided_ that (i) the Company shall first notify
Parent in writing of its  intention to take such action, which notice shall
include a reasonably detailed description of such Company Intervening Event,
(ii) if requested by Parent, the Company and its Representatives shall discuss
and negotiate in good faith  with Parent and its Representatives (to the
extent that Parent desires to so negotiate) during the four (4) Business Day
period following such notice regarding any proposal by Parent to amend the
terms of this Agreement in response to  such Company Intervening Event, and
(iii) the Board of Directors of the Company shall not effect any Company
Adverse Recommendation Change involving or relating to a Company Intervening
Event unless, after the four (4) Business Day  period described in the
foregoing clause (ii), the Board of Directors of the Company determines in
good faith, after consultation with its outside legal counsel and taking into
account any proposal by Parent to amend the terms of this  Agreement during
such four (4) Business Day period, that the failure to take such action would
continue to be reasonably likely to be inconsistent with its fiduciary duties
under Applicable Law.

 


 

 

(e) Without limiting or affecting _Section 6.02(a)_ , _Section 6.02(b)_ or
_Section 6.02(c)_ , the Board of Directors of the Company shall not make a
Company Adverse  Recommendation Change involving or relating to a Company
Superior Proposal or terminate this Agreement to enter into a definitive
agreement with respect to a Company Superior Proposal unless (i) the Company
first notifies Parent, in  writing at least four (4) Business Days before
taking such action, that the Company intends to take such action, which notice
attaches the most current version of each proposed Contract or other agreement
providing for such Company  Superior Proposal and the identity of the Third
Party(ies) making the Company Superior Proposal, (ii) if requested by Parent,
during such four (4) Business Day period, the Company and its Representatives
have discussed and negotiated in  good faith with Parent (to the extent that
Parent desires to so negotiate) regarding any proposal by Parent to amend the
terms of this Agreement in response to such Company Superior Proposal and
(iii) after such four (4) Business Day  period, the Board of Directors of the
Company determines in good faith, after consultation with its financial
advisor and outside legal counsel and taking into account any proposal by
Parent to amend the terms of this Agreement, that  such Company Acquisition
Proposal continues to constitute a Company Superior Proposal and that the
failure to take such action would continue to be reasonably likely to be
inconsistent with its fiduciary duties under Applicable Law (it  being
understood and agreed that in the event of any amendment to the financial
terms or other material terms of any such Company Superior Proposal, a new
written notification from the Company consistent with that described in
clause  (i) of this _Section 6.02(e)_ shall be required, and a new notice
period under clause (i) of this _Section 6.02(e)_ shall commence, during which
notice period the Company shall be required to comply with the requirements
of  this _Section 6.02(e)_ anew, except that such new notice period shall be
for two (2) Business Days (as opposed to four (4) Business Days)). After
delivery of such written notice pursuant to the immediately preceding
sentence, the  Company shall keep Parent reasonably informed on a reasonably
current basis of all material developments affecting the material terms of any
such Company Superior Proposal (and the Company shall provide Parent with
copies of any  additional written materials received that provide for or that
are material to such Company Superior Proposal).

 


 

 

 

75  

(f) " _Company Superior Proposal_ " means any bona fide, written Company 
Acquisition Proposal (other than a Company Acquisition Proposal which has
resulted from a violation of this _Section 6.02)_ (with all references to
"twenty percent (20%)" in the definition of Company Acquisition Proposal
being  deemed to be references to "fifty percent (50%)") on terms that the
Board of Directors of the Company determines in good faith, after consultation
with its financial advisor and outside legal counsel, and taking into account
all the  terms and conditions of the Company Acquisition Proposal that the
Board of Directors of the Company considers to be appropriate (including the
identity of the Person making the Company Acquisition Proposal and the
expected timing and  likelihood of consummation, any governmental or other
approval requirements (including divestitures and entry into other commitments
and limitations), break-up fees, expense reimbursement provisions, conditions
to consummation and the  availability of necessary financing (including, if a
cash transaction (in whole or in part), the availability of such funds and the
nature, terms and conditionality of any committed financing), would result in
a transaction (i) that, if  consummated, is more favorable to the Company's
stockholders from a financial point of view than the Merger (taking into
account any proposal by Parent to amend the terms of this Agreement), and (ii)
that is reasonably capable of being  completed on the terms proposed, taking
into account the identity of the Person making the Company Acquisition
Proposal, any approval requirements and all other financial, regulatory, legal
and other aspects of such Company Acquisition  Proposal.

 


 

 

(g) " _Company Intervening Event_ " means any material event, fact, change,
effect, development or occurrence that (i) was not known, or the material
consequences of which were not known, in each case to the Board of Directors
of the Company as of or prior  to the date of this Agreement and (ii) does
not relate to or involve any Company Acquisition Proposal.

 


 

 

(h) The Company shall, and shall cause its Subsidiaries and its and its
Subsidiaries' directors and officers to, and shall use its reasonable best
efforts to cause its and its Subsidiaries'  other Representatives to, cease
immediately and cause to be terminated any and all existing activities,
discussions or negotiations, if any, with any Third Party conducted prior to
the date of this Agreement with respect to any Company  Acquisition Proposal
or with respect to any indication, proposal or inquiry that could reasonably
be expected to lead to a Company Acquisition Proposal and shall use its
reasonable best efforts to cause any such party (and any of its 
Representatives) in possession of confidential information about the Company
or any of its Subsidiaries that was furnished by or on behalf of the Company
to return or destroy all such information.

 


 

 

 

76  

Section 6.03 _Financing Assistance_.

 


 

 

(a) Prior to the Closing, the Company shall, and shall cause its Subsidiaries
to, use its and their commercially reasonable efforts to provide such
customary cooperation as may be reasonably  requested by Parent in writing to
assist Parent in arranging, obtaining or syndicating the Debt Financing (which
term shall include, for purposes of this _Section 6.03_ , any of the permanent
financing referred to in the Debt  Commitment Letters) ( _provided_ that such
requested cooperation does not unreasonably interfere with the ongoing
business or operations of the Company and its Subsidiaries), including using 
commercially reasonable efforts to:

 


 

 

 

 

(i) reasonably         cooperate with the marketing efforts or due
diligence efforts of Parent or the Financing Sources, in each case, in
connection with the Debt Financing, including using commercially reasonable
efforts to cause members of management with  appropriate seniority and
expertise to participate in a reasonable number of meetings, due diligence
sessions, rating agency sessions and road shows, at times and at locations
reasonably acceptable to the Company and upon reasonable  notice;

 


 

 

(ii) reasonably assist Parent  in preparing customary offering memoranda,
rating agency presentations, lender and investor presentations, confidential
information memoranda, private placement memoranda, prospectuses and other
similar documents for the Debt Financing,  and as promptly as practicable
provide historical financial and other customary information relating to the
Company to Parent and the Financing Sources to the extent reasonably requested
by Parent, including delivering and consenting to  the inclusion or
incorporation in any SEC filing related to the Debt Financing or the
Alternative Financing of (A) audited consolidated balance sheets and related
audited consolidated statements of income, comprehensive income, 
stockholders' equity and cash flows of the Company for each of the three
fiscal years most recently ended more than sixty (60) days prior to the
Closing Date (and audit reports for such financial statements shall not be
subject to any  "going concern" qualifications), (B) unaudited consolidated
balance sheets and related unaudited consolidated statements of income,
comprehensive income and cash flows of the Company for each subsequent fiscal
quarter ended more than  forty five (45) days prior to the Closing Date and
(C) all other historical financial and other customary information regarding
the Company reasonably necessary to permit Parent to prepare pro forma
financial statements customary for the  bank financing and the debt
securities offering contemplated by the Debt Financing or the Alternative
Financing ( _provided_ , that, without limiting the foregoing,  nothing in
this _Section 6.03(a)_ or _Section 6.04_ shall require the Company to 
prepare any pro forma financial information or projections, which shall be the
sole responsibility of Parent);

 


 

 

(iii) provide to Parent and  the Financing Sources promptly, and in any event
at least four (4) Business Days prior to the Closing Date, all documentation
and other information about the Company and its Subsidiaries required by the
Financing Sources or regulatory  authorities with respect to the Debt
Financing under applicable "know your customer" and anti-money laundering
rules and regulations, including the PATRIOT Act, that is required under any
Debt Commitment Letter or any definitive agreement  related to the Debt
Financing to the extent such documentation and other information is requested
in writing to the Company at least ten (10) Business Days prior to the Closing
Date,

 


 

 

 

77  

(iv) in connection with any  securities offering contemplated as part of the
Debt Financing or the Alternative Financing, (A) obtain customary comfort
letters from the Company's independent public accounting firm, (B) cause the
Company's independent public accounting  firm to consent to the inclusion or
incorporation of their audit reports with respect to the financial statements
of the Company provided pursuant to _Section 6.03(ii)(A)_   in any
registration statement of Parent with the SEC or any prospectus, offering
memoranda, private placement memoranda, marketing material or similar
documentation, including by providing customary representation letters and (C)
cause  the Company's independent public accounting firm to cooperate with
Parent and its Representatives, including by participating in accounting due
diligence sessions at times and at locations reasonably acceptable to the
Company and its  independent public accounting firm and upon reasonable
notice,

 


 

 

(v) subject to customary  confidentiality provisions and disclaimers, provide
customary authorization letters to the Financing Sources authorizing the
distribution of information to prospective lenders or investors,

 


 

 

(vi) (A) deliver notices of  prepayment and/or notices for termination of
commitments within the time periods required by the Credit Agreement and
obtain customary payoff letters and if applicable, instruments of discharge to
be delivered at Closing to allow for the  payoff, discharge and termination
in full on the Closing Date of the Credit Agreement; _provided_ that any such
notice or payoff letter shall be expressly  conditioned on the Closing and
(B) assist Parent in delivering, on the Closing Date, the supplemental
indentures and officers' certificates required to be delivered under Section
6.1 of each of the applicable Indentures due to the  consummation of the
Merger,

 


 

 

(vii) provide information  concerning the Company and its Subsidiaries
reasonably necessary for the completion of the definitive documentation for
the Debt Financing, including any schedules thereto,

 


 

 

(viii) provide or cause to be  provided any customary certificates, or other
customary closing documents as may reasonably be requested in connection with
the Debt Financing and the Alternative Financing, and

 


 

 

(ix) consent to the use of the  trademarks, service marks and logos of the
Company or any of its Subsidiaries in connection with the Debt Financing;
_provided_ that such trademarks, service marks and logos are used solely in a
manner that is not intended to or is reasonably likely to harm or disparage
the Company or its Subsidiaries  or the reputation or goodwill of the Company
or any of its Subsidiaries.

 


 

 

 

78  

(b) Notwithstanding the foregoing or anything the contrary set forth in
_Section 6.04_ below, neither the Company nor any of its Subsidiaries shall be
required to (i) take or permit the taking of any action pursuant to _Section
6.03(a)_ or _Section 6.04_ that (A) would require the Company, its
Subsidiaries or any Persons  who are directors or officers of the Company or
its Subsidiaries to pass resolutions or consents to approve or authorize the
execution of the Debt Financing, or any Company Note Offers and Consent
Solicitations or execute or deliver any  certificate, document, instrument or
agreement or agree to any change or modification of any existing certificate,
document, instrument or agreement, in each case, that is effective prior to
the Closing, or that would be effective if  the Closing does not occur (other
than (x) authorization letters contemplated by _Section 6.03(a)(v)_ and (y) to
the extent required by _Section 6.04_ , applicable Company Supplemental
Indentures and Company Indenture Officers' Certificates); (B) would cause any
representation or warranty in this Agreement to be breached by the Company or
any of its Subsidiaries (unless  waived by Parent); (C) would require the
Company or any of its Subsidiaries to pay any commitment or other similar fee
prior to the Closing or incur any other expense, liability or obligation in
connection with the Debt Financing or  any Company Note Offers and Consent
Solicitations that is not, subject to the limitations contained therein,
subject to reimbursement or is not otherwise indemnified by Parent pursuant to
_Section 6.03(c)_ ; (D) would cause any  director, officer or employee or
stockholder of the Company or any of its Subsidiaries to incur any personal
liability; or (E) would result in a material violation or breach of, or a
default under, any material Contract to which the  Company or any of its
Subsidiaries is a party, the organizational documents of the Company or its
Subsidiaries or any Applicable Law; (ii) provide access to or disclose
information that the Company or any of its Subsidiaries reasonably 
determines would jeopardize any attorney-client privilege of the Company or
any of its Subsidiaries or (iii) deliver or cause to be delivered any opinion
of counsel (other than, to the extent required by _Section 6.04_ in connection
with the entry into a Company Supplemental Indenture, a Company Opinion  of
Counsel if the trustee under the applicable Indenture that the Company
Supplemental Indenture amends requires an opinion of counsel to the Company).
Nothing contained in this _Section 6.03_ or _Section 6.04_ or otherwise shall
require the Company or any of its Subsidiaries, prior to the  Closing, to be
an issuer or other obligor with respect to the Debt Financing or to commence
any Company Note Offers and Consent Solicitations.

 


 

 

(c) Parent and Merger Sub shall, on a joint and several basis, promptly upon
written request by the Company, reimburse the Company for all reasonable and
documented out-of-pocket costs and  expenses (including reasonable attorneys'
fees) incurred by the Company or any of its Subsidiaries in connection with
the Debt Financing or any Company Note Offers and Consent Solicitations or
satisfying its obligations under this _Section      6.03_ or _Section
6.04_ , whether or not the Merger is consummated  or this Agreement is
terminated. Parent and Merger Sub shall, on a joint and several basis,
indemnify and hold harmless the Company and its Subsidiaries and their
respective Representatives from and against any and all losses, claims, 
damages, liabilities, reasonable out-of-pocket costs, reasonable out-of-pocket
attorneys' fees, judgments, fines, penalties and amounts paid in settlement
(including all interest, assessments and other charges paid or payable in 
connection with or in respect of any thereof) suffered or incurred in
connection with the Debt Financing or any Company Note Offers and Consent
Solicitations or otherwise in connection with any action taken by the Company,
any of its  Subsidiaries or any of their respective Representatives pursuant
to this _Section 6.03_ or _Section 6.04_ (other than the use of any
information provided by the Company, any of its Subsidiaries or any of their
respective Representatives in writing for use in connection with the Debt
Financing or  Company Note Offers and Consent Solicitations), except (A) in
the event such losses, claims, damages, liabilities, costs, attorneys' fees,
judgments, fines, penalties and amounts paid in settlement are determined by a
final  non-appealable judgment of a court of competent jurisdiction to have
arisen out of, or resulted from, the fraud, gross negligence or willful
misconduct of the Company, any of its Subsidiaries or any of their respective
Representatives  or (B) if this Agreement is terminated by Parent pursuant to
_Section 10.01(c)(ii)_.

 


 

 

 

79  

(d) Notwithstanding anything to the contrary in this Agreement, the Company's
breach of any of the covenants required to be performed by it under this
_Section 6.03_ or _Section 6.04_ will not be considered in determining the
satisfaction of the  condition set forth in _Section 9.02(a)_ unless such
breach is the primary cause of Parent being unable to obtain the proceeds of
the Debt Financing at the Closing.

 


 

 

Section 6.04 _Cooperation as to Certain Indebtedness_. Parent or one of its
Subsidiaries may  (a) commence any of the following: (i) one or more offers
to purchase any or all of the outstanding debt issued under the Indentures for
cash (the " _Offers        to Purchase_ "); or (ii) one or more offers
to exchange any or all of the outstanding debt issued under the Indentures for
securities issued by Parent  (or its Affiliates) (the " _Offers to Exchange_
"); and (b) solicit the  consent of the holders of debt issued under the
Indentures regarding certain proposed amendments to the applicable Indenture
(the " _Consent Solicitations_ " and, together with the Offers to Purchase and
Offers to Exchange, if any, the " _Company        Note Offers and
Consent Solicitations_ "); _provided_ that the closing of any such transaction
shall not be consummated until the Closing and any such transaction shall be
funded using consideration provided by Parent. Any  Company Note Offers and
Consent Solicitations shall be made on such terms and conditions (including
price to be paid and conditionality) as are proposed by Parent and which are
permitted by the terms of the applicable Indenture and  applicable Laws,
including SEC rules and regulations. Parent shall consult with the Company
regarding the material terms and conditions of any Company Note Offers and
Consent Solicitations, including the timing and commencement of any  Company
Note Offers and Consent Solicitations and any tender deadlines. Parent shall
have provided the Company with the necessary offer to purchase, offer to
exchange, consent solicitation statement, letter of transmittal, press 
release, if any, in connection therewith, and each other document relevant to
the transaction that will be distributed by the Parent in the applicable
Company Note Offers and Consent Solicitations (collectively, the " _Debt Offer
Documents_ ") a reasonable period of time in advance of commencing the 
applicable Company Note Offers and Consent Solicitations to allow the Company
and its counsel to review and comment on such Debt Offer Documents, and Parent
shall give reasonable and good faith consideration to any comments made or 
input provided by the Company and its legal counsel. Subject to the receipt of
the requisite holder consents, in connection with any or all of the Consent
Solicitations, the Company shall execute a supplemental indenture to the 
applicable Indenture in accordance with the terms thereof amending the terms
and provisions of such Indenture as described in the applicable Debt Offer
Documents in a form as reasonably requested by Parent (each, a " _Company
Supplemental Indenture_ "); _provided_ that such supplemental indenture shall
not become effective until the Closing. The Company shall,  and shall cause
each of its Subsidiaries to, and shall use commercially reasonable efforts to
cause its and their Representatives to, provide all reasonable and customary
cooperation as may be reasonably requested by Parent in writing  to assist
Parent in connection with any Company Note Offers and Consent Solicitations
(including, but not limited to, upon Parent's written request, using
commercially reasonable efforts to cause the Company's independent accountants
to  provide customary consents for use of their reports to the extent
required in connection with any Company Note Offers and Consent Solicitations)
( _provided_ that such requested cooperation does not unreasonably interfere
with  the ongoing business or operations of the Company and its
Subsidiaries); _provided_ that neither the Company nor counsel for the Company
shall be required to furnish any certificates, legal opinions or negative
assurance letters in connection with any Company Note Offers and Consent
Solicitations (other  than, in connection with the execution of any Company
Supplemental Indenture relating to the Consent Solicitations, with respect to
which the Company shall (x) deliver customary officer's certificates (a "
_Company Indenture Officers ' Certificate_") and (y) use commercially
reasonable efforts to cause  counsel for the Company to deliver customary
legal opinions to the trustee under the applicable Indenture in the form
required by Section 10.3 of the applicable Indenture (a " _Company Opinion of
Counsel_ "), if the trustee under the applicable Indenture that the Company
Supplemental Indenture amended  requires an opinion of counsel to the Company
thereunder, to the extent such certificates and opinions would not conflict
with applicable Laws and would be accurate in light of the facts and
circumstances at the time delivered) or  execute any other instruments or
agreements in connection therewith other than the Company Supplemental
Indenture described in the immediately preceding sentence. The dealer manager,
solicitation agent, information agent, depositary or  other agent retained in
connection with any Company Note Offers and Consent Solicitations will be
selected by Parent, retained by Parent, and their fees and out-of-pocket
expenses will be paid directly by Parent. If, at any time prior  to the
completion of the Company Note Offers and Consent Solicitations, the Company
or any of its Subsidiaries, on the one hand, or Parent or any of its
Subsidiaries, on the other hand, discovers any information that should be set
forth  in an amendment or supplement to the Debt Offer Documents, so that the
Debt Offer Documents shall not contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary
in order  to make the statements therein, in light of circumstances under
which they are made, not misleading, such party that discovers such
information shall use commercially reasonable efforts to promptly notify the
other party, and an  appropriate amendment or supplement prepared by Parent
describing such information shall be disseminated to the holders of the
applicable notes, debentures or other debt securities of the Company
outstanding under the applicable  Indenture. The consummation of any or all
of the Company Note Offers and Consent Solicitations shall not be a condition
to Closing.

 


 

 

 

80  

Section 6.05   _Abraxis CVR Agreement_. The Company shall use commercially
reasonable  efforts to, in accordance with the provisions of the Abraxis CVR
Agreement and prior to the Merger Effective Time, (a) provide or cause to be
provided to the Abraxis CVR Trustee any certificate, notice, legal opinion or
other  documentation and (b) take or cause to be taken such other actions, in
the case of each of clause (a) and (b), to the extent required under the
Abraxis CVR Agreement in connection with this Agreement and the transactions
contemplated  hereby (including the Merger). Parent and its counsel shall be
given a reasonable opportunity to review and comment on any such notice,
certificate, legal opinion or other documentation and be consulted with in
connection with the  taking of any such action, in each case before such
notice, certificate, legal opinion or other documentation is provided to
Abraxis CVR Trustee or such action is taken, and the Company shall give
reasonable and good faith consideration  to any comments made and other input
provided by Parent and its counsel in connection therewith.

 


 

 

 

81  

ARTICLE VII 
  
  COVENANTS OF PARENT

 


 

 

Parent agrees that:

 


 

 

Section 7.01 _Conduct of Parent_. From the date of this Agreement until the
earlier of the  Merger Effective Time and the termination of this Agreement,
except (x) as prohibited or required by Applicable Law, (y) as set forth in
_Section 7.01_ of the Parent Disclosure Schedule, or (z) as otherwise required
or expressly  contemplated by this Agreement, unless the Company shall
otherwise consent in writing (which consent shall not be unreasonably
withheld, conditioned or delayed), Parent shall, and shall cause each of its
Subsidiaries to, use  commercially reasonable efforts to conduct its business
in all material respects in the ordinary course of business consistent with
past practice; _provided_ that (i) no action by the Parent or any of its
Subsidiaries to the extent expressly permitted by an exception to any of
_Section 7.01(a)_ through _Section  7.01(f)_ will be a breach of this
sentence and (ii) if Parent or any of its Subsidiaries seeks the consent of
the Company to take any action prohibited by any of _Section 7.01(a)_ through
_Section 7.01(f)_ , and such  consent is withheld by the Company, the failure
to take such action will not be deemed to be a breach of this sentence.
Without limiting the generality of the foregoing, except (A) as prohibited or
required by Applicable Law, (B) as  set forth in _Section 7.01_ of the Parent
Disclosure Schedule, or (C) as otherwise required or expressly contemplated by
this Agreement, without the Company's prior written consent (which consent
shall not be unreasonably  withheld, conditioned or delayed), Parent shall
not, and shall cause each of its Subsidiaries not to:

 


 

 

(a) adopt or propose any change to the Parent Organizational Documents or the
certificate of incorporation or bylaws of Merger Sub (whether by merger,
consolidation or otherwise);

 


 

 

(b) (i) merge or consolidate with any other Person, (ii) acquire (including by
merger, consolidation or acquisition of stock or assets) any interest in any
corporation, partnership, other  business organization or any division
thereof or any assets, securities or property, (iii) otherwise purchase,
lease, license or otherwise enter into a transaction, or (iv) agree to do any
of the foregoing, in each of cases (i), (ii),  (iii) or (iv), that would
reasonably be expected to prevent or delay in any material respect the
consummation of the transactions contemplated by this Agreement, or (v) adopt
a plan of complete or partial liquidation or dissolution with  respect to
Parent or Merger Sub;

 


 

 

(c) (i) split, combine or reclassify any shares of its capital stock (other
than transactions (1) solely among Parent and one or more of its wholly owned
Subsidiaries or (2) solely among  Parent's wholly owned Subsidiaries), (ii)
declare, set aside or pay any dividend or make any other distribution (whether
in cash, stock, property or any combination thereof) in respect of any shares
of its capital stock or other Equity  Securities, other than (A) in the case
of Parent, regular cash dividends in the ordinary course of business
consistent with past practice (including with respect to the timing of
declaration, and the record and payment dates) in an  amount not to exceed
$0.41 per share of Parent Common Stock per quarter (appropriately adjusted to
reflect any stock dividends, subdivisions, splits, combinations or other
similar events relating to Parent Common Stock), or (B)  dividends or
distributions by a Subsidiary of Parent to Parent or a wholly owned Subsidiary
of Parent, or (iii) redeem, repurchase, cancel or otherwise acquire or offer
to redeem, repurchase, or otherwise acquire any of its Equity  Securities or
any Equity Securities of any Subsidiary of Parent, other than (A) repurchases
of shares of Parent Common Stock at market price, or (B) repurchases of shares
of Parent Common Stock in connection with the exercise of Parent  Stock
Options or the vesting or settlement of Parent Restricted Stock Units, Market
Based Units, Performance Share Units and other Parent Equity Awards (including
in satisfaction of any amounts required to be deducted or withheld under 
Applicable Law), in each case outstanding as of the date of this Agreement in
accordance with the present terms of such Parent Equity Awards or granted
after the date of this Agreement to the extent permitted by this Agreement;

 


 

 

 

82  

(d) issue, deliver or sell, or authorize the issuance, delivery or sale of,
any shares of its capital stock or other Equity Securities, other than (i) the
issuance of any shares of Parent  Common Stock upon the exercise of Parent
Equity Awards or other equity and equity-linked awards that are outstanding on
the date of this Agreement or are granted after the date of this Agreement,
(ii) with respect to capital stock or  other Equity Securities of any
Subsidiary of Parent, in connection with transactions (A) solely among Parent
and one or more of its wholly owned Subsidiaries or (B) solely among Parent's
wholly owned Subsidiaries, (iii) the grant of  Parent Equity Awards or other
equity and equity-linked awards to employees, directors or individual
independent contractors of Parent or any of its Subsidiaries pursuant to
Parent's equity compensation plans or (iv) in connection with  the Parent
Share Issuance;

 


 

 

(e) make any material change in any method of financial accounting or
financial accounting principles or practices, except for any such change
required by reason of (or, in the reasonable  good-faith judgment of Parent,
advisable under) a change in GAAP or Regulation S-X, as approved by its
independent public accountants; or

 


 

 

(f) agree, commit or propose to do any of the foregoing.

 


 

 

Section 7.02 _No Solicitation by Parent_.

 


 

 

(a) From the date of this Agreement until the earlier of the Merger Effective
Time and the termination of this Agreement, except as otherwise set forth in
this _Section 7.02_ , Parent  shall not, and shall cause its Subsidiaries and
its and its Subsidiaries' directors and officers to not, and shall use its
reasonable best efforts to cause its and its Subsidiaries' other
Representatives to not, directly or indirectly,  (i) solicit, initiate or
take any action to knowingly facilitate or knowingly encourage (including by
way of furnishing information) the submission of any Parent Acquisition
Proposal, (ii) enter into or participate in any discussions or  negotiations
with, furnish any information relating to Parent or any of its Subsidiaries or
afford access to the business, properties, assets, books or records of Parent
or any of its Subsidiaries to, otherwise cooperate in any way  with, or
knowingly assist, participate in, knowingly facilitate or knowingly encourage
any effort by, any Third Party that Parent knows is seeking to make, or has
made, a Parent Acquisition Proposal, (iii) (A) withdraw or qualify, amend  or
modify in any manner adverse to the Company, the Parent Board Recommendation,
(B) fail to include the Parent Board Recommendation in the Joint Proxy
Statement/Prospectus or (C) recommend, adopt or approve or publicly propose
to  recommend, adopt or approve any Parent Acquisition Proposal (any of the
foregoing in this clause (iii), a " _Parent Adverse Recommendation Change_ "),
or (iv) take any action to make any "moratorium", "control share acquisition",
"fair price", "supermajority", "affiliate transactions" or "business
combination  statute or regulation" or other similar anti-takeover laws and
regulations of the State of Delaware, including Section 203 of the DGCL,
inapplicable to any Third Party or any Parent Acquisition Proposal.

 


 

 

 

83  

(b) Notwithstanding the foregoing, if at any time prior to the receipt of the
Parent Stockholder Approval (the " _Parent         Approval Time_ ")
(and in no event after the Parent Approval Time), the Board of Directors of
Parent receives a bona fide written Parent Acquisition Proposal made after the
date hereof which has not  resulted from a violation of this _Section 7.02_ ,
the Board of Directors of Parent, directly or indirectly through its
Representatives, may (x) contact the Third Party that has made such Parent
Acquisition Proposal in order to  ascertain facts or clarify terms for the
sole purpose of the Board of Directors of Parent informing itself about such
Parent Acquisition Proposal and such Third Party and (y) subject to compliance
with this _Section 7.02(b)_ , _Section     7.02(c)_ and _Section 7.02(e)_
, (i) engage in negotiations or discussions with any Third Party that, subject
to Parent's compliance with _Section 7.02(a)_ , has made after the date of
this Agreement a Parent Superior  Proposal or an unsolicited bona fide
written Parent  Acquisition Proposal that the Board of Directors of Parent
determines in good faith, after consultation with its financial advisor and
outside legal counsel, is or could reasonably be expected to lead to a Parent
Superior Proposal,  (ii) furnish to such Third Party and its Representatives
and financing sources nonpublic information relating to Parent or any of its
Subsidiaries pursuant to a confidentiality agreement with confidentiality and
use provisions no less  favorable and other provisions no less favorable in
the aggregate, in each case, to Parent than those contained in the
Confidentiality Agreement, a copy of which shall be provided, promptly after
its execution, to the Company for  informational purposes; _provided_ that
all such non-public information (to the extent that such information has not
been previously provided or made available to the Company) is provided or
made  available to the Company, as the case may be, substantially
concurrently with the time it is provided or made available to such Third
Party and (iii) following receipt of a Parent Superior Proposal after the date
of this Agreement,  (A) make a Parent Adverse Recommendation Change and/or
(B) terminate this Agreement in accordance with _Section 10.01(c)(iii)_ to
enter into a definitive agreement providing for such Parent Superior Proposal,
but in the case of  this clause (iii) only if the Board of Directors of
Parent determines in good faith, after consultation with Parent's outside
legal counsel and financial advisor, that the failure to take such action
would be reasonably likely to be  inconsistent with its fiduciary duties
under Applicable Law. Nothing contained herein shall prevent the Board of
Directors of Parent from (x) complying with Rule 14e-2(a) under the 1934 Act
with regard to a Parent Acquisition Proposal,  so long as any action taken or
statement made to so comply is consistent with this _Section 7.02_ , or (y)
making any required disclosure to the stockholders of Parent if the Board of
Directors of Parent determines in good faith,  after consultation with its
outside legal counsel, that the failure to take such action would be
reasonably likely to be inconsistent with Applicable Law; _provided_ that any
Parent Adverse Recommendation Change involving or relating  to a Parent
Acquisition Proposal may only be made in accordance with the provisions of
this _Section 7.02(b)_ , _Section 7.02(c)_ and _Section 7.02(e)_. A "stop,
look and listen" disclosure or similar communication of  the type
contemplated by Rule 14d-9(f) under the 1934 Act shall not be a Parent Adverse
Recommendation Change.

 


 

 

 

84  

(c) In addition to the requirements set forth in _Section 7.02(b)_ , the Board
of Directors of Parent shall not take any of the actions referred to in
clauses (i) through (iii) of _Section         7.02(b)_ unless Parent
shall have first delivered to the Company written notice advising the Company
that Parent intends to take such action. Parent shall notify the Company as
promptly as practicable (but in no event later than  forty eight (48) hours)
after receipt by Parent (or any of its Representatives) of any Parent
Acquisition Proposal or any request for information relating to Parent or any
of its Subsidiaries or for access to the business, properties,  assets, books
or records of Parent or any of its Subsidiaries by any Third Party that, to
the knowledge of Parent, is reasonably likely to make or has made any Parent
Acquisition Proposal, which notice shall be provided in writing and  shall
identify the Third Party making, and the material terms and conditions of, any
such Parent Acquisition Proposal or request. Parent shall thereafter (x) keep
the Company reasonably informed, on a reasonably current basis, of any 
material changes in the status and details of any such Parent Acquisition
Proposal or request and (y) as promptly as practicable (but in no event later
than twenty four (24) hours after receipt) provide to the Company copies of
all  material correspondence and written materials sent or provided to Parent
or any of its Subsidiaries that describes any terms or conditions of any
Parent Acquisition Proposal (as well as written summaries of any material
oral  communications relating to the terms and conditions of any Parent
Acquisition Proposal).

 


 

 

(d) Notwithstanding anything in this Agreement to the contrary, at any time
prior to the Parent Approval Time (and in no event after the Parent Approval
Time), the Board of Directors of  Parent may effect a Parent Adverse
Recommendation Change involving or relating to a Parent Intervening Event if
the Board of Directors of Parent determines in good faith, after consultation
with its outside legal counsel, that the  failure to take such action would
be reasonably likely to be inconsistent with its fiduciary duties under
Applicable Law; _provided_ that (i) Parent shall first notify the Company in
writing of its  intention to take such action, which notice shall include a
reasonably detailed description of such Company Intervening Event, (ii) if
requested by the Company, Parent and its Representatives shall discuss and
negotiate in good faith  with the Company and its Representatives (to the
extent that the Company desires to so negotiate) during the four (4) Business
Day period following such notice regarding any proposal by the Company to
amend the terms of this Agreement  in response to such Parent Intervening
Event, and (iii) the Board of Directors of Parent shall not effect any Parent
Adverse Recommendation Change involving or relating to a Parent Intervening
Event unless, after the four (4) Business  Day period described in the
foregoing clause (ii), the Board of Directors of Parent determines in good
faith, after consultation with its outside legal counsel and taking into
account any proposal by the Company to amend the terms of  this Agreement
during such four (4) Business Day period, that the failure to take such action
would continue to be reasonably likely to be inconsistent with its fiduciary
duties under Applicable Law.

 


 

 

(e) Without limiting or affecting Section 7.02(a), Section 7.02(b) or Section
7.02(c), the Board of Directors of Parent shall not make a Parent Adverse
Recommendation Change involving or  relating to a Parent Superior Proposal or
terminate this Agreement to enter into a definitive agreement with respect to
a Parent Superior Proposal unless (i) Parent first notifies the Company, in
writing at least four (4) Business Days  before taking such action, that
Parent intends to take such action, which notice attaches the most current
version of each proposed Contract or other agreement providing for such Parent
Superior Proposal and the identity of the Third  Party(ies) making the Parent
Superior Proposal, (ii) if requested by the Company, during such four (4)
Business Day period, Parent and its Representatives have discussed and
negotiated in good faith with the Company (to the extent that  the Company
desires to so negotiate) regarding any proposal by the Company to amend the
terms of this Agreement in response to such Parent Superior Proposal and (iii)
after such four (4) Business Day period, the Board of Directors of  Parent
determines in good faith, after consultation with its financial advisor and
outside legal counsel and taking into account any proposal by the Company to
amend the terms of this Agreement, that such Parent Acquisition Proposal 
continues to constitute a Parent Superior Proposal and that the failure to
take such action would continue to be reasonably likely to be inconsistent
with its fiduciary duties under Applicable Law (it being understood and agreed
that in  the event of any amendment to the financial terms or other material
terms of any such Parent Superior Proposal, a new written notification from
Parent consistent with that described in clause (i) of this Section 7.02(e)
shall be  required, and a new notice period under clause (i) of this Section
7.02(e) shall commence, during which notice period Parent shall be required to
comply with the requirements of this Section 7.02(e) anew, except that such
new notice  period shall be for two (2) Business Days (as opposed to four (4)
Business Days)). After delivery of such written notice pursuant to the
immediately preceding sentence, Parent shall keep the Company reasonably
informed on a reasonably  current basis of all material developments
affecting the material terms of any such Parent Superior Proposal (and Parent
shall provide the Company with copies of any additional written materials
received that provide for or that are  material to such Parent Superior
Proposal).

 


 

 

 

85  

(f) " _Parent Superior Proposal_ " means any bona fide, written Parent 
Acquisition Proposal (other than a Parent Acquisition Proposal which has
resulted from a violation of this _Section 7.02_ ) (with all references to
"twenty percent (20%)" in the definition of Parent Acquisition Proposal
being  deemed to be references to "fifty percent (50%)") on terms that the
Board of Directors of Parent determines in good faith, after consultation with
its financial advisor and outside legal counsel, and taking into account all
the terms  and conditions of the Parent Acquisition Proposal that the Board
of Directors of Parent considers to be appropriate (including the identity of
the Person making the Parent Acquisition Proposal and the expected timing and
likelihood of  consummation, any governmental or other approval requirements
(including divestitures and entry into other commitments and limitations),
break-up fees, expense reimbursement provisions, conditions to consummation
and the availability of  necessary financing (including, if a cash
transaction (in whole or in part), the availability of such funds and the
nature, terms and conditionality of any committed financing), would result in
a transaction (i) that, if consummated, is  more favorable to Parent's
stockholders from a financial point of view than the Merger (taking into
account any proposal by the Company to amend the terms of this Agreement), and
(ii) that is reasonably capable of being completed on the  terms proposed,
taking into account the identity of the Person making the Parent Acquisition
Proposal, any approval requirements and all other financial, regulatory, legal
and other aspects of such Parent Acquisition Proposal.

 


 

 

(g) " _Parent Intervening Event_ " means any material event, fact, change,
effect, development or occurrence that (i) was not known, or the material
consequences of which were not known, in each case to the Board of Directors
of Parent as of or prior to  the date of this Agreement and (ii) does not
relate to or involve any Parent Acquisition Proposal.

 


 

 

 

86  

(h) Parent shall, and shall cause its Subsidiaries to and its and its
Subsidiaries' directors and officers to, and shall use its reasonable best
efforts to cause its and its Subsidiaries'  other Representatives to, cease
immediately and cause to be terminated any and all existing activities,
discussions or negotiations, if any, with any Third Party conducted prior to
the date of this Agreement with respect to any Parent  Acquisition Proposal
or with respect to any indication, proposal or inquiry that could reasonably
be expected to lead to a Parent Acquisition Proposal and shall use its
reasonable best efforts to cause any such party (and any of its 
Representatives) in possession of confidential information about Parent or any
of its Subsidiaries that was furnished by or on behalf of Parent to return or
destroy all such information.

 


 

 

Section 7.03 _Obligations of Merger Sub_. Until the Merger Effective Time,
Parent shall at all  times be the direct or indirect owner of all of the
outstanding shares of capital stock of Merger Sub. Parent shall take all
action necessary to cause each of Merger Sub to perform its obligations under
this Agreement and to consummate  the Merger on the terms and subject to the
conditions set forth in this Agreement. Promptly following the execution of
this Agreement, Parent, in its capacity as the sole stockholder of Merger Sub,
shall execute and deliver a written  consent of Merger Sub adopting this
Agreement in accordance with the DGCL.

 


 

 

Section 7.04 _Director and Officer Liability_.

 


 

 

(a) For a period of not less than six years from the Merger Effective Time,
Parent shall cause the Surviving Corporation or any applicable Subsidiary
thereof (collectively, the " _D andO Indemnifying Parties_"), to the fullest
extent each such DandO  Indemnifying Party is so authorized or permitted by
Applicable Law, as now or hereafter in effect, to: (i) indemnify and hold
harmless each person who is at the date hereof, was previously, or during the
period from the date hereof  through the date of the Merger Effective Time
will be, serving as a director or officer of the Company or any of its
Subsidiaries or, at the request or for the benefit of the Company or any of
its Subsidiaries, as a director, trustee or  officer of any other entity or
any benefit plan maintained by the Company or any of its Subsidiaries
(collectively, the " _D andO Indemnified Parties_"), as now or hereafter in
effect, in connection with any DandO Claim and any losses, claims, damages,
liabilities, Claim Expenses, judgments, fines, penalties and  amounts paid in
settlement (including all interest, assessments and other charges paid or
payable in connection with or in respect of any thereof) relating to or
resulting from such DandO Claim; and (ii) promptly advance to such  DandO
Indemnified Party any Claim Expenses incurred in defending, serving as a
witness with respect to or otherwise participating with respect to any DandO
Claim in advance of the final disposition of such DandO Claim, including 
payment on behalf of or advancement to the DandO Indemnified Party of any Claim
Expenses incurred by such DandO Indemnified Party in connection with enforcing
any rights with respect to such indemnification and/or advancement, in  each
case without the requirement of any bond or other security, but subject to the
DandO Indemnifying Party's receipt of a written undertaking by or on behalf of
such DandO Indemnified Party to repay such Claim Expenses if it is  ultimately
determined under Applicable Law that such DandO Indemnified Party is not
entitled to be indemnified. All rights to indemnification and advancement
conferred hereunder shall continue as to a Person who has ceased to be a 
director or officer of the Company or any of its Subsidiaries after the date
hereof and shall inure to the benefit of such Person's heirs, successors,
executors and personal and legal representatives. As used in this _Section
7.04_ :  (x) the term " _D andO Claim_" means any threatened, asserted,
pending  or completed claim, action, suit, proceeding, inquiry or
investigation, whether instituted by any party hereto, any Governmental
Authority or any other Person, whether civil, criminal, administrative,
investigative or other, including  any arbitration or other alternative
dispute resolution mechanism, arising out of or pertaining to matters that
relate to such DandO Indemnified Party's duties or service (A) as a director or
officer of the Company or the applicable  Subsidiary thereof at or prior to
the Merger Effective Time (including with respect to any acts, facts, events
or omissions occurring in connection with the approval of this Agreement, the
Merger or the consummation of the other  transactions contemplated by this
Agreement, including the consideration and approval thereof and the process
undertaken in connection therewith and any DandO Claim relating thereto) or (B)
as a director, trustee or officer of any  other entity or any benefit plan
maintained by the Company or any of its Subsidiaries (for which such DandO
Indemnified Party is or was serving at the request or for the benefit of the
Company or any of its Subsidiaries) at or prior  to the Merger Effective
Time; and (y) the term " _Claim Expenses_ " means  reasonable out-of-pocket
attorneys' fees and all other reasonable out-of-pocket costs, expenses and
obligations (including experts' fees, travel expenses, court costs, retainers,
transcript fees, legal research, duplicating, printing  and binding costs, as
well as telecommunications, postage and courier charges) paid or incurred in
connection with investigating, defending, being a witness in or participating
in (including on appeal), or preparing to investigate,  defend, be a witness
in or participate in (including on appeal) any DandO Claim for which
indemnification is authorized pursuant to this _Section 7.04(a)_ , including
any action relating to a claim for indemnification or  advancement brought by
a DandO Indemnified Party.

 


 

 

 

87  

(b) For a period of not less than six (6) years from the Merger Effective
Time, Parent shall cause the organizational documents of the Surviving
Corporation to contain provisions no less  favorable with respect to
indemnification, advancement of expenses and limitations on liability of
directors and officers than are set forth in the Company Organizational
Documents, which provisions shall not be amended, repealed or  otherwise
modified for a period of at least six (6) years from the Merger Effective Time
in any manner that would affect adversely the rights thereunder of any DandO
Indemnified Party, unless any modification or amendment is required  by
Applicable Law (but then only to the minimum extent required by Applicable
Law). At the Company's option and expense, prior to the Merger Effective Time,
the Company may purchase (and pay in full the aggregate premium for) a six 
(6)-year prepaid "tail" insurance policy (which policy by its express terms
shall survive the Merger) of at least the same coverage and amounts and
containing terms and conditions that are no less favorable to the covered
individuals as  the Company's and its Subsidiaries' existing directors' and
officers' insurance policy or policies with a claims period of six (6) years
from the Merger Effective Time for DandO Claims arising from facts, acts, events
or omissions  that occurred on or prior to the Merger Effective Time;
_provided_ that the premium for such tail policy shall not exceed three
hundred percent (300%) of the aggregate annual amounts currently paid by  the
Company and its Subsidiaries for such insurance (such amount being the "
_Maximum Premium_ "). If the Company fails to obtain such tail policy prior to
the Merger Effective Time, Parent or the Surviving Corporation shall obtain
such a tail policy; _provided_ , _however_ , that the premium for such tail
policy shall not exceed the Maximum Premium; _provided_ , _further_ , that if
such tail policy  cannot be obtained or can be obtained only by paying
aggregate annual premiums in excess of the Maximum Premium, Parent, the
Company or the Surviving Corporation shall only be required to obtain as much
coverage as can be obtained by  paying an annual premium equal to the Maximum
Premium. Parent and the Surviving Corporation shall cause any such policy
(whether obtained by Parent, the Company or the Surviving Corporation) to be
maintained in full force and effect,  for its full term, and Parent shall
cause the Surviving Corporation to honor all its obligations thereunder.

 


 

 

 

88  

 

 

   

 

(c) If any of Parent or the Surviving Corporation or any of their respective
successors or assigns (i) consolidates with or merges with or into any other
Person and shall not be the continuing or surviving company, partnership or 
other Person of such consolidation or merger or (ii) liquidates, dissolves or
winds-up, or transfers or conveys all or substantially all of its properties
and assets to any Person, then, and in each such case, proper provision shall
be  made so that the successors and assigns of Parent or the Surviving
Corporation, as applicable, assume the obligations set forth in this _Section
7.04_.

 

 


 

 

Section 7.05 _Employee Matters_.

 


 

 

(a) From the Closing Date through the one (1) year anniversary thereof (the "
_Compensation Continuation Period_ "), the Surviving Corporation shall
provide, and Parent shall cause the Surviving Corporation to provide, to each
individual who is employed by the Company and its Subsidiaries immediately
prior to the  Merger Effective Time, while such individual continues to be
employed by the Surviving Corporation, Parent or any of Parent's Subsidiaries
(including Subsidiaries of the Surviving Corporation) during the Compensation
Continuation Period  (collectively, the " _Affected Employees_ ") (i) a base
salary or wage rate that is not less  than the base salary or wage rate
provided to such Affected Employee immediately prior to the Merger Effective
Time, (ii) cash incentive compensation (including bonus opportunity and other
cash incentive compensation opportunities) and  equity incentive compensation
no less favorable in the aggregate than the cash incentive compensation
(including bonus opportunity and other cash incentive compensation
opportunities) and equity incentive compensation provided to such  Affected
Employee immediately prior to the Merger Effective Time, and (iii) severance
benefits in amounts and on terms and conditions that are no less favorable
than those provided to the Affected Employees immediately prior to the
Merger  Effective Time, as set forth in the Company's Severance Pay Plans
disclosed to Parent before the date hereof. From the Closing Date through
December 31, 2019, Affected Employees shall be provided with employee benefits
substantially  similar in the aggregate than the employee benefits provided
to such Affected Employee under the Company Employee Plans immediately prior
to the Merger Effective Time; _provided_ that, for purposes of determining
that such employee benefits are no less favorable in the  aggregate, defined
benefit pension plan benefits, retention or change in control payments or
awards provided by the Company or any of its Subsidiaries prior to the Merger
Effective Time shall not be taken into account.

  
   

(b) With respect to any employee  benefit plan in which any Affected Employee
first becomes eligible to participate on or after the Merger Effective Time
(the " _New Company Plans_ "), Parent  shall use commercially reasonable
efforts to: (i) waive all pre-existing conditions, exclusions and waiting
periods with respect to participation and coverage requirements applicable to
such Affected Employee under any New Company Plan that  is a health plan in
which such Affected Employee may be eligible to participate after the Merger
Effective Time, and (ii) if applicable, cause to be credited, in any New
Company Plan that is a health plan in which Affected Employees  participate,
any deductibles or out-of-pocket expenses incurred by such Affected Employee
and such Affected Employee's eligible beneficiaries and dependents during the
portion of the calendar year in which the Merger Effective Time occurs  prior
to such Affected Employee's commencement of participation in such New Company
Plan providing health benefits with the objective that there be no double
counting during the year in which the Merger Effective Time occurs of such 
deductibles or out-of-pocket expenses. Parent shall recognize service of
Affected Employees (to the extent credited by the Company or its Subsidiaries)
accrued prior to the Merger Effective Time for all purposes under (but not for
the  purposes of benefit accrual under any defined benefit pension plan) any
New Company Plan in which such Affected Employees may be eligible to
participate after the Merger Effective Time, _provided_ , _however_ , that in
no event shall any credit be given to the extent it would result in the
duplication of benefits for the same period of service.

 


 

 

 

89    

(c) Parent agrees that, with respect to the annual cash incentive plans set
forth on _Section 7.05(c)_ of the Company Disclosure Schedule (the "
_Annual     Incentive Plans_ "), it shall, or shall cause the Surviving
Corporation, to provide each participant in an Annual Incentive Plan (each an
" _Incentive Plan Participant_ ") who remains employed with the Surviving
Corporation through the end of the  year during which the Closing occurs,
with an annual cash incentive award for the year during which the Closing
occurs, the amount of which shall be determined as the product of (i) the sum
of the following: (a) a pro-rated portion of the  bonus with respect to the
portion of the year of the Closing that occurs prior to the Closing, which
bonus shall be determined based upon actual corporate performance through the
Closing Date, as determined by the Company prior to the  Merger Effective
Time _plus_ (b) a pro-rated portion of the bonus with respect to the portion
of the year of the Closing that occurs after the Closing, which bonus shall be
no less than the bonus payable at the applicable Incentive  Plan
Participant's target incentive level under such Annual incentive Plan,
multiplied by (ii) the Incentive Plan Participant's individual performance
multiplier determined in accordance with the terms of the Annual Incentive
Plan; _provided_ that,  contingent upon the execution and non-revocation of a
customary release of claims in a form that is reasonably satisfactory to
Parent and does not contain any restrictive covenants, each Incentive Plan
Participant who experiences a  termination of employment on or after the
Closing due to death or disability (as defined in the Company's long-term
disability plan), or with respect to which such Incentive Plan Participant is
eligible to receive severance benefits under  any Company Employee Plan or
applicable Law, shall be entitled to the prorated payment of the amount that
would otherwise have been payable under this _Section 7.05(c)_ _(i)_ (i.e.,
without applying the individual performance multiplier referred to in clause
(ii)); and _provided_ , _further_ , that in no event shall payment of any
amounts under the Annual Incentive Plans (or any  pro-rated portion thereof)
pursuant to this _Section 7.05(c)_ result in the duplication of payments to
any Incentive Plan Participant under any other incentive, severance or other
similar arrangement.

 


 

 

(d) Nothing contained in this _Section 7.05_ or elsewhere in this Agreement,
express or implied (i) shall cause either Parent or any of its Affiliates to
be obligated to continue to employ any Person, including any  Affected
Employees, for any period of time following the Merger Effective Time, (ii)
shall prevent Parent or its Affiliates from revising, amending or terminating
any Company Employee Plan or any other employee benefit plan, program or 
policy in effect from time to time, (iii) shall be construed as an amendment
of any Company Employee Plan or Parent Employee Plan, or (iv) shall create any
third-party beneficiary rights in any director, officer, employee or
individual  Person, including any present or former employee, officer,
director or individual independent contractor of the Company or any of its
Subsidiaries (including any beneficiary or dependent of such individual).

 


 

 

 

90  

Section 7.06 _Financing_.

 


 

 

(a) Each of Parent and Merger Sub shall, and shall cause their respective
Subsidiaries to, use reasonable best efforts to take, or shall use reasonable
best efforts to cause to be taken, all actions and to do, or cause to  be
done, all things necessary to obtain the Debt Financing including (i) using
reasonable best efforts to (A) maintain in effect the Debt Commitment Letter
and in all material respects comply with all of their respective obligations 
thereunder and (B) negotiate, enter into and deliver the definitive agreements
with respect thereto on the terms and conditions not less favorable in the
aggregate, to Parent than those contained in the Debt Commitment Letter
(including,  as necessary, the "market flex" provisions contained in any
related fee letter) by the Closing Date, and (ii) using reasonable best
efforts to satisfy (or if determined advisable by Parent, obtain the waiver
of) on a timely basis all  conditions to obtaining the Debt Financing within
Parent's (or its Subsidiary's) control and to comply with all of its
obligations pursuant to the Debt Commitment Letters or other definitive
agreements related thereto to the extent the  failure to comply with such
obligations would adversely impact the timing of the Closing or the
availability at the Closing of sufficient aggregate proceeds of the Debt
Financing to consummate the transactions contemplated by this  Agreement. In
the event that all conditions to funding the commitments contained in the Debt
Commitment Letters have been satisfied, each of Parent and Merger Sub shall,
and shall cause their respective Subsidiaries to, use reasonable  best
efforts to cause the Financing Sources to fund the Debt Financing required to
consummate the transactions contemplated by this Agreement and to pay related
fees and expenses on the Closing Date. Parent shall use its reasonable best 
efforts to enforce all of its rights under the Debt Commitment Letters. Parent
and/or Merger Sub shall pay, or cause to be paid, as the same shall become due
and payable, all fees and other amounts under the Debt Commitment Letters.

 


 

 

(b) In the event that any portion of the Debt Financing becomes unavailable
and such portion is necessary to consummate the transactions contemplated by
this Agreement (except in accordance with the express terms set forth  in the
Debt Commitment Letters, including as a result of the entry into definitive
agreements for a "Qualifying Term Loan Facility" under the applicable Debt
Commitment Letters with commitments subject to substantially the same
conditions  as those set forth in the applicable Debt Commitment Letters or
unless concurrently replaced on a dollar-for-dollar basis by commitments
subject to substantially the same conditions as those set forth in the
applicable Debt Commitment  Letters from other Financing Sources or from
proceeds of other sources of financing or cash), Parent and Merger Sub shall
(i) use their reasonable best efforts to obtain, as promptly as practicable
following the occurrence of such event,  alternative debt financing for any
such portion from alternative debt sources on terms and conditions, taken as a
whole, no less favorable to Parent and Merger Sub than the terms and
conditions set forth in the Debt Commitment Letter  (taking into account any
"market flex" provisions thereof) and in an amount that will still enable
Parent and Merger Sub to consummate the transactions contemplated by this
Agreement (" _Alternative Financing_ "), and (ii) promptly notify the Company
of such unavailability and the reason therefor. If obtained, Parent shall 
deliver to the Company true and complete copies of all commitment letters and
other definitive agreements (including redacted copies of fee letters,
removing only fee amounts, the rates and amounts included in the "market flex"
provisions  and certain other economic terms (none of which could adversely
affect the amounts, availability, timing or conditionality of the Debt
Financing)) pursuant to which any such alternative source shall have committed
to provide Parent or the  Surviving Corporation with Alternative Financing.

 


 

 

 

91  

(c) Parent and Merger Sub shall not, without the Company's prior written
consent (not to be unreasonably withheld, conditioned or delayed), permit any
amendment, modification to, or any waiver of any provision or remedy  under,
any Debt Commitment Letter or any definitive agreement related thereto unless
the terms of such Debt Commitment Letter or definitive agreement related
thereto, in each case as so amended, modified or waived, are substantially 
similar to those in such Debt Commitment Letter or definitive agreement
related thereto, prior to giving effect to such amendment, modification or
waiver (other than economic terms, which shall be as good as or better for
Parent and  Merger Sub than those in such Debt Commitment Letter or
definitive agreement relating thereto prior to giving effect to such
amendment, modification or waiver); _provided_ that in the case of amendments
or modifications or waivers of any Debt Commitment Letter or any definitive
agreement relating thereto, such amendment, modification or waiver would  not
reasonably be expected to (i) (A) add additional conditions precedent that
would adversely affect the ability or likelihood of Parent or Merger Sub
timely consummating the transactions contemplated by this Agreement or
otherwise  adversely affect the ability or likelihood of Parent or Merger Sub
timely consummating the transactions contemplated by this Agreement or (B)
make the timely funding of the Debt Financing or the satisfaction of the
conditions to obtaining  the Debt Financing materially less likely to occur,
(ii) reduce the aggregate amount of the Debt Financing or (iii) materially and
adversely affect the ability of Parent to enforce its rights against other
parties to the Debt Commitment  Letters or the definitive agreements relating
thereto, it being understood and agreed that in any event, Parent may amend
any of the Debt Commitment Letters or any definitive agreement relating
thereto to add lenders, arrangers,  bookrunners, agents, managers or similar
entities that have not executed such Debt Commitment Letters as of such time
and consent to the assignment of lending commitments under the Debt Commitment
Letters to other lenders.

 


 

 

(d) Parent shall provide the Company with prompt written notice of the receipt
of any notice or other communication from any Financing Source with respect to
such Financing Source's failure or anticipated failure to fund  its
commitments under any Debt Commitment Letter or definitive agreement in
connection therewith in a manner that would reasonably be expected to render
it unable to consummate the transactions contemplated by this Agreement.
Parent  shall keep the Company reasonably informed on a reasonably current
basis of the status of Parent's and its Subsidiaries' efforts to consummate
the Debt Financing, including providing copies of any amendment, modification
or replacement of  the Debt Commitment Letter (provided that any fee letter
may be redacted to remove fee amounts, the rates and amounts included in the
"market flex" provisions and certain other economic terms (none of which could
adversely affect the  amounts, availability, timing or conditionality of the
Debt Financing)). Parent shall give the Company prompt notice of any (i)
material breach or material default by any party to the Debt Commitment
Letters or the definitive agreements  related thereto of which Parent obtains
knowledge, (ii) actual or, to the knowledge of Parent, threatened in writing
withdrawal, repudiation, or termination of any of the Debt Commitment Letters
or such definitive agreements, or (iii)  material dispute or disagreement
between or among any parties to any of the Debt Commitment Letters or such
definitive agreements with respect to the obligations to fund the Debt
Financing or the amount of the Debt Financing to be funded  at Closing.

 


 

 

 

92  

(e) Notwithstanding anything contained in this Agreement to the contrary,
Parent expressly acknowledges and agrees that Parent's and Merger Sub's
obligations hereunder are not conditioned in any manner upon Parent or 
Merger Sub obtaining any financing.

 


 

 

Section 7.07 _New CVR Agreement_. At or immediately prior to the Merger
Effective Time, Parent will execute and deliver, and Parent will cause the New
CVR Trustee to execute and deliver, the New CVR Agreement,  subject to any
changes to the New CVR Agreement that are requested by the New CVR Trustee and
approved prior to the Merger Effective Time by Parent and the Company (which
approval, in the case of the Company, shall not be unreasonably  withheld,
conditioned or delayed).

 


 

 

ARTICLE VIII 
  
  COVENANTS OF PARENT AND THE COMPANY

 


 

 

The parties hereto agree that:

 


 

 

Section 8.01 _Access to Information; Confidentiality_.

 


 

 

(a) All information furnished pursuant to this Agreement shall be subject to
the letter agreement, dated as of November 23, 2018 (as amended, supplemented
or otherwise modified from time to time in accordance with its  terms, the "
_Confidentiality Agreement_ "), between Parent and the Company. Upon
reasonable  notice, during normal business hours during the period from the
date of this Agreement to the earlier of the Merger Effective Time or the
termination of this Agreement, solely for purposes of furthering the Merger
and the other  transactions contemplated hereby or integration planning
relating thereto, (i) the Company shall, and shall cause its Subsidiaries to,
afford to Parent and its Representatives, reasonable access, to all of its
properties, books, contracts  and records, and (ii) the Company shall, and
shall cause its Subsidiaries to, make available to Parent all other
information not made available pursuant to clause (i) of this _Section
8.01(a)_ concerning its businesses, properties  and personnel as the other
may reasonably request (in the case of each of clause (i) and (ii), in a
manner so as to not unreasonably interfere with the normal business operations
of the Company or any of its Subsidiaries). During such  period described in
the immediately preceding sentence, upon reasonable notice and subject to
Applicable Law and during normal business hours, the Company shall instruct
its pertinent Representatives to reasonably cooperate with Parent in  its
review of any such information provided or made available pursuant to the
immediately preceding sentence. No information or knowledge obtained in any
review or investigation pursuant to this _Section 8.01_ shall affect or be 
deemed to modify any representation or warranty made by the Company or Parent
pursuant to this Agreement.

 


 

 

 

93  

(b) Notwithstanding anything to the contrary in this _Section 8.01_ , _Section
8.02_ or _Section 8.03_ , none of the Company, Parent or any of their
respective Subsidiaries shall be required to provide  access to, disclose
information to or assist or cooperate with the other party, in each case if
such access, disclosure, assistance or cooperation (i) would, as reasonably
determined based on the advice of outside counsel, jeopardize any  attorney-
client privilege with respect to such information, or (ii) would contravene
any Applicable Law or Contract to which the applicable party is a subject or
bound; _provided_ that the Company and Parent shall, and each shall  cause
its Subsidiaries to, use reasonable best efforts to make appropriate
substitute disclosure arrangements under circumstances in which such
restrictions apply (including redacting such information (A) to remove
references concerning  valuation, (B) as necessary to comply with any
Contract in effect on the date hereof or after the date hereof and (C) as
necessary to address reasonable attorney-client, work-product or other
privilege or confidentiality concerns) and to  provide such information as to
the applicable matter as can be conveyed. Each of the Company and Parent may,
as each deems advisable and necessary, reasonably designate any competitively
sensitive material provided to the other under  this _Section 8.01_ or
_Section 8.02_ as "Outside Counsel Only Material". Such materials and the
information contained therein shall be given only to the outside counsel of
the recipient and, subject to any additional  confidentiality or joint
defense agreement the parties may mutually propose and enter into, will not be
disclosed by such outside counsel to employees, officers or directors of the
recipient unless express permission is obtained in  advance from the source
of the materials (the Company or Parent, as the case may be) or its legal
counsel.

 


 

 

Section 8.02 _Reasonable Best Efforts_.

 


 

 

(a) Subject to the terms and conditions of this Agreement, including _Section
8.02(b)_ and _Section 8.02(c)_ , each of the Company and Parent shall, and
each shall cause its Subsidiaries to, use their respective  reasonable best
efforts to take, or cause to be taken, all actions and to do, or cause to be
done, all things necessary, proper or advisable under Applicable Law to
consummate the Merger and other transactions contemplated hereby as  promptly
as practicable, including (i) (A) preparing and filing as promptly as
practicable with any Governmental Authority or other Third Party all
documentation to effect all Filings as are necessary, proper or advisable to
consummate  the Merger and the other transactions contemplated hereby, (B)
using reasonable best efforts to obtain, as promptly as practicable, and
thereafter maintain, all Consents required to be obtained from any
Governmental Authority or other  Third Party that are necessary, proper or
advisable to consummate the Merger or other transactions contemplated hereby,
and complying with the terms and conditions of each Consent (including by
supplying as promptly as reasonably  practicable any additional information
and documentary material that may be requested pursuant to the HSR Act or
other applicable Antitrust Laws), and (C) cooperating, to the extent
reasonable, with the other parties hereto in their  efforts to comply with
their obligations under this Agreement, including in seeking to obtain as
promptly as practicable any required Consents and (ii) using reasonable best
efforts to contest (which includes by litigation) any (A)  action, suit,
investigation or proceeding brought by any Governmental Authority in a court
of competent jurisdiction seeking to enjoin, restrain, prevent, prohibit or
make illegal consummation of the Merger or any of the other  transactions
contemplated hereby or seeking damages or to impose any terms or conditions in
connection with the Merger or any of the other transactions contemplated
hereby or (B) Order that has been entered by a court of competent 
jurisdiction that enjoins, restrains, prevents, prohibits or makes illegal
consummation of the Merger or any of the other transactions contemplated
hereby or imposes any damages, terms or conditions in connection with the
Merger or any of  the other transactions contemplated hereby. The parties
understand and agree that, subject to _Section 8.02(b)_ and _Section 8.02(g)_
, Parent's obligation to use its reasonable best efforts set forth in this
_Section  8.02(a)_ includes taking and agreeing to take all actions and doing
or agreeing to do all things necessary, proper or advisable under Applicable
Law (including divestitures, hold separate arrangements, the termination,
assignment,  novation or modification of Contracts (or portions thereof) or
other business relationships, the acceptance of restrictions on business
operations and the entry into other commitments and limitations) to satisfy
the conditions set forth  in _Section 9.01_ _(f)_ or _Section 9.01(c)_ (if
the injunction or other Order  relates to any Antitrust Law) and to
consummate the Merger and the other transactions contemplated hereby.

 


 

 

 

94  

(b) Notwithstanding _Section 8.02(a)_ or anything else in this Agreement to
the contrary, nothing in this Agreement will obligate or require Parent,
Merger Sub or any of their respective Subsidiaries to take or cause  to be
taken any action (or refrain or cause to refrain from taking any action) or
agree or cause to agree to any term, condition or limitation (including, in
each case, any of the actions or items referred to in the last sentence of
_Section         8.02(a)_ ) as a condition to, or in connection with,
(i) the expiration or termination of any applicable waiting period relating to
the Merger under the HSR Act, (ii) any Foreign Antitrust Law or (iii)
obtaining any other Consent from  a Governmental Authority or otherwise, in
each case if such action (or refraining from such action), term, condition or
limitation would have or would reasonably be expected to have, individually or
in the aggregate, a material adverse  effect on the financial condition,
business or results of operations of the Company, Parent and their respective
Subsidiaries, taken as a whole, after giving effect to the Merger.

 


 

 

(c) Without limiting in any respect Parent's obligations under this _Section
8.02_ , __ Parent shall have the right to (i) direct, devise and implement the
strategy for obtaining any necessary approval of, for responding to any
request from, inquiry or investigation by (including directing the timing, 
nature and substance of all such responses), and shall have the right to lead
all meetings and communications (including any negotiations) with, any
Governmental Authority that has authority to enforce any Antitrust Law and
(ii) without  limiting the generality of clause (i) of this _Section 8.02(c)_
or the obligations of the Company under this _Section 8.02_ , control the
defense and settlement of any litigation, action, suit, investigation or
proceeding  brought by or before any Governmental Authority that has
authority to enforce any Antitrust Law. Parent shall consult with the Company
in a reasonable manner and consider in good faith the views and comments of
the Company in connection  with the foregoing.

 


 

 

(d) In furtherance and not in limitation of the foregoing, each of the Company
and Parent shall, and each shall cause its Subsidiaries to, as promptly as
practicable following the date of this Agreement, make all Filings  with all
Governmental Authorities that are necessary, proper or advisable under this
Agreement or Applicable Law to consummate and make effective the Merger and
the other transactions contemplated hereby, including: (i) not later than
ten  (10) Business Days following the date of this Agreement (unless the
parties otherwise agree to another time period), the Company and Parent each
making an appropriate Filing of a notification and report form pursuant to the
HSR Act with  the Federal Trade Commission and the Antitrust Division of the
United States Department of Justice with respect to the Merger and the other
transactions contemplated hereby and requesting early termination of the
waiting period under the  HSR Act; (ii) as promptly as practicable following
the date hereof the Company and Parent each making any other Filing that is
necessary, proper or advisable under any Foreign Antitrust Law; and (iii) as
promptly as practicable following  the date hereof the Company and Parent
each making any other Filing that is necessary, proper or advisable under any
other Applicable Laws or by any Governmental Authority with jurisdiction over
enforcement of any of the foregoing.

 


 

 

 

95  

(e) To the extent permitted by Applicable Law, the Company and Parent shall,
as promptly as practicable, (i) upon request from a Governmental Authority,
furnish to such Governmental Authority, any information or  documentation
concerning themselves, their Affiliates, directors, officers and stockholders
information or documentation concerning the Merger and the other transactions
contemplated hereby and such other matters as may be requested and  (ii) make
available their respective Representatives to, upon reasonable request, any
Governmental Authority, in the case of each of clause (i) and (ii), in
connection with (A) the preparation of any Filing made by or on their behalf
to  any Governmental Authority in connection with the Merger or any of the
other transactions contemplated hereby or (B) any Governmental Authority
investigation, review or approval process.

 


 

 

(f) Subject to _Section 8.02(c)_ , Applicable Laws relating to the sharing of
information and the terms and conditions of the Confidentiality Agreement and
all other agreements entered into by the parties to this  Agreement, and
subject to the proviso at the end of this _Section 8.02(f)_ , each of the
Company and Parent shall, and each shall cause its Subsidiaries to: (i) (A) as
far in advance as practicable, notify the other party of, and  provide the
other party with an opportunity to consult with respect to, any Filing or non-
ministerial communication or inquiry it or any of its Affiliates intends to
make with any Governmental Authority relating to the matters that are  the
subject of this Agreement, (B) prior to submitting any such Filing or making
any such communication or inquiry, the submitting or making party shall
provide the other party and its counsel a reasonable opportunity to review,
and shall  consider in good faith the comments of the other party and such
other party's Representatives in connection with any such Filing,
communication or inquiry, and (C) promptly following the submission of such
Filing or making of such  communication or inquiry, provide the other party
with a copy of any such Filing or, if in written form, communication or
inquiry, or, if in oral form, a summary of any such communication or inquiry;
_provided_ , _however_ , that this _Section 8.02(f)_ _(i)_ shall not  apply
to any initial filings made pursuant to the HSR Act; (ii) as promptly as
practicable following receipt, furnish the other party with a copy of any
Filing or, if in written form, non-ministerial communication or inquiry, or,
if in  oral form, a summary of any non-ministerial communication or inquiry,
that it or any of its Affiliates receives from any Governmental Authority
relating to matters that are the subject of this Agreement; and (iii)
coordinate and  reasonably cooperate with the other party in exchanging such
information and providing such other assistance as the other party may
reasonably request in connection with this _Section 8.02_ (including in
seeking early termination of  any applicable waiting periods under the HSR
Act). Subject to _Section 8.02(c)_ , none of the Company, Parent or their
respective Representatives shall agree to participate in any meeting or non-
ministerial conference (including by  telephone) with any Governmental
Authority, or any member of the staff of any Governmental Authority, in
respect of any Filing, proceeding, investigation (including the settlement of
any investigation), litigation or other inquiry  regarding the Merger or any
of the other transactions contemplated hereby unless it consults with the
other party in advance and, to the extent permitted by such Governmental
Authority, allows the other party to participate; _provided_ , _however_ ,
materials provided to the other party pursuant to this _Section 8.02_ may be
redacted to remove references concerning the valuation of Parent, the Company
or any of their  Subsidiaries.

 


 

 

 

96  

(g) Notwithstanding anything in this Agreement to the contrary, in no event
shall (i) Parent or any of its Affiliates or the Company or any of its
Affiliates be required to agree to take or enter into any action which is 
not conditioned upon, and shall become effective from and after, the Closing,
or (ii) the Company or any of its Affiliates agree to any obligation,
restriction, requirement, limitation, qualification, condition, remedy or
other action in  connection with obtaining the Consents under Antitrust Laws
required to be obtained by the parties or their respective Subsidiaries in
connection with the Merger without the prior written consent of Parent
(including in connection with  obtaining any of the governmental approvals
described in _Section 8.02(b)_ ) (which consent shall not be withheld, delayed
or conditioned if doing so would be inconsistent with Parent's obligations
under this _Section 8.02)_ ,  but, if requested by Parent in writing, the
Company shall, and shall cause its Subsidiaries to, subject to clause (i) of
this _Section 8.02(g)_ , take any such actions to obtain any of the
governmental approvals described in _Section         8.02(b)_.

 


 

 

Section 8.03 _Certain Filings; SEC Matters_.

 


 

 

(a) As promptly as practicable following the date of this Agreement, (i) the
Company and Parent shall jointly prepare and file with the SEC a proxy
statement relating to the Company Stockholder Meeting and the Parent 
Stockholder Meeting (together with all amendments and supplements thereto, the
" _Joint Proxy Statement/Prospectus_ ") in preliminary form, and (ii) Parent
shall prepare and file with the SEC a Registration Statement on Form S-4 which
shall include the Joint Proxy Statement/Prospectus (together with all
amendments and supplements  thereto, the " _Registration Statement_ ")
relating to the registration of the shares of Parent  Common Stock to be
issued to the stockholders of the Company pursuant to the Parent Share
Issuance and the New CVRs to be issued to the stockholders of the Company in
connection with the Merger. The Joint Proxy Statement/Prospectus and  the
Registration Statement shall comply as to form in all material respects with
the applicable provisions of the 1933 Act, the 1934 Act and other Applicable
Law.

 


 

 

(b) Each of the Company and Parent shall use its reasonable best efforts to
have the Joint Proxy Statement/Prospectus cleared by the SEC as promptly as
practicable after its filing, and Parent shall use its reasonable best 
efforts to have the Registration Statement declared effective under the 1933
Act as promptly as practicable after its filing and keep the Registration
Statement effective for so long as necessary to consummate the Merger and, if
required  by Applicable Law, to have the New CVR Agreement become qualified
under the Trust Indenture Act. Each of the Company and Parent shall, as
promptly as practicable after the receipt thereof, provide the other party
with copies of any  written comments and advise the other party of any oral
comments with respect to the Joint Proxy Statement/Prospectus and the
Registration Statement received by such party from the SEC or any other
Governmental Authority, including any  request from the SEC for amendments or
supplements to the Joint Proxy Statement/Prospectus and the Registration
Statement, and shall provide the other with copies of all material or
substantive correspondence between it and its  Representatives, on the one
hand, and the SEC or any other Governmental Authority, on the other hand,
related to the foregoing. Notwithstanding the foregoing, prior to filing the
Registration Statement or mailing the Joint Proxy  Statement/Prospectus or
responding to any comments of the SEC with respect thereto, each of the
Company and Parent shall reasonably cooperate and provide the other party and
its counsel a reasonable opportunity to review such document or  response
(including the proposed final version of such document or response) and
consider in good faith the comments of the other party or such other party's
Representatives in connection with any such document or response. None of
the  Company, Parent or any of their respective Representatives shall agree
to participate in any material or substantive meeting or conference (including
by telephone) with the SEC, or any member of the staff thereof, in respect of
the  Registration Statement or the Joint Proxy Statement/Prospectus unless it
consults with the other party in advance and, to the extent permitted by the
SEC, allows the other party to participate. Parent shall advise the Company,
promptly  after receipt of notice thereof, of the time of effectiveness of
the Registration Statement, and the issuance of any stop order relating
thereto or the suspension of the qualification of shares of Parent Common
Stock for offering or sale  in any jurisdiction, and each of the Company and
Parent shall use its reasonable best efforts to have any such stop order or
suspension lifted, reversed or otherwise terminated.

 


 

 

 

97  

(c) Each of the Company and Parent shall use its reasonable best efforts to
take any other action required to be taken by it under the 1933 Act, the 1934
Act, the DGCL and the rules of the NYSE and Nasdaq in connection  with the
filing and distribution of the Joint Proxy Statement/Prospectus and the
Registration Statement, and the solicitation of proxies from the stockholders
of each of the Company and Parent thereunder. Subject to _Section 6.02_ , 
the Joint Proxy Statement/Prospectus shall include the Company Board
Recommendation, and, subject to _Section 7.02_ , the Joint Proxy
Statement/Prospectus shall include the Parent Board Recommendation.

 


 

 

(d) Parent shall use its reasonable best efforts to take, or cause to be
taken, all actions, and to do or cause to be done all things, necessary,
proper or advisable under Applicable Laws and the rules and policies of the 
NYSE and the SEC to enable the listing of the Parent Common Stock and the New
CVRs being registered pursuant to the Registration Statement on the NYSE (or
other national securities exchange) no later than the Merger Effective Time, 
subject to official notice of issuance. Parent shall also use its reasonable
best efforts to obtain all necessary state securities law or "blue sky"
permits and approvals required to carry out the transactions contemplated by
this  Agreement ( _provided_ that in no event shall Parent be required to
qualify to do business in any jurisdiction in which it is not now so qualified
or file a general consent to service of process).

 


 

 

(e) Each of the Company and Parent shall, upon request, furnish to the other
all information concerning itself, its Subsidiaries, directors, officers and
(to the extent reasonably available to the applicable party)  stockholders
and such other matters as may be reasonably necessary or advisable in
connection with any statement, Filing, notice or application made by or on
behalf of the Company, Parent or any of their respective Subsidiaries, to
the  SEC or the NYSE in connection with the Merger and the other transactions
contemplated by this Agreement, including the Registration Statement and the
Joint Proxy Statement/Prospectus: _provided_ , _however_ , that neither party
shall use any such information for any purposes other than those contemplated
by this Agreement unless such party obtains the prior written consent of the
other. In addition, each of  the Company and Parent shall use its reasonable
best efforts to provide information concerning it necessary to enable the
Company and Parent to prepare required pro forma financial statements and
related footnotes in connection with the  preparation of the Registration
Statement and/or the Joint Proxy Statement/Prospectus.

 


 

 

 

98  

(f) If at any time prior to the later of the Company Approval Time and the
Parent Approval Time, any information relating to the Company or Parent, or
any of their respective Affiliates, officers or directors, should be 
discovered by the Company or Parent that should be set forth in an amendment
or supplement to either of the Registration Statement or the Joint Proxy
Statement/Prospectus, so that either of such documents would not include any 
misstatement of a material fact or omit to state any material fact necessary
to make the statements therein, in light of the circumstances under which they
were made, not misleading, the party that discovers such information shall 
promptly notify the other party hereto, and each party shall use reasonable
best efforts to, and reasonably cooperate with the other to, promptly prepare
and file with the SEC an appropriate amendment or supplement describing such 
information and, to the extent required under Applicable Law, disseminate such
amendment or supplement to the stockholders of each of the Company and Parent.

 


 

 

Section 8.04 _Stockholder Meetings_.

 


 

 

(a) Promptly following the effectiveness of the Registration Statement (and,
in the case of clause (iii), within forty (40) days of the Company Record
Date), the Company shall, in consultation with Parent, in accordance  with
Applicable Law and the Company Organizational Documents, (i) establish a
record date (the " _Company Record Date_ ") for, duly call and give notice of
a meeting of the stockholders of the Company entitled to vote on the Merger
(the " _Company  Stockholder Meeting_ ") at which meeting the Company shall
seek the Company Stockholder Approval (and will use reasonable best efforts to
conduct "broker searches"  in a manner to enable the Company Record Date to
be held promptly following the effectiveness of the Registration Statement),
(ii) cause the Joint Proxy Statement/Prospectus (and all other proxy materials
for the Company Stockholder  Meeting) to be mailed to its stockholders and
(iii) duly convene and hold the Company Stockholder Meeting. Subject to
_Section 6.02_ , the Company shall use its reasonable best efforts to take, or
cause to be taken, all actions, and  do or cause to be done all things,
necessary, proper or advisable on its part to cause the Company Stockholder
Approval to be received at the Company Stockholder Meeting or any adjournment
or postponement thereof, and shall comply with  all legal requirements
applicable to the Company Stockholder Meeting. The Company shall not, without
the prior written consent of Parent, adjourn, postpone or otherwise delay the
Company Stockholder Meeting; _provided_ that  the Company may,
notwithstanding the foregoing, without the prior written consent of Parent,
adjourn or postpone the Company Stockholder Meeting (A) if, after consultation
with Parent, the Company believes in good faith that such  adjournment or
postponement is reasonably necessary to allow reasonable additional time to
(1) solicit additional proxies necessary to obtain the Company Stockholder
Approval, or (2) distribute any supplement or amendment to the Joint  Proxy
Statement/Prospectus that the Board of Directors of the Company has determined
in good faith after consultation with outside legal counsel is necessary under
Applicable Law and for such supplement or amendment to be reviewed by the 
Company's stockholders prior to the Company Stockholder Meeting, (B) for an
absence of a quorum or (C) if the Parent Stockholder Meeting has been
adjourned or postponed by Parent in accordance with _Section 8.04(b)_ , to the
extent  necessary to enable the Company Stockholder Meeting and the Parent
Stockholder Meeting to be held within a single period of twenty-four (24)
consecutive hours as contemplated by _Section 8.04(d)_. Notwithstanding the
foregoing,  the Company may not, without the prior written consent of Parent
(such consent not to be unreasonably withheld, conditioned or delayed),
postpone the Company Stockholder Meeting more than a total of three (3) times
pursuant to clause  (A)(1) or (B) of the immediately preceding sentence, and
no such postponement or adjournment pursuant to clause (A)(1) or (B) of the
immediately preceding sentence shall be, without the prior written consent of
Parent (such consent not to  be unreasonably withheld, conditioned or
delayed), for a period exceeding ten (10) Business Days. Without the prior
written consent of Parent, the matters contemplated by the Company Stockholder
Approval shall be the only matters (other  than matters of procedure and
maters required by Applicable Law to be voted on by the Company's stockholders
in connection therewith) that the Company shall propose to be voted on by the
stockholders of the Company at the Company  Stockholder Meeting.

 


 

 

 

99  

(b) Promptly following the effectiveness of the Registration Statement (and,
in the case of clause (iii), within forty (40) days of the Company Record
Date, subject to an extension of up to fifteen (15) additional Business  Days
as contemplated by the last sentence of this _Section 8.04(b)_ ), Parent
shall, in  consultation with the Company, in accordance with Applicable Law
and the Parent Organizational Documents, (i) establish a record date (which
date shall be the same as the Company Record Date) for, duly call and give
notice of a meeting of  the stockholders of Parent entitled to vote on the
Parent Share Issuance (the " _Parent Stockholder Meeting_ ") at which meeting
Parent shall seek the Parent Stockholder Approval (and will use reasonable
best efforts to conduct "broker searches" in a manner to enable the such
record date to be held on such date), (ii) cause the  Joint Proxy
Statement/Prospectus (and all other proxy materials for the Parent Stockholder
Meeting) to be mailed to its stockholders and (iii) duly convene and hold the
Parent Stockholder Meeting. Subject to _Section 7.02_ , Parent  shall use its
reasonable best efforts to take, or cause to be taken, all actions, and do or
cause to be done all things, necessary, proper or advisable on its part to
cause the Parent Stockholder Approval to be received at the Parent 
Stockholder Meeting or any adjournment or postponement thereof, and shall
comply with all legal requirements applicable to the Parent Stockholder
Meeting. Parent shall not, without the prior written consent of the Company,
adjourn,  postpone or otherwise delay the Parent Stockholder Meeting;
_provided_ that Parent may, notwithstanding the foregoing, without the prior
written consent of the Company, adjourn or postpone the Parent Stockholder
Meeting (A) if, after consultation with  the Company, Parent believes in good
faith that such adjournment or postponement is reasonably necessary to allow
reasonable additional time to (1) solicit additional proxies necessary to
obtain the Parent Stockholder Approval, or (2)  distribute any supplement or
amendment to the Joint Proxy Statement/Prospectus that the Board of Directors
of Parent has determined in good faith after consultation with outside legal
counsel is necessary under Applicable Law and for such  supplement or
amendment to be reviewed by Parent's stockholders prior to the Parent
Stockholder Meeting, (B) for an absence of a quorum or (C) if the Company
Stockholder Meeting has been adjourned or postponed by the Company in
accordance  with _Section 8.04(a)_ , to the extent necessary to enable the
Company Stockholder Meeting and the Parent Stockholder Meeting to be held
within a single period of twenty-four (24) consecutive hours as contemplated
by _Section  8.04(d)_. Notwithstanding the foregoing, Parent may not, without
the prior written consent of the Company (such consent not to be unreasonably
withheld, conditioned or delayed), postpone the Parent Stockholder Meeting
more than a  total of three (3) times pursuant to clause (A)(1) or (B) of the
immediately preceding sentence, and no such postponement or adjournment
pursuant to clause (A)(1) or (B) of the immediately preceding sentence shall
be, without the prior  written consent of the Company (such consent not to be
unreasonably withheld, conditioned or delayed), for a period exceeding ten
(10) Business Days. Without the prior written consent of the Company, the
matters contemplated by the Parent  Stockholder Approval shall be the only
matters (other than matters of procedure and matters required by Applicable
Law to be voted on by Parent's stockholders in connection therewith) that
Parent shall propose to be voted on by the  stockholders of Parent at the
Parent Stockholder Meeting; _provided_ , that, subject to  Applicable Law,
the Parent Organizational Documents and _Section 8.04(d)_ , the Parent 
Stockholder Meeting may, in the sole discretion of Parent also constitute its
annual meeting of stockholders so long as (i) doing so would not delay the
Parent Stockholder Meeting by more than fifteen (15) Business Days beyond the
date on  which Parent would otherwise be able to hold the Parent Stockholder
Meeting and (ii) the annual meeting does not contain any matters to be voted
on that are not matters customarily submitted to a vote of stockholders at an
annual meeting  involving only an uncontested election of directors and other
routine matters (including duly submitted stockholder proposals pursuant to
Rule 14a-8 under the Exchange Act that are not eligible to be excluded).

 


 

 

 

100  

(c) Notwithstanding (i) any Company Adverse Recommendation Change or Parent
Adverse Recommendation Change, (ii) the public proposal or announcement or
other submission to the Company or any of its Representatives of a  Company
Acquisition Proposal or the public proposal or announcement or other
submission to Parent or any of its Representatives of a Parent Acquisition
Proposal or (iii) anything in this Agreement to the contrary, unless this
Agreement is  terminated in accordance with its terms, the obligations of the
Company and Parent under _Section 8.03_ and this _Section 8.04_ shall continue
in full force and effect.

 


 

 

(d) Notwithstanding anything to the contrary herein, it is the intention of
the parties that, and each of the parties shall reasonably cooperate and use
their commercially reasonable efforts to cause, the date and time of  the
Company Stockholder Meeting and the Parent Stockholder Meeting be coordinated
such that they occur within a single period of twenty-four (24) consecutive
hours (and in any event as close in time as possible).

 


 

 

Section 8.05 _Public Announcements_. The initial press release concerning this
Agreement and the transactions contemplated hereby shall be a  joint press
release to be in the form agreed upon by the Company and Parent prior to the
execution of this Agreement. Following such initial press release, Parent and
the Company shall consult with each other before issuing any  additional
press release, making any other public statement or scheduling any press
conference, conference call or meeting with investors or analysts with respect
to this Agreement or the transactions contemplated hereby and, except as  may
be required by Applicable Law or any listing agreement with or rule of any
national securities exchange or association, shall not issue any such press
release, make any such other public statement or schedule any such press 
conference, conference call or meeting before such consultation (and, to the
extent applicable, shall provide copies of any such press release, statement
or agreement (or any scripts for any conference calls) to the other party and
shall  consider in good faith the comments of the other party); _provided_
that the restrictions set forth in this _Section 8.05_ shall not apply to any
release or public statement (a) made or proposed to be made by the Company in
compliance with _Section        6.02_ with respect to the matters
contemplated by _Section 6.02_ , or made or proposed to be made by Parent in
response or related to any such release or public statement that is not in
violation of _Section 7.02_ , (b) made or proposed to be made by Parent in
compliance with _Section 7.02_ with  respect to the matters contemplated by
_Section 7.02_ , or made or proposed to be made by the Company in response or
related to any such release or public statement that is not in violation of
_Section 6.02_ , (c) in connection with any dispute between the parties
regarding this Agreement, the Merger or the other  transactions contemplated
hereby or (d) if the information contained therein substantially reiterates
(and is not inconsistent with) previous releases or public statements made by
the Company and Parent in compliance with this _Section  8.05_.

 


 

 

 

101  

Section 8.06 _Notices of Certain Events_. Each of the Company and Parent shall
use commercially reasonable efforts to promptly notify the  other of (a) any
material written notice or other material written communication received by
such party from any Person alleging that the consent of such Person is or may
be required in connection with the transactions contemplated by  this
Agreement, (b) any material written notice or other material written
communication received by such party from any Governmental Authority in
connection with the transactions contemplated by this Agreement, (c) to the
knowledge of  such party, any event, change, effect, development or
occurrence that would have Company Material Adverse Effect, in the case of the
Company, or a Parent Material Adverse Effect, in the case of Parent, or (d) to
the knowledge of such  party, any event, change, development or occurrence
has occurred that would reasonably be expected to cause or result in any of
the conditions set forth in _Article IX_ not being satisfied; _provided_ that,
notwithstanding the  foregoing, a failure to comply with this _Section 8.06_
shall not constitute the failure of any condition set forth in _Article IX_ to
be satisfied unless the underlying change or event would independently result
in the  failure of a condition set forth in _Article IX_ to be satisfied.

 


 

 

Section 8.07 _Section 16 Matters_. Prior to the Merger Effective Time, Parent
and the Company shall take all such steps as may be required (to  the extent
permitted under Applicable Law) to cause any dispositions of Company Common
Stock (including derivative securities with respect to Company Common Stock)
or acquisitions of Parent Common Stock (including derivative securities  with
respect to Parent Common Stock) resulting from the transactions contemplated
by this Agreement by each individual who is subject to the reporting
requirements of Section 16(a) of the 1934 Act with respect to the Company, or
will  become subject to such reporting requirements with respect to Parent,
to be exempt under Rule 16b-3 promulgated under the 1934 Act.

 


 

 

Section 8.08 _Transaction Litigation_. Subject to the last sentence of this
_Section 8.08_ , each of the Company and Parent shall  promptly notify the
other of any stockholder demands, litigations, arbitrations or other similar
claims, actions, suits or proceedings (including derivative claims) commenced
against it, its Subsidiaries and/or its or its Subsidiaries'  respective
directors or officers relating to this Agreement or any of the transactions
contemplated hereby or any matters relating thereto (collectively, "
_Transaction        Litigation_ ") and shall keep the other party
informed regarding any Transaction Litigation. Other than with respect to any
Transaction Litigation where the  parties are adverse to each other or in the
context of any Transaction Litigation related to or arising out of a Company
Acquisition Proposal or a Parent Acquisition Proposal, each of the Company and
Parent shall reasonably cooperate with  the other in the defense or
settlement of any Transaction Litigation, and shall give the other party the
opportunity to consult with it regarding the defense and settlement of such
Transaction Litigation, shall consider in good faith the  other party's
advice with respect to such Transaction Litigation and, in the case of any
Transaction Litigation involving the Company, its Subsidiaries or their
respective directors or officers, the Company shall give Parent the 
opportunity to participate in (but not control), at Parent's expense, in the
defense and settlement of such Transaction Litigation. Prior to the Merger
Effective Time, other than with respect to any Transaction Litigation where
the  parties are adverse to each other or in the context of any Transaction
Litigation related to or arising out of a Company Acquisition Proposal or a
Parent Acquisition Proposal, none of the Company or any of its Subsidiaries
shall settle or  offer to settle any Transaction Litigation without the prior
written consent of Parent (which consent shall not be unreasonably withheld,
conditioned or delayed). Notwithstanding anything to the contrary in this
_Section 8.08, (a)_   in the event of any conflict with any other covenant or
agreement contained in _Section 8.02_ that expressly addresses the subject
matter of this _Section 8.08_ , _Section 8.02_ shall govern and control, and
(b) nothing  in this _Section 8.08_ shall limit or otherwise modify the
parties obligations under _Section 6.02_ , _Section 7.02_ or any other
provisions of this Agreement.

 


 

 

 

102  

Section 8.09 _Stock Exchange Delisting_. Each of the Company and Parent agrees
to cooperate with the other party in taking, or causing to be  taken, all
actions necessary to delist the Company Common Stock from the Nasdaq and
terminate its registration under the 1934 Act; _provided_ that such delisting
and termination shall not be effective until the Merger Effective  Time.

 


 

 

Section 8.10 _Governance_. Parent shall take all necessary corporate action to
cause, effective at the Merger Effective Time, (a) the number  of members of
the Board of Directors of Parent to be increased by two (2) and (b) the
vacancies created by the foregoing clause (b) to be filled by two (2)
individuals who are serving as directors of the Company immediately prior to
the  Merger Effective Time, who are jointly designated by the Company and
Parent prior to the Closing.

 


 

 

Section 8.11 _State Takeover Statutes_. Each of Parent, Merger Sub and the
Company shall (a) take all action necessary so that no  "moratorium,"
"control share acquisition," "fair price," "supermajority," "affiliate
transactions" or "business combination statute or regulation" or other similar
state anti-takeover laws or regulations, or any similar provision of the 
Company Organizational Documents or the Parent Organizational Documents, as
applicable, is or becomes applicable to the Merger or any of the other
transactions contemplated hereby, and (b) if any such anti-takeover law,
regulation or  provision is or becomes applicable to the Merger or any other
transactions contemplated hereby, cooperate and grant such approvals and take
such actions as are reasonably necessary so that the transactions contemplated
hereby may be  consummated as promptly as practicable on the terms
contemplated hereby and otherwise act to eliminate or minimize the effects of
such statute or regulation on the transactions contemplated hereby.

 


 

 

ARTICLE IX 
  
  CONDITIONS TO THE MERGER

 


 

 

Section 9.01 _Conditions to the Obligations of Each Party_. The obligations of
the Company, Parent and Merger Sub to consummate the Merger are  subject to
the satisfaction (or, to the extent permitted by Applicable Law, waiver) of
the following conditions:

 


 

 

(a) the Company Stockholder Approval shall have been obtained;

 


 

 

(b) the Parent Stockholder Approval shall have been obtained;

 


 

 

 

103  

(c) no injunction or other Order shall have been issued by any court or other
Governmental Authority of competent jurisdiction and remain in effect that
enjoins, prevents or prohibits the consummation of the Merger;

 


 

 

(d) the Registration Statement shall have been declared effective, no stop
order suspending the effectiveness of the Registration Statement shall be in
effect and no proceedings for such purpose shall be pending before the  SEC;

 


 

 

(e) the shares of Parent Common Stock to be issued in the Parent Share
Issuance and the New CVRs to be issued in the Merger shall have been approved
for listing on the NYSE, subject to official notice of issuance; and

 


 

 

(f) any applicable waiting period under the HSR Act shall have expired or been
terminated and any applicable waiting period or other Consent under each
Foreign Antitrust Law set forth on _Section 9.01(f)_ of the  Company
Disclosure Schedule relating to the transactions contemplated by this
Agreement shall have expired, been terminated or obtained, as applicable.

 


 

 

Section 9.02 _Conditions to the Obligations of Parent and Merger Sub_. The
obligations of Parent and Merger Sub to consummate the Merger is subject to
the satisfaction (or, to the extent permitted by Applicable  Law, waiver by
Parent) of the following further conditions:

 


 

 

(a) the Company shall have performed, in all material respects, all of its
obligations hereunder required to be performed by it at or prior to the Merger
Effective Time;

 


 

 

(b) (i) the representations and warranties of the Company contained in
_Section 4.01_ (other than the third sentence thereof), _Section 4.02_ (other
than the last sentence of _Section 4.02(b)_ ), _Section 4.04_ _(a)_ , _Section
4.05_ _(a)_ , _Section 4.05(b)_ , _Section 4.26_ , _Section 4.27_ and _Section
4.28_ shall be true and  correct in all material respects at and as of the
date of this Agreement and at and as of the Closing as if made at and as of
the Closing (or, if such representations and warranties are given as of
another specific date, at and as of such  date); (ii) the representations and
warranties of the Company contained in _Section 4.10(a)_ _(ii)_ shall be true
and correct in all respects at and as of the date of this Agreement and at and
as of the Closing as if made at and as of the Closing; and (iii) the other
representations and warranties of the Company contained  in this Agreement,
disregarding all qualifications and exceptions contained therein relating to
materiality or Company Material Adverse Effect, shall be true and correct at
and as of the date of this Agreement and at and as of the Closing  as if made
at and as of the Closing (or, if such representations and warranties are given
as of another specific date, at and as of such date), except, in the case of
this clause (iii) only, where the failure of such representations and 
warranties to be true and correct has not had and would not reasonably be
expected to have, individually or in the aggregate, a Company Material Adverse
Effect (or, in the case of _Section 4.16_ , a Parent Material Adverse
Effect);  and

 


 

 

(c) Parent shall have received a certificate from an executive officer of the
Company confirming the satisfaction of the conditions set forth in _Section
9.02(a)_ and _Section 9.02(b)_.

 


 

 

 

104  

Section 9.03 _Conditions to the Obligations of the Company_. The obligations
of the Company to consummate the Merger are subject to the  satisfaction (or,
to the extent permitted by Applicable Law, waiver by the Company) of the
following further conditions:

 


 

 

(a) each of Parent and Merger Sub shall have performed, in all material
respects, all of its obligations hereunder required to be performed by it at
or prior to the Merger Effective Time;

 


 

 

(b) (i) the representations and warranties of Parent contained in _Section
5.01_ (other than the third and last sentences thereof), _Section 5.02_ (other
than the last sentence of _Section 5.02(b)_ ), _Section 5.04_ _(a)_ , _Section
5.05_ , _Section 5.23_ , _Section 5.24_ and _Section 5.25_ shall be true and
correct in all material respects at and  as of the date of this Agreement and
at and as of the Closing as if made at and as of the Closing (or, if such
representations and warranties are given as of another specific date, at and
as of such date); (ii) the representations and  warranties of Parent
contained in _Section 5.10(a)_ _(ii)_ shall be true and correct in  all
respects at and as of the date of this Agreement and at and as of the Closing
as if made at and as of the Closing; and (iii) the other representations and
warranties of Parent contained in this Agreement, disregarding all 
qualifications and exceptions contained therein relating to materiality or
Parent Material Adverse Effect, shall be true and correct at and as of the
date of this Agreement and at and as of the Closing as if made at and as of
the Closing  (or, if such representations and warranties are given as of
another specific date, at and as of such date), except, in the case of this
clause (iii) only, where the failure of such representations and warranties to
be true and correct has  not had and would not reasonably be expected to
have, individually or in the aggregate, a Parent Material Adverse Effect; and

 


 

 

(c) the Company shall have received a certificate from an executive officer of
Parent confirming the satisfaction of the conditions set forth in _Section
9.03(a)_ and _Section 9.03(b)_.

 


 

 

ARTICLE X 
  
  TERMINATION

 


 

 

Section 10.01 _Termination_. This Agreement may be terminated and the Merger
and the other transactions contemplated hereby may be abandoned at  any time
prior to the Merger Effective Time (notwithstanding receipt of the Company
Stockholder Approval or the Parent Stockholder Approval):

 


 

 

(a) by mutual written agreement of the Company and Parent;

 


 

 

(b) by either the Company or Parent, if:

 


 

 

105  

(i) the  Merger has not been consummated on or before January 2, 2020 (as
such date may be extended pursuant to the following proviso, the "End Date");
provided that, (A) if on such date, the conditions to the Closing set forth in
_Section 9.01(f)_ or _Section 9.01(c)_ (if the injunction or other  Order
relates to the matters referenced in _Section 9.01(f)_ ) shall not have been
satisfied, but all other conditions to the Closing shall have been satisfied
(or in the case of conditions that by their terms are to be satisfied at  the
Closing, shall be capable of being satisfied on such date) or waived, then the
End Date may be extended by either Parent or the Company for a period of sixty
(60) days by written notice to the other party and (B) if on such date as 
extended by the immediately preceding clause (A), the conditions to the
Closing set forth in _Section 9.01(f)_ or _Section 9.01(c)_ (if the injunction
or other Order relates to the matters referenced in _Section 9.01(f))_  
shall not have been satisfied, but all other conditions to the Closing shall
have been satisfied (or in the case of conditions that by their terms are to
be satisfied at the Closing, shall be capable of being satisfied on such date)
or  waived, then the End Date may be further extended by either Parent or the
Company for another period of sixty (60) days by written notice to the other
party; _provided_ ,  further, that the right to terminate this Agreement or
to extend the End Date, as applicable, pursuant to this _Section 10.01(b)(i)_
shall not be available to any party whose breach of any provision of this
Agreement has been the  proximate cause of the failure of the Merger to be
consummated by such time;

 


 

 

 

(ii) a  court or other Governmental Authority of competent jurisdiction shall
have issued an injunction or other Order that permanently enjoins, prevents or
prohibits the consummation of the Merger and such injunction or other Order
shall have  become final and non-appealable; _provided_ that  the right to
terminate this Agreement pursuant to this _Section 10.01(b)(ii)_ shall not be
available to any party whose breach of any provision of this Agreement has
been the proximate cause of such injunction or other Order;

 

 

 


 

 

(iii) the Company  Stockholder Approval shall not have been obtained upon a
vote taken thereon at the Company Stockholder Meeting (including any
adjournment or postponement thereof); or

 


 

(iv) the         Parent Stockholder Approval shall not have been
obtained upon a vote taken thereon at the Parent Stockholder Meeting
(including any adjournment or postponement thereof); or

 

 


 

 

 

 

(c) by Parent:

 

 

 

  
 

(i) prior to the receipt of the Company Stockholder Approval, if (A) a
Company Adverse Recommendation  Change shall have occurred, or (B) at any
time after a Company Acquisition Proposal shall have been publicly disclosed
the Board of Directors of the Company shall have failed to publicly confirm
the Company Board Recommendation within ten  (10) Business Days after a
written request by Parent that it do so (provided that Parent may not make
such a request more than once for each (x) Company Acquisition Proposal or (y)
material modification thereto);

  
 

 

(ii) if a breach of any representation or warranty or failure to perform any
covenant or agreement on the  part of the Company set forth in this Agreement
shall have occurred that would cause any condition set forth in _Section
9.02(a)_ or _Section 9.02(b)_ not to be satisfied, and such breach or failure
to perform (A) is incapable  of being cured by the End Date or (B) has not
been cured by the Company within the earlier of (x) thirty (30) days following
written notice to the Company from Parent of such breach or failure to perform
and (y) the End Date; _provided_   that this Agreement may not be terminated
pursuant to this _Section 10.01(c)(ii)_ if Parent or Merger Sub is then in
breach of any of its representations, warranties, covenants or agreements set
forth in this Agreement, which breach  by Parent or Merger Sub would cause
any condition set forth in _Section 9.03(a)_ or _Section 9.03(b)_ not to be
satisfied; or

 

 


 

 

 

106  

 

(iii) prior to obtaining the Parent Stockholder Approval, in order to enter
into a definitive agreement  providing for a Parent Superior Proposal in
accordance with, and subject to the terms and conditions of, _Section 7.02_ ;
or

 


 

 

(d) by the Company:

 


 

 

(i) prior to the receipt of the Parent Stockholder Approval, if (A) a Parent
Adverse  Recommendation Change shall have occurred, or (B) at any time after
a Parent Acquisition Proposal has been publicly disclosed the Board of
Directors of Parent shall have failed to publicly confirm the Parent Board
Recommendation within  ten (10) Business Days after a written request by the
Company that it do so (provided that the Company may not make such a request
more than once for each (x) Parent Acquisition Proposal or (y) material
modification thereto);

 


 

 

(ii) if a breach of any representation or warranty or failure to perform any
covenant or  agreement on the part of Parent or Merger Sub set forth in this
Agreement shall have occurred that would cause any condition set forth in
_Section 9.03(a)_ or _Section 9.03(b)_ not to be satisfied, and such breach or
failure  to perform (A) is incapable of being cured by the End Date or (B)
has not been cured by Parent or Merger Sub, as applicable, within the earlier
of (x) thirty (30) days following written notice to Parent from the Company of
such breach or  failure to perform and (y) the End Date; _provided_ that this
Agreement may not be terminated pursuant to this _Section 10.01(d)(ii)_ if the
Company is then in breach of any of its representations, warranties, covenants
or  agreements set forth in this Agreement, which breach by the Company would
cause any condition set forth in _Section 9.02(a)_ or _Section 9.02(b)_ not to
be satisfied; or

 


 

 

(iii) prior to obtaining the Company Stockholder Approval, in order to enter
into a  definitive agreement providing for a Company Superior Proposal in
accordance with, and subject to the terms and conditions of, _Section 6.02_.

 


 

 

The party desiring to terminate this Agreement pursuant to this _Section
10.01_ (other than  pursuant to _Section 10.01(a)_ ) shall give written
notice of such termination to the other party.

 


 

 

Section 10.02 _Effect of Termination_. If this Agreement is terminated
pursuant to _Section 10.01_ ,  this Agreement shall become void and of no
effect without liability of any party (or any of its Affiliates or its or
their respective stockholders or Representatives) to the other party hereto,
except as provided in _Section 10.03_ ;  _provided_ that, subject to _Section
10.03(f)_ , neither Parent nor the Company shall be released from any
liabilities or damages arising out of any (i) fraud by any party or (ii) the
Willful Breach of any covenant or agreement  set forth in this Agreement. The
provisions of _Section 6.03(a)_ , the first sentence of _Section 8.01(a)_ ,
this _Section 10.02_ , _Section 10.03_ , _Article XI_ (other than _Section
11.13_ , except to the  extent that _Section 11.13_ relates to the specific
performance of the provisions of this Agreement that survive termination) and
_Section 1.01_ (to the extent related to the foregoing) shall survive any
termination of this  Agreement pursuant to _Section 10.01_. In addition, the
termination of this Agreement shall not affect the parties' respective
obligations under the Confidentiality Agreement.

 


 

 

 

 

107  

Section 10.03 _Termination Fees_.

 


 

 

(a) If this Agreement is terminated: (i) by Parent pursuant to _Section
10.01(c)(i)_ ; (ii) by the Company pursuant to _Section 10.01(d)(iii)_ ; (iii)
by the Company or Parent pursuant to _Section 10.01(b)(iii)_ , and in the case
of clause (iii) of this sentence: (I) at or prior to the Company Stockholder
Meeting a  Company Acquisition Proposal shall have been publicly disclosed or
announced and shall not have been publicly and irrevocably withdrawn at least
four (4) days prior to the Company Stockholder Meeting; and (II) within the
first (1st)  anniversary of such termination of this Agreement: (1) a
transaction relating to any Company Acquisition Proposal is consummated; or
(2) a definitive agreement relating to any Company Acquisition Proposal is
entered into by the Company or  any of its Affiliates; or (iv) by Parent
pursuant to _Section 10.01(c)(ii)_ as a result of a material breach by the
Company of its obligations set forth in _Section 6.02_ or _Section 8.04(a)_
and, at the time of such  termination, the Company Stockholder Approval shall
not have been obtained, and in the case of clause (iv) of this sentence: (I)
at or prior to the date of such termination a Company Acquisition Proposal
shall have been made and shall not  have been publicly and irrevocably
withdrawn at least four (4) days prior to the Company Stockholder Meeting; and
(II) within the first (1st) anniversary of such termination of this Agreement:
(1) a transaction relating to any Company  Acquisition Proposal is
consummated; or (2) a definitive agreement relating to any Company Acquisition
Proposal is entered into by the Company or any of its Subsidiaries, then (x)
in the case of each of the foregoing clauses (i), (ii) and  (iv), the Company
shall pay to Parent (or its designee), in cash at the time specified in the
following sentence, a fee in an amount equal to $2.2 billion (the "
_Company     Termination Fee_ ") and (y) in the case of the foregoing
clause (iii), the Company shall pay to Parent (or its designee), in cash at
the time specified in the  following sentence, a fee in an amount equal to
the Company Termination Fee, less any amounts paid to Parent (or its designee)
as of such time with respect to the Parent Fee Reimbursement. The Company
Termination Fee shall be paid as  follows: (x) in the case of clause (i) of
the preceding sentence, within three (3) Business Days after the date of
termination of this Agreement, (y) in the case of clause (ii) of the preceding
sentence, on or prior to the date of such  termination and (z) in the case of
clause (iii) or (iv) of the preceding sentence, on or prior to the earlier of
the date of the consummation of the applicable transaction and the date upon
which the definitive agreement is entered into.   "Company Acquisition
Proposal" for purposes of this _Section 10.03(a)_ shall have the meaning
assigned thereto in the definition thereof set forth in _Section 1.01_ ,
except that references in the definition to "twenty percent  (20%)" shall be
replaced by "fifty percent (50%)".

 


 

 

 

108  

(b) If this Agreement is terminated: (i) by the Company pursuant to _Section
10.01(d)(i)_ ; (ii) by Parent pursuant to _Section 10.01(c)(iii)_ , (iii) by
the Company or Parent pursuant to _Section 10.01(b)(iv)_ ,  and in the case
of clause (iii) of this sentence: (I) at or prior to the Parent Stockholder
Meeting a Parent Acquisition Proposal shall have been publicly disclosed or
announced and shall not have been publicly and irrevocably withdrawn  at
least four (4) days prior to the Parent Stockholder Meeting; and (II) within
the first (1st) anniversary of such termination of this Agreement: (1) a
transaction relating to any Parent Acquisition Proposal is consummated; or (2)
a  definitive agreement relating to any Parent Acquisition Proposal is
entered into by Parent or any of its Subsidiaries; or (iv) by the Company
pursuant to _Section 10.01(d)(ii)_ as a result of a material breach by Parent
or Merger  Sub of its obligations set forth in _Section 7.02_ or _Section
8.04(b)_ and, at the  time of such termination, the Parent Stockholder
Approval shall not have been obtained, and in the case of clause (iv) of this
sentence: (I) at or prior to the date of such termination a Parent Acquisition
Proposal shall have been made  and shall not have been publicly and
irrevocably withdrawn at least four (4) days prior to the Parent Stockholder
Meeting; and (II) within the first (1st) anniversary of such termination of
this Agreement: (1) a transaction relating to  any Parent Acquisition
Proposal is consummated; or (2) a definitive agreement relating to any Parent
Acquisition Proposal is entered into by Parent or any of its Subsidiaries,
then (x) in the case of each of the foregoing clauses (i),  (ii) and (iv),
Parent shall pay to the Company, in cash at the time specified in the
following sentence, a fee in an amount equal to $2.2 billion (the " _Parent 
Termination Fee_ ") and (y) in the case of the foregoing clause (iii), Parent
shall pay to the Company (or its designee), in cash at the time specified in
the  following sentence, a fee in an amount equal to the Parent Termination
Fee, less any amounts paid to the Company (or its designee) as of such time
with respect to the Company Fee Reimbursement. The Parent Termination Fee
shall be paid as  follows: (x) in the case of clause (i) of the preceding
sentence, within three (3) Business Days after the date of termination of this
Agreement, (y) in the case of clause (ii) of the preceding sentence, on or
prior to the date of such  termination, and (z) in the case of clause (iii)
or (iv) of the preceding sentence, on or prior to the earlier of the date of
the consummation of the applicable transaction and the date upon which the
definitive agreement is entered into.  "Parent Acquisition Proposal" for
purposes of this _Section 10.03(b)_ shall have the meaning assigned thereto in
the definition thereof set forth in _Section 1.01_ , except that references in
the definition to "twenty percent  (20%)" shall be replaced by "fifty percent
(50%)".

 


 

 

(c) If this Agreement is terminated by Parent or the Company pursuant to
_Section 10.01(b)(iii)_ , then the Company shall pay to Parent (or its
designee) an amount equal to all out-of-pocket costs, fees and expenses 
(including legal fees and expenses) incurred by Parent and any of its
Affiliates in connection with this Agreement and the transactions contemplated
hereby (including obtaining the Debt Financing), subject to cap on such
reimbursement of  $40,000,000 (" _Parent Fee Reimbursement_ "), within one
Business Day after the date of the  termination of the Agreement (in the case
of any such termination by Parent) or at or prior to, and as a condition
precedent to, the termination of the Agreement (in the case of any such
termination by the Company).

 


 

 

(d) If this Agreement is terminated by Parent or the Company pursuant to
_Section 10.01(b)(iv)_ , then Parent shall pay to the Company (or its
designee) an amount equal to all out-of-pocket costs, fees and expenses 
(including legal fees and expenses) incurred by the Company and any of its
Affiliates in connection with this Agreement and the transactions contemplated
hereby, subject to cap on such reimbursement of $40,000,000 (the " _Company
Fee Reimbursement_ "), within one Business Day after the date of the
termination of the Agreement  (in the case of any such termination by the
Company) or concurrently with, and as a condition precedent to, the
termination of the Agreement (in the case of any such termination by Parent).

 


 

 

(e) Any payment of the Company Termination Fee, the Parent Termination Fee,
the Parent Fee Reimbursement or the Company Fee Reimbursement shall be made by
wire transfer of immediately available funds to an account  designated in
writing by Parent or the Company, as applicable.

 


 

 

 

109  

(f) The parties agree and understand that (x) in no event shall the Company be
required to pay the Company Termination Fee on more than one occasion, and in
no event shall Parent be required to pay the Parent Termination  Fee on more
than one occasion, in each case, under any circumstances, and (y) except in
the case of fraud or Willful Breach of any covenant or agreement set forth in
this Agreement by the other party, (1) in no event shall Parent be  entitled,
pursuant to this _Section 10.03_ , to receive an amount greater than the
Company Termination Fee and any applicable additional amounts pursuant the
last two sentences of this _Section 10.03(f)_ (such additional  amounts,
collectively, the " _Parent Additional Amounts_ "), and (2) in no event shall
the  Company be entitled, pursuant to this _Section 10.03_ , to receive an
amount greater than the Parent Termination Fee and any applicable additional
amounts pursuant to _Section 6.03(a)_ and/or the last two sentences of this
_  Section 10.03(f)_ (such additional amounts, collectively, the " _Company
Additional Amounts_ "). Notwithstanding anything to the contrary in this
Agreement, except in the case of fraud or Willful Breach of any covenant or
agreement set forth in this Agreement by the other party, (i) if Parent
receives the Company  Termination Fee and any applicable Parent Additional
Amounts from the Company pursuant to this _Section 10.03_ , or if the Company
receives the Parent Termination Fee and any applicable Company Additional
Amounts from Parent pursuant  to this _Section 10.03_ , such payment shall be
the sole and exclusive remedy of the receiving party against the paying party
and its Subsidiaries and their respective former, current or future partners,
equityholders, managers,  members, Affiliates and Representatives, and none
of the paying party, any of its Subsidiaries or any of their respective
former, current or future partners, equityholders, managers, members,
Affiliates or Representatives shall have any  further liability or
obligation, in each case relating to or arising out of this Agreement or the
transactions contemplated hereby, and (ii) if (A) Parent or Merger Sub receive
any payments from the Company in respect of any breach of  this Agreement and
thereafter Parent receives the Company Termination Fee pursuant to this
_Section 10.03_ or (B) the Company receives any payments from Parent or Merger
Sub in respect of any breach of this Agreement and thereafter  the Company
receives the Parent Termination Fee, the amount of such Company Termination
Fee or such Parent Termination Fee, as applicable, shall be reduced by the
aggregate amount of such payments made by the party paying the Company 
Termination Fee or the Parent Termination Fee, as applicable, in respect of
any such breaches (in each case, after taking into account any Parent
Additional Amounts or Company Additional Amounts, as applicable). The parties
acknowledge  that the agreements contained in this _Section 10.03_ are an
integral part of the transactions contemplated hereby, that, without these
agreements, the parties would not enter into this Agreement and that any
amounts payable  pursuant to this _Section 10.03_ do not constitute a
penalty. Accordingly, if any party fails to promptly pay any amount due
pursuant to this _Section 10.03_ , such party shall also pay any out-of-pocket
costs and expenses  (including reasonable legal fees and expenses) incurred
by the party entitled to such payment in connection with a legal action to
enforce this Agreement that results in a judgment for such amount against the
party failing to promptly pay  such amount. Any amount not paid when due
pursuant to this _Section 10.03_ shall bear interest from the date such amount
is due until the date paid at a rate equal to the prime rate as published in
The Wall Street Journal, Eastern Edition in effect on the date of such
payment.

 


 

 

 

110  

(g) None of the Financing Sources shall have any liability to the Company or
any Person that is an Affiliate of the Company relating to or arising out of
this Agreement or the Debt Financing, whether at law, or equity, in 
contract, in tort or otherwise, and neither the Company nor any Person that is
an Affiliate of the Company shall have any rights or claims directly against
any of the Financing Sources hereunder or thereunder. The foregoing shall
not  impair, supplement, or otherwise modify any of the commitments and other
obligations that the Financing Sources have under any Debt Commitment Letter
and/or any definitive agreement related to the Debt Financing to Parent or
Merger Sub or  any of the rights of Parent or Merger Sub against any of the
Financing Sources under any Debt Commitment Letter and/or any definitive
agreement related to the Debt Financing and this _Section 10.03(g)_ shall not
limit the rights of  the Company or any Person that is an Affiliate of the
Company from and after the Merger Effective Time under any Debt Commitment
Letter or any definitive agreement related to the Debt Financing (but not, for
the avoidance of doubt, under  this Agreement) to the extent the Company or
any Person that is an Affiliate of the Company are party thereto.

 


 

 

ARTICLE XI 
  
  MISCELLANEOUS

 


 

 

Section 11.01 _Notices_. All notices, requests and other communications to any
party hereunder shall be in writing (including facsimile or  email
transmission, the receipt of which is confirmed in writing) and shall be
given,

 

 


 

 

        

    |  

If to the Company, to: 
 

    
---|--- 
     

    |  


 

    
     

    |  

Celgene Corporation 
 

    
     

    | 86 Morris Avenue  
     

    | Summit, New Jersey 07901  
     

    | Attention:  | Executive Vice President and General Counsel  
     

    | Email: 
    | jbiller@celgene.com  
     

    |  


 

    
     

    | with a copy to (which shall not constitute notice):  
     

    |  


 

    
     

    | Wachtell, Lipton, Rosen and Katz  
     

    | 51 West 52nd Street  
     

    | New York, New York 10019  
     

    | Attention:  | Steven A. Cohen  
      |   | David K. Lam  
      |   | Edward J. Lee  
      | Facsimile:  | (212) 403 2000  
      | Email:  | SACohen@wlrk.com  
      |   | DKLam@wlrk.com  
      |   | EJLee@wlrk.com  
    

 

 


 

 

 

111  

 

        

    | If to Parent or Merger Sub or, post-Closing, the Surviving
Corporation, to:  
---|--- 
     

    |  

    
     

    | Bristol-Myers Squibb Company  
     

    | 430 E. 29th Street, 14th Floor  
     

    | New York, New York 10016  
     

    | Attention: 
    | Executive Vice President, General Counsel  
     

    | Email:  | sandra.leung@bms.com  
     

    |  


 

    
     

    | with a copy to (which shall not constitute notice):  
     

    |  


 

    
     

    | Bristol-Myers Squibb Company  
     

    | Route 206 and Province Line Road  
     

    | Princeton, New Jersey 08540  
     

    | Attention:  | Senior Vice President and Deputy General Counsel,  
     

    |  

    | Transactional Practice Group  
      | Email: 
    | joseph.campisi@bms.com  
      |   
      | with a copy to (which shall not constitute notice):   
      |   
      | Kirkland and Ellis LLP   
      | 601 Lexington Avenue   
      | New York, New York 10022   
      | Attention:  | David Fox, P.C.  
      |   | Daniel Wolf, P.C.  
      |   | Jonathan Davis, P.C.  
      | Facsimile:  | (212) 446-4900  
      | Email: 
    | david.fox@kirkland.com  
      |   | daniel.wolf@kirkland.com  
      |   | jonathan.davis@kirkland.com  
    

 


 

 

 

or to such other address, facsimile number or email address as such party may
hereafter specify for the purpose by notice to the other parties  hereto. All
such notices, requests and other communications shall be deemed received on
the date of receipt by the recipient thereof if received prior to 5:00 p.m. on
a Business Day. Otherwise, any such notice, request or communication  shall
be deemed to have been received on the next succeeding Business Day.

 


 

 

Section 11.02 _Survival_. The representations, warranties, covenants and
agreements contained in this Agreement and in any certificate or other 
writing delivered pursuant hereto shall not survive the Merger Effective Time,
except for the covenants and agreements set forth in _Article II_ , _Section
7.04_ , _Section 7.05_ , _Section 8.10_ and this _Article  XI_.

 


 

 

Section 11.03 _Amendments and Waivers_.

 


 

 

(a) Any provision of this Agreement may be amended or waived prior to the
Merger Effective Time if, but only if, such amendment or waiver is in writing
and is signed, in the case of an amendment, by each party to this  Agreement
or, in the case of a waiver, by each party against whom the waiver is to be
effective; _provided_ that, after the Company Stockholder Approval or the
Parent Stockholder Approval has been obtained, there shall be no amendment 
or waiver that would require the further approval of the stockholders of the
Company or the stockholders of Parent under Applicable Law without such
approval having first been obtained.

 


 

 

 

112  

(b) Notwithstanding anything to the contrary in this Agreement, the provisions
in _Section 10.03(g)_ , this _Section 11.03(b)_ , _Section 11.06(a)_ ,
_Section 11.07_ , _Section 11.08(b)_ or _Section        11.09_ may not
be amended in a manner that is adverse to the Financing Sources without the
prior written consent of the applicable Financing Source.

 


 

 

(c) No failure or delay by any party in exercising any right, power or
privilege hereunder shall operate as a waiver thereof, nor shall any single or
partial exercise thereof preclude any other or further exercise thereof  or
the exercise of any other right, power or privilege. The rights and remedies
provided in this Agreement shall be cumulative and not exclusive of any rights
or remedies provided by Applicable Law.

 


 

 

Section 11.04 _Expenses_. Except as otherwise provided in this Agreement, all
costs and expenses incurred in connection with this Agreement  shall be paid
by the party incurring such cost or expense.

 


 

 

Section 11.05 _Disclosure Schedule References and SEC Document References_.

 


 

 

(a) The parties hereto agree that each section or subsection of the Company
Disclosure Schedule or the Parent Disclosure Schedule, as applicable, shall be
deemed to qualify the corresponding section or subsection of this  Agreement,
irrespective of whether or not any particular section or subsection of this
Agreement specifically refers to the Company Disclosure Schedule or the Parent
Disclosure Schedule, as applicable. The parties hereto further agree  that
disclosure of any item, matter or event in any particular section or
subsection of either the Company Disclosure Schedule or the Parent Disclosure
Schedule shall be deemed disclosure with respect to any other section or
subsection of  the Company Disclosure Schedule or the Parent Disclosure
Schedule, as applicable, to which the relevance of such disclosure would be
reasonably apparent, notwithstanding the omission of a cross-reference to such
other section or  subsections.

 


 

 

(b) The parties hereto agree that, for purpose of clause (i) of the lead-in to
_Article IV_ and clause (i) of the lead-in to _Article V_, as applicable, in
no  event shall any disclosure contained in any part of any Company SEC
Document or Parent SEC Document entitled "Risk Factors", "Forward-Looking
Statements", "Cautionary Statement Regarding Forward-Looking Statements",
"Special Note  Regarding Forward Looking Statements" or "Note Regarding
Forward Looking Statements" or any other disclosures in any Company SEC
Document or Parent SEC Document that are cautionary, predictive or forward-
looking in nature be deemed to be  an exception to (or a disclosure for
purposes of or otherwise qualify) any representations and warranties of any
party contained in this Agreement.

 


 

 

 

113  


 

Section 11.06 _Binding Effect; Benefit; Assignment_.

 

  
   

(a) The provisions of this Agreement shall be binding upon and shall inure
solely to the benefit of the parties hereto, except for: (i) only following
the Merger Effective Time, (w) the right of the Company's stockholders  to
receive the Merger Consideration in respect of shares of Company Common Stock
pursuant to _Article II_ , (v) the right of the holders of Company Stock
Options to receive the Assumed In-the-Money Options and/or the Assumed  Out-
of-the-Money Options in respect of Company Stock Options pursuant to _Section
2.06(a)_ , (w) the right of the holders of Company RSU Awards to receive the
Assumed Restricted Unit Awards in respect of the Company RSU Awards  pursuant
to _Section_ _2.06(b)_ , (x) the right of the holders of Company PSU Awards
to  receive the Assumed Performance Unit Awards in respect of the Company PSU
Awards pursuant to _Section_ _2.06(c)_ , (y) the right of the holders of
Company RSAs to receive the Assumed Restricted Unit Awards in respect of the
Company RSAs pursuant to _Section     2.06(d)_ , and (z) the right of
holders of unvested In-the-Money Options, Company RSU Awards, Company PSU
Awards and Company RSAs to receive the Unvested Equity  Award CVR
Consideration pursuant to _Section 2.06(e)_ , (ii) the right of the DandO 
Indemnified Parties to enforce the provisions of _Section 7.04_ only, and
(iii) the right of each of the Financing Sources as an express third-party
beneficiary of _Section 10.03(g)_ , _Section 11.03(b)_ , this _Section 
11.06(a)_ , _Section 11.07_ , _Section 11.08(b)_ and _Section 11.09_.

 


 

 

(b) No party may assign, delegate or otherwise transfer any of its rights or
obligations under this Agreement without the prior written consent of each
other party hereto, except that Parent may transfer or assign its  rights and
obligations under this Agreement, in whole or from time to time in part, to
one or more of its wholly owned Subsidiaries at any time or any other Person
after the Closing, and Merger Sub may transfer or assign its rights and 
obligations under this Agreement, in whole or from time to time in part, to
any other wholly owned Subsidiary of Parent that is a Delaware corporation;
_provided_ that such transfer or assignment by Parent or Merger Sub shall not
relieve Parent or  Merger Sub of its obligations hereunder or otherwise alter
or change any obligation of any other party hereto or delay the consummation
of the Merger or any of the other transactions contemplated hereby.

 


 

 

Section 11.07 _Governing Law_. This Agreement, and all disputes, claims,
actions, suits or proceedings based upon, arising out of or related to  this
Agreement or the transactions contemplated hereby, shall be governed by and
construed in accordance with the laws of the State of Delaware, without regard
to the conflicts of law rules or principles that would result in the 
application of the law of any other state.

 


 

 

Section 11.08 _Jurisdiction/Venue_.

 


 

 

(a) Each of the parties hereto (i) irrevocably consents to the service of the
summons and complaint and any other process with respect to any dispute,
claim, action, suit or proceeding based upon, arising out of or related  to
this Agreement or any of the transactions contemplated hereby, on behalf of
itself or its property, in accordance with _Section 11.01_ or in such other
manner as may be permitted by Applicable Law, and nothing in this _Section 
11.08_ shall affect the right of any party to serve legal process in any other
manner permitted by Applicable Law, (ii) irrevocably and unconditionally
consents and submits itself and its property with respect to any such
dispute,  claim, action, suit or proceeding to the exclusive general
jurisdiction of the Delaware Court of Chancery and any state appellate court
therefrom within the State of Delaware (or, only if the Delaware Court of
Chancery declines to accept  jurisdiction over a particular matter, any
federal court within the State of Delaware), and for recognition and
enforcement of any judgment in respect thereof, (iii) agrees that it shall not
attempt to deny or defeat such personal  jurisdiction by motion or other
request for leave from any such court, (iv) irrevocably and unconditionally
agrees that any dispute, claim, action, suit or proceeding based upon, arising
out of or related to this Agreement or any of the  transactions contemplated
hereby shall be brought, tried and determined only in the Delaware Court of
Chancery (or, only if the Delaware Court of Chancery declines to accept
jurisdiction over a particular matter, any federal court within  the State of
Delaware), (v) waives any objection that it may now or hereafter have to the
venue of any such action or proceeding in any such court or that any such
dispute, claim, action, suit or proceeding was brought in an inconvenient 
court and agrees not to plead or claim the same and (vi) agrees that it shall
not bring any dispute, claim, action, suit or proceeding based upon, arising
out of or related to this Agreement or any of the transactions contemplated
hereby  in any court other than the aforesaid courts. Each of Parent, Merger
Sub and the Company agrees that a final judgment in any action or proceeding
in such court as provided above shall be conclusive and may be enforced in
other  jurisdictions by suit on the judgment or in any other manner provided
by Applicable Law.

 


 

 

 

114  

(b) Notwithstanding anything herein to the contrary, the parties hereto
acknowledge and irrevocably agree (i) that any action or proceeding, whether
in law or in equity, whether in contract or tort or otherwise, involving  the
Financing Sources arising out of or related to the transactions contemplated
hereby, the Debt Financing or the performance of services thereunder or
related thereto shall be subject to the exclusive jurisdiction of any state
or  federal court sitting in the Borough of Manhattan, New York, New York,
and any appellate court thereof and each party hereto submits for itself and
its property with respect to any such action or proceeding to the exclusive
jurisdiction  of such court and (ii) that, except as expressly contemplated
by the terms of any Debt Commitment Letter, any such action or proceeding
shall be governed by, and construed in accordance with, the laws of the State
of New York, without  regard to the conflicts of law rules of such State that
would result in the application of the laws of any other State.

 


 

 

Section 11.09 _WAIVER OF JURY TRIAL_. EACH PARTY ACKNOWLEDGES AND AGREES THAT
ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO  INVOLVE
COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY
IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A
TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT
OF OR  RELATING TO THIS AGREEMENT, THE MERGER OR THE OTHER TRANSACTIONS
CONTEMPLATED HEREBY (INCLUDING WITH RESPECT TO THE FINANCING SOURCES). EACH
PARTY CERTIFIES AND ACKNOWLEDGES THAT (i) NO REPRESENTATIVE, AGENT OR ATTORNEY
OF ANY OTHER  PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER
PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING
WAIVER, (ii) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF
THIS WAIVER, (iii) EACH  PARTY MAKES THIS WAIVER VOLUNTARILY, AND (iv) EACH
PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS,
THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS _SECTION 11.09_.

 


 

 

Section 11.10 _Counterparts; Effectiveness_. This Agreement may be signed in
any number of counterparts, including by facsimile or by email  with .pdf
attachments, each of which shall be an original, with the same effect as if
the signatures thereto and hereto were upon the same instrument. This
Agreement shall become effective when each party hereto shall have received
a  counterpart hereof signed and delivered (by electronic communication,
facsimile or otherwise) by all of the other parties hereto. Until and unless
each party has received a counterpart hereof signed by the other party hereto,
this  Agreement shall have no effect, and no party shall have any right or
obligation hereunder (whether by virtue of any other oral or written agreement
or other communication).

 


 

 

 

115  

Section 11.11 _Entire Agreement_. This Agreement and the Confidentiality
Agreement constitute the entire agreement between the parties with  respect
to the subject matter thereof and supersede all prior agreements and
understandings, both oral and written, between the parties with respect to the
subject matter thereof.

 


 

 

Section 11.12 _Severability_. If any term, provision, covenant or restriction
of this Agreement is held by a court of competent jurisdiction or  other
Governmental Authority to be invalid, void or unenforceable, the remainder of
the terms, provisions, covenants and restrictions of this Agreement shall
remain in full force and effect and shall in no way be affected, impaired or 
invalidated so long as the economic or legal substance of the transactions
contemplated hereby is not affected in any manner materially adverse to any
party. Upon such a determination, the parties shall negotiate in good faith to
modify  this Agreement so as to effect the original intent of the parties as
closely as possible in an acceptable manner in order that the transactions
contemplated hereby be consummated as originally contemplated to the fullest
extent possible.

 


 

 

Section 11.13 _Specific Performance_. The parties acknowledge and agree that
irreparable harm would occur and that the parties would not have  any
adequate remedy at law (a) for any breach of any of the provisions of this
Agreement or (b) in the event that any of the provisions of this Agreement
were not performed in accordance with their specific terms. It is
accordingly  agreed that, except where this Agreement is validly terminated
in accordance with _Section 10.01_ , the parties shall be entitled to an
injunction or injunctions to prevent breaches or threatened breaches of this
Agreement and to  specifically enforce the terms and provisions of this
Agreement, without proof of actual damages, and each party further agrees to
waive any requirement for the securing or posting of any bond in connection
with such remedy. The parties  further agree that (x) by seeking the remedies
provided for in this _Section 11.13_ , a party shall not in any respect waive
its right to any other form of relief that may be available to a party under
this Agreement, including,  subject to _Section 10.03(f)_ , monetary damages
in the event that the remedies provided for in this _Section 11.13_ are not
available or otherwise are not granted, and (y) nothing contained in this
_Section 11.13_ shall  require any party to institute any proceeding for (or
limit any party's right to institute any proceeding for) specific performance
under this _Section 11.13_ before exercising any termination right under
_Section 10.01_   (and/or pursuing damages), nor shall the commencement of
any action pursuant to this _Section 11.13_ or anything contained in this
_Section 11.13_ restrict or limit any party's right to terminate this
Agreement in accordance  with the terms of _Section 10.0_ 1 or pursue any
other remedies under this Agreement that may be available then or thereafter.
For the avoidance of doubt, in no event shall the Company or Parent be
entitled to both (i) specific  performance to cause the other party to
consummate the Closing and (ii) the payment of the Parent Termination Fee or
the Company Termination Fee, as applicable.

 


 

 

[Remainder of page intentionally left blank; signature pages  follow]

 


 

 

 

116  

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed by their respective authorized officers as  of the day and year
first above written.

 


 

 

        

    |  

BRISTOL-MYERS SQUIBB COMPANY

    
---|--- 
     

    |  

    |  

    
     

    | By:   |  

/s/ Giovanni Caforio

    
     

    | Name:  |  

Giovanni Caforio

    
     

    |  

Title:

    |  

Chief Executive Officer

    
      |   |   
     

    | BURGUNDY MERGER SUB, INC.   
      |   
     

    | By:   |  

 

 

/s/ Paul Biondi

 

 

    
     

    | Name:  |  

 

Paul Biondi

 

    
     

    | Title:  |  

President

    
    


 

 

 

[Signature Page to Merger Agreement]

   

         |  

CELGENE CORPORATION

    
---|--- 
      |   |   
      |  

By:

    |  

/s/ Mark J. Alles

    
      | Name:   | Mark J. Alles 
    
      |  

Title:

    | Chairman and Chief Executive Officer 
    
    


 

 

 

[Signature Page to Merger Agreement]

 

 


 

 


 

   

 

 

 

 

 

     '

